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Rheumatoid arthritis
Rheumatoid arthritis (RA) is an inflamma-
tory autoimmune disease, which is charac-
terized by pain, swelling, loss of strength 
and loss of mobility and ultimately leads 
to cartilage damage and destruction of the 
underlying bone (Figure 1). Many cell ty-
pes including macrophages, fibroblasts and 
dendritic cells (DCs) are believed to play a 
pathogenic role in the inflammatory casca-
de of synovitis. 
DCs are believed to be the most potential 
antigen presenting cells that regulate the 
delicate balance between immunity and to-
lerance (1). The function of DCs depends 
on their maturation state; immature DCs are 
located throughout the body, including the 
synovial tissue. Here they function as senti-
nels of the immune system that are specia-
lized in antigen recognition, uptake and pro-
cessing. Upon recognition of antigens, DCs 
differentiate into so-called mature DCs, a 
process that is characterized by upregula-
tion of MHC and co-stimulatory molecules 
(Figure 2), which is essential for antigen 
presentation to T cells in the lymph nodes 
or secondary lymphoid organs. This matu-
ration process is accompanied by a large 
production of pro-inflammatory mediators, 
such as cytokines, chemokines and metal-
loproteinases. 
Synovial fibroblasts play critical roles in 
normal joint functioning, for example by 
production of collagen and other connective 
tissue molecules that form and maintain the 
joint capsule. In RA however, synovial fibro-
blasts are linked to the invasive character of 
the synovial tissue, by invading surrounding 
Figure 1. Schematic presentation of a healthy joint and the features that characterize an arthritic joint. This figure was 
adapted from the thesis of Marije Koenders; Interleukin 17 and its relation to IL-1 and TNF in experimental arthritis, 
2007.
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bone and cartilage. Furthermore, RA syno-
vial fibroblasts produce and secrete a wide 
range of pro-inflammatory mediators, such 
as cytokines and growth factors(2). Macro-
phages are located in the synovial layers of 
the synovial tissue and involved in inflam-
matory responses by production of pro-in-
flammatory mediators, such as cytokines, 
chemokines and metalloproteinases, which 
all are likely to facilitate tissue destruction. 
The pro-inflammatory cytokine IL-1β was 
one of the first cytokines of interest in the 
field of RA, because of its biological role 
in joint destruction as shown in models of 
experimental arthritis. It was followed by 
TNFα, which acts strongly synergistic with 
IL-1β (3;4). For several years, anti-TNFα 
therapy has successfully been used in the 
clinic to improve the outcome of severe RA 
by suppression the inflammatory response 
in a substantial number of RA patients who 
were resistant for common disease-modi-
fying anti-rheumatic drugs (DMARD). Un-
fortunately, anti-TNFα therapy is still inef-
fective in about 35% of the patients. In this 
light it is essential to identify other factors 
that are involved in the pathogenesis and 
the chronicity of RA, which might reveal 
promising therapeutic targets for the future. 
Although the exact mechanisms that are 
responsible for the initiation and perpetua-
tion of the disease remain obscure, recent 
evidence points to a role for Toll-like recep-
tors (TLRs).
Toll-like receptors (TLRs)
TLRs belong to the family of pattern-recog-
nition receptors (PRRs) and to the Toll/IL-1R 
(TIR) superfamily. The cytoplasmic region 
of the TLR shares strong homology with the 
IL-1 receptor and therefore this region is re-
ferred to as the TIR domain. In contrast, the 
extracellular TLR regions do not contain Ig-
like domains like the IL-1R, but several leu-
cine-rich regions (LRR) instead (Figure 3). 
TLRs are able to recognize microbial com-
ponents, known as pathogen-associated 
molecular patterns (PAMPs) and are con-
stitutively expressed by numerous cell ty-
pes and tissues (5-10), where they detect 
pathogens leading to the induction of an 
Figure 2. Specific characteristics for immature and mature DCs; where immature DCs are specialized in antigen recogni-
tion, uptake and processing, mature DCs have the capacity for antigen presentation and subsequent T cell stimulation.
Figure 3. Schematic presentation of the Toll-like receptor 
structure.
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immune response (Table 1). Nowadays, 11 
TLRs have been identified in humans. TLR2 
(as heterodimer in combination with TLR1 
or TLR6) and TLR4 are able to recognize 
lipid-based structures from gram-positive 
and gram-negative bacteria, such as lipo-
peptides and lipopolysaccharides (LPS)(11-
13), whereas TLR3, TLR7, TLR8 and TLR9 
are involved in the recognition of viral and 
bacterial nucleic acids, such as double 
stranded RNA and CpG motifs in DNA (14-
16). TLR10, which is believed to originate 
from the TLR1/TLR6 precursor, has only 
been identified in human and no specific li-
gands have been described thus far. TLR5 
is able to recognize the bacterial protein 
flagellin (17) and although profilin has been 
described as a ligand for mouse TLR11 (18), 
ligands for human TLR11 have not yet been 
identified.
Endogenous TLR agonists
Due to extensive research the last few 
years, it was established that, besides mi-
crobial components, TLRs were also able to 
recognize endogenous agonists (Table 1). 
From all the potential endogenous TLR ago-
nists described, heat-shock proteins (HSPs) 
have been studied the most thoroughly thus 
far. In 2000, Ohashi et al. identified HSP60 
as a putative endogenous agonist of the 
TLR4 complex in mice (24), followed by Va-
bulas et al who described that both TLR2 
and TLR4 were involved in the recognition 
of self HSP60 in humans (32). Later on, it 
became clear that cell activation by other 
members of the HSP family, such as HSP70, 
gp96 and small HSPB8, were also media-
ted by TLRs (25;33;34). Where low levels of 
endogenous HSPs can be detected in the 
blood of healthy individuals (35), elevated 
Table 1: Toll-like receptors and their exogenous as well as endogenous ligands
TOLL-LIKE RECEPTOR EXOGENOUS & ENDOGENOUS LIGANDS REFERENCES
TLR1 (+TLR2) Bacterial tri-acyl lipopeptides (19)
TLR2
Lipoproteins (gram-positive bacteria)
Necrotic cells
(20)
(21)
TLR3
Double stranded viral RNA
Endogenous RNA from necrotic cells
(14)
(22)
TLR4
Lipid-based structures (gram-negative bacteria)
Heat-shock proteins
Hyaluronan
Fibronectin
(20;23)
(24;25)
(26)
(27;28)
TLR5 Bacterial flaggelin (17)
TLR6 (+TLR2) Bacterial di-acyl lipopeptides (13)
TLR7 Single stranded viral RNA (15;29)
TLR8 Single stranded viral RNA (30)
TLR9
Bacterial and viral DNA
Chromatin IgG complexes
(16;31)
TLR10 - -
TLR11 - -
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levels of HSPs are produced by cells under 
stress conditions, which for example occurs 
during acute infection and trauma- or (au-
toimmune-induced) inflammation. Be-yond 
cell stress, infection and inflammation also 
often coincides with tissue damage, resul-
ting in the release of extracellular matrix 
(ECM) products. Hyaluronic acid (HA) is 
one of the major glycosaminoglycans of the 
ECM, which undergoes degradation at sites 
of inflammation, leading to increased tis-
sue concentrations of HA fragments. It has 
been shown that HA is able to induce an im-
mune response upon recognition by TLR4 
(26). Otherwise, TLR4 was also found to 
be important in the recognition of heparan 
sulphate, which is released from the ECM 
during tissue damage as well (36). 
Nevertheless, as most of the evidence about 
the ability of endogenous agonists to induce 
TLR-mediated cell activation was derived 
using recombinant proteins, the possibility 
exists that endotoxin contamination interfe-
red with the experiments, as recombinant 
protein preparations (especially those gene-
rated in E. coli) may contain small amounts 
of endotoxins, such as LPS (37). Therefore 
further studies are warranted to completely 
exclude the effects of endotoxin contamina-
tion in immune activation induced by endo-
genous TLR ligands.      
TLR driven immune responses
Upon stimulation of all TLRs, except TLR3, 
myeloid differentiation factor 88 (MyD88) is 
recruited. Myd88 was the first adaptor mole-
cule described and its activation ultimately 
leads to the activation of nuclear factor kap-
pa B (NF-κB) (38-41) and the production of 
pro-inflammatory cytokines such as TNFα, 
IL-6, IL-1β and IL-12. 
Another important adaptor molecule termed 
TIR-related adaptor protein inducing interfe-
ron (TRIF), is involved in the signaling cas-
cade of both TLR3 and TLR4. Recruitment 
of TRIF eventually leads to the activation 
of the IRF-3 transcription factor leading to 
the production of e.g. type I interferon and 
RANTES (42-43). Furthermore, TRIF acti-
vation is also involved in MyD88-indepen-
dent transcription of NF-κB
For TLR4, it has been described that the MD-
2 molecule, which is physically associated 
with TLR4 on the cell surface, is required to 
confer an accurate signaling by stabilization 
of TLR4 dimers (44). In addition, also CD14 
(soluble or membrane-bound) that is able 
to form a physical complex with TLR4, and 
LPS binding protein (LBP) that is present in 
serum are essential for the LPS-mediated 
TLR4 signaling. The requirement of CD14 
and LBP are described for TLR2 signaling 
as well (45) (Figure 4).
Besides production of pro-inflammatory cy-
tokines such as TNFα, IL-6, IL-1β and type 
I IFN, TLR activation also results in matu-
ration of antigen-presenting cells, which in 
turn, interact with T cells to induce a proper 
adaptive immune response. Adaptive im-
mune responses of the Th1 type are dri-
Figure 4. Simplified schematic representation of the hu-
man TLR signaling pathway. This figure is adapted from 
S. Akira et al., Biochem Soc Trans, 2003.
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ven by IL-12 and are characterized by the 
production of IFNγ, whereas IL-10, IL-4 and 
IL-13 are associated with a Th2 type res-
ponse. TLR stimulation generally leads to 
production of IL-12 and thereby favors a Th1 
type response (46). Recently, a new T cell 
subset has been identified, the Th17 cells, 
which are driven by IL-23, TGFβ and IL-6 
and are characterized by production of IL-17 
(47;48). Since TLR stimulation also leads to 
the production of IL-23 and IL-6, it is con-
ceivable that TLR activation also results 
in a Th17 type response. Furthermore, the 
Notch ligands Delta-4 and Jagged-1 can be 
expressed by DCs and selectively induce 
T helper cell differentiation. Interestingly, 
co-stimulation of different TLRs results in a 
synergistically increased Delta-4/Jagged-1 
ratio and higher production of IL-12 and IL-
23 by human DCs, leading to DCs with en-
hanced Th1/Th17-polarizing capacity (49). 
Although there is lots of evidence for TLRs 
in Th1-mediated immune responses, only 
little data suggest that TLRs can regulate 
Th2-mediated responses as well. Netea et 
al. demonstrated that TLR2-deficient mice 
showed severely impaired production of 
IL-10 accompanied by a 50% decrease in 
regulatory T cell population (Treg) upon C. 
Albicans infection, concluding that immuno-
suppression through TLR2-derived signals 
acts via increased IL-10 production and sur-
vival of Treg (50).
Single nucleotide polymorphisms of 
Toll-like receptors   
Genetic polymorphisms, mainly single nu-
cleotide polymorphisms (SNP), are common 
variants within a population and are found at 
a frequency of over 1%. Many genetic va-
riations have been described in TLRs, and 
since SNP could result in an altered amino 
acid sequence, one might expect that SNP 
could affect TLR-mediated immune respon-
ses. Several years ago, Arbour et al. descri-
bed two common co-segregating missense 
mutations (Asp299Gly and Thr399Ile) af-
fecting the extracellular domain of TLR4, 
which were associated with hyporespon-
siveness to bacterial lipopolysaccharide 
(LPS). In addition, transfection of THP-1 
cells with either wild-type or mutant alleles 
of TLR4 demonstrated that cells transfected 
with the Asp299Gly allele showed a decre-
ased response to LPS, whereas cells trans-
fected with the Thr399Ile allele did not (51). 
Ever since, many studies were performed 
that investigated the potential association 
of the TLR4 polymorphisms with the sus-
ceptibility to infectious diseases, such as 
respiratory virus infections and septic shock 
(52;53),  and  non-infectious disorders, such 
as Crohn’s disease, acute allograft rejection 
and asthma (54-56). Also for TLR2 several 
SNP have been described. Most frequent is 
the Arg753Gln polymorphism, which is loca-
ted in the cytoplasmic domain of TLR2 and, 
as demonstrated for the Asp299Gly SNP in 
TLR4, showed hyporesponsiveness upon 
TLR2-induced activation (57;58). Since 
TLR2 and TLR4 seemed to be the most im-
portant receptors involved in infectious di-
seases, most studies have been focused on 
these two receptors. However, to a lesser 
extent, also polymorphisms in other TLRs 
have been described (59-61). 
TLRs in rheumatoid arthritis
The first evidence that demonstrated a role 
for TLRs in rheumatoid arthritis (RA) origi-
nated from Leadbetter et al. who described 
that B cells from rheumatoid factor positive 
(RF+) MyD88-deficient mice were comple-
tely unresponsive to chromatin-containing 
immune complexes. In addition, autoim-
mune sera that effectively stimulated RF+ 
14
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MyD88 positive B cells, seemed ineffective 
in the RF+ MyD88-deficient mice, demon-
strating that autoantibody-autoantigen im-
mune complexes act via a MyD88-depen-
dent receptor, probably TLR9 (31). The role 
of TLRs in RA was shown not to be limited 
to TLR9 since RA synovial fibroblasts, iso-
lated from RA synovial tissue, showed clear 
upregulation of TLR2 upon stimulation with 
the pro-inflammatory cytokines TNFα and 
IL-1β, which were both the first cytokines of 
interest in the field of RA (62). Furthermore, 
it was demonstrated that RNA released 
from necrotic RA synovial fluid cells were 
able to activate RA synovial fibroblasts via 
TLR3 (22). The role of TLRs had also been 
demonstrated in experimental models of 
arthritis as mice deficient for the adaptor 
molecule MyD88 did not develop Strepto-
coccal cell wall (SCW)-induced arthritis, 
shown by complete absence of joint swel-
ling, influx of inflammatory cells as well as 
cartilage matrix proteoglycan loss (63). 
Furthermore, soluble ST2 (sST2), which is 
known as an endogenous inhibitor of TLR4, 
could attenuate the disease severity in the 
murine model of collagen-induced arthritis. 
Moreover, specific RA pathology, such as 
cellular infiltration in the joints, synovial 
hyperplasia and joint erosion were deeply 
reduced in mice treated with sST2. Finally, 
recently it was demonstrated that a natu-
rally occurring TLR4 antagonist was able 
to suppress the clinical and histological 
characteristics of arthritis as demonstrated 
in several models of experimental arthritis 
(64). Altogether, preliminary evidence, 
which indicates a role for TLRs in arthritis, 
prompted us to introduce a line of research 
aiming to reveal the involvement of TLRs in 
the pathogenesis of RA as well as in the 
chronic phase of the disease.    
Aim & outline of this thesis
At the start of this project the evidence that 
suggested a role for TLRs in RA was very li-
mited and was mainly gathered using sever-
al models of experimental arthritis. The aim 
of this thesis was to investigate the role of 
TLRs in the pathogenesis and the chronicity 
of RA in a human setting. This was done to 
determine whether TLRs could serve as a 
possible therapeutic target in RA. 
In the first part of the thesis (chapter 2 and 
chapter 3), the presence of TLRs in RA sy-
novial tissue was studied using immunohis-
tochemistry and this was compared to syno-
vial tissue from patients with osteoarthritis 
(OA) and healthy controls. We found that all 
TLRs investigated were highly expressed in 
synovial tissue from RA patients and that 
this expression was significantly enhanced 
compared to patients with OA and healthy 
controls. Subsequently we investigated 
whether cytokines, which were present in 
RA synovial tissue, could regulate these 
TLRs and we found that TLR2 and TLR4 
could strongly be upregulated by IL-12 and 
IL-18 (chapter 2), whereas the expression of 
TLR3 and TLR7 was strongly regulated by 
IFNα (chapter 6). 
Besides the presence of TLRs in RA synovi-
al tissue, we also investigated the presence 
of endogenous TLR ligands in serum and 
synovial fluid from RA patients, using a sta-
bly TLR4 transfected CHO reporter cell line, 
which revealed that presence of endoge-
nous TLR4 ligands was strongly enhanced 
in serum and synovial fluid of RA patients 
compared to healthy controls and patients 
with systemic sclerosis or systemic lupus 
erythematosus (chapter 3). In addition, 
using immunohistochemistry and Western 
blot analysis, we identified small heat-shock 
protein B8 (HSPB8) as an endogenous li-
gand present in RA synovial tissue and in 
15
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vitro experiments demonstrated that this 
ligand was able to induce an immune res-
ponse via TLR4 (chapter 4).
In terms of TLR stimulation, we investiga-
ted the effects of TLR co-stimulation and 
found that simultaneous stimulation of dif-
ferent TLR pathways resulted in a syner-
gistic effect with regard to the production of 
pro-inflammatory mediators TNFα and IL-6 
(chapter 3). Furthermore, we investigated 
the potential differences in TLR-mediated 
immune responses between RA patients 
and healthy controls. Stimulation of mono-
cytes-derived DC using specific ligands for 
TLR2, TLR3, TLR4 and TLR7/8 showed 
that cells from RA patients produced much 
higher amounts of the pro-inflammatory 
cytokines IL-6 and TNFα upon TLR2- and 
TLR4-mediated stimulation than cells from 
healthy controls, whereas cytokine pro-
duction upon TLR3 and TLR7 stimulation 
was not enhanced (chapter 3). In chapter 
5, using microarray analysis, we identified 
allograft-inflammatory factor 1 (AIF-1) as a 
factor that might be involved in the enhan-
ced TLR2/4-mediated immune response in 
RA patients. 
Finally, we investigated the potential effect 
of the Asp299Gly TLR4 polymorphism in 
RA. Therefore mononuclear cells (PBMC) 
from RA patients carrying and not carrying 
the genetic Asp299Gly TLR4 variant were 
compared with respect to TLR4 mRNA 
expression, TLR4 protein expression and 
cytokine production upon TLR stimulation 
with exogenous as well as endogenous 
TLR4 agonists. We demonstrate that cyto-
kine production by cells from patients with 
the genetic TLR4 variant was significantly 
diminished upon exogenous as well as en-
dogenous TLR stimulation, despite the fact 
that the TLR4 expression was unaffected 
(chapter 7). 
In the final chapter (chapter 8) the results 
described in this thesis are summarized and 
discussed. 
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Objective. To study the expression of TLR2 and TLR4 and its association with pro-inflammatory 
cytokines in synovial tissue from patients with rheumatoid arthritis (RA), osteoarthritis (OA), and 
healthy individuals. 
Methods. Synovial tissue specimens from 29 RA patients were stained for TLR2, TLR4, and 
pro-inflammatory cytokines IL-1β, IL-12, IL-17, IL-18, and TNFα. The expression of TLR2, TLR4, 
and cytokines as well as the degree of inflammation in synovial tissue were compared between 
patients with RA, patients with OA (n = 5), and healthy individuals (n = 3). Peripheral blood mo-
nonuclear cells (PBMCs) were incubated with IL-12 and IL-18, and TLR expression was assessed 
using fluorescence-activated cell sorter analysis. Production of TNFα and IL-6 was measured 
using Luminex bead array technology. 
Results. In RA synovial tissue, the expression of TLR2 was slightly higher than that of TLR4. Inte-
restingly, both TLR2 and TLR4 were expressed at higher levels in moderately inflamed synovium, 
as compared with synovial tissue with no or severe inflammation. TLR expression in both the lining 
and the sublining was associated with the presence of IL-12 and IL-18, but no other cytokines, in 
the lining. The expression of both TLRs was low in synovial tissue from OA patients and healthy 
donors. Stimulation of PBMCs with IL-12 and IL-18 resulted in increased expression of both TLR2 
and TLR4; this could be blocked with anti-IFNγ antibodies, suggesting a role for IFNγ. Lipopolysac-
charide- or lipoteichoic acid-mediated triggering of PBMCs incubated with IL-12/IL-18 or IFNγ led to 
an increased production of both TNFα and IL-6, indicating the functionality of TLR2 and TLR4. 
Conclusion. TLR2 and TLR4 are expressed in synovial tissue of patients with clinically active 
disease and are associated with the levels of both IL-12 and IL-18. The synergistic effect of IL-12 
and IL-18 on T cell IFNγ production seems to regulate expression of TLR2 and TLR4 in the synovial 
tissue of RA patients. 
Introduction
Rheumatoid arthritis (RA) is a systemic au-
toimmune inflammatory disease that pre-
dominantly affects synovial joints. Althou-
gh the exact pathophysiologic mechanisms 
are still largely unknown, it is generally ac-
cepted that numerous inflammatory cells, 
such as T and B cells, fibroblast-like syno-
viocytes, and antigen-presenting cells, and 
their extensive production of pro-inflamma-
tory mediators are implicated (1-4). During 
RA, the synovial tissue undergoes many 
changes, including neoangiogenesis, cel-
lular hyperplasia, and influx of inflammato-
ry cells, which are potentially orchestrated 
by a complex interplay of pro-inflammatory 
mediators such as cytokines and chemoki-
nes (5-8). The recognition of HLA-DR sub-
types that are associated with RA, and the 
presence of autoantibodies, such as rheu-
matoid factor and citrinullated peptides, 
suggest an autoimmune component in the 
pathogenesis of RA (9-11). Furthermore, 
recent studies have suggested the involve-
ment of Fc receptors and Toll-like receptors 
(TLRs) in arthritis, and these are of critical 
importance in autoimmunity (12-16).
TLRs are phylogenetically conserved re-
ceptors that recognize pathogen-associ-
ated molecular patterns (PAMPs) and are 
involved in the uptake and processing of 
various exogenous and endogenous anti-
gens (17). However, TLRs are not only in-
volved in antigen uptake, but also mediate 
maturation of dendritic cells and promote 
naive T cells toward a Th0, Th1, or Th2 
phenotype. Thus, TLRs play a crucial role 
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in the regulation of innate and adaptive im-
mune responses (18,19).
To date, 11 human TLRs have been des-
cribed, of which TLR2 and TLR4 are the 
most thoroughly investigated. In addition 
to being involved in the recognition of lipo-
polysaccharide (LPS), TLR4 also interacts 
with endogenous ligands such as heat-
shock proteins (HSPs) (20), fragments of 
hyaluronic acid (21), and fibronectin (22). 
These endogenous ligands are probably 
released by cells undergoing stress, da-
mage, or necrotic death and are present 
in the stressed synovium. Increased cell 
turnover in conditions of minor trauma or 
inflammation, leading to increased levels 
of endogenous TLR ligands, is therefore 
likely to initiate a reaction leading to TLR-
mediated triggering of inflammatory cells in 
RA. Recent evidence underscores such a 
critical role of TLRs in the onset of autoim-
munity (12,23,24).
TLR2 and TLR4 are constitutively expres-
sed on various cell members of the immune 
system, including macrophages, neutrop-
hils, and dendritic cells. The expression 
of TLR2 and TLR4 is tightly regulated by 
several pro-inflammatory cytokines. Stimu-
lation of mouse macrophages and hepato-
cytes with interleukin-1 beta (IL-1β), inter-
feron-gamma (IFNγ), and tumor necrosis 
factor-alpha  (TNFα) resulted in an up-re-
gulation of both TLR2 and TLR4 messen-
ger RNA (mRNA). In addition, expression 
of mRNA for TLR2 and TLR4 increased 
upon stimulation of endothelial cells and 
renal epithelial cells with IFNγ (25,26). Sti-
mulation with TNFα in renal epithelial cells 
also led to a clear increase of TLR2 and 
TLR4 protein expression (25). In contrast, 
human monocytes seem to regulate TLR4 
expression differentially, since stimulation 
with TNFα resulted in a decreased protein 
expression of TLR4, whereas stimulation 
with IL-6 led to an increased expression of 
TLR4 protein (27).
Although their roles are obviously impor-
tant in inflammation, clear results with re-
gard to the effects of IL-12 and IL-18 on the 
expression of TLR2 and TLR4 are lacking. 
IL-12 generates the development of naive 
T cells into Th1 cells and stimulates IFNγ 
secretion by differentiated Th1 cells. IL-12 
is produced by phagocytic cells, dendri-
tic cells, B lymphocytes, and natural killer 
cells upon stimulation with LPS, bacteria, 
and parasites (28,29). The potentially im-
portant role of IL-12 in synovial inflamma-
tion was illustrated by the finding that lo-
cal overexpression of IL-12 transforms an 
experimental model of acute arthritis into a 
chronic destructive immune-mediated pro-
cess (30).
Recently, it was demonstrated that IL-18 
can act as a costimulus for IFNγ production 
and natural killer cell cytotoxicity induced 
by IL-12 (31). However, IL-18 itself is not a 
strong inducer of IFNγ in the absence of 
other cytokines. IL-18 is a pro-inflamma-
tory cytokine member of the IL-1 cytokine 
superfamily and was originally identified as 
IFNγ-inducing factor (31). On T cells, IL-18 
stimulates Th1 differentiation, promotes 
secretion of IFNγ, TNFα, and granulocye-
macrophage colony-stimulating factor, and 
enhances natural killer cell cytotoxicity. A 
critical role for IL-18 in RA was further sub-
stantiated by the finding that the synovial 
expression of IL-18 was accompanied by 
the coexpression of IL-1β and TNFα and 
was associated with local inflammation in 
RA (6). Since both cytokines are known to 
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potentiate Th1-driven responses and sti-
mulate the secretion of IFNγ, it is generally 
accepted that, in conjunction with IL-1β and 
TNFα, IL-12 and IL-18 are key inflamma-
tory cytokines in the inflammatory cascade 
of RA.
Seibl et al recently demonstrated an incre-
ased expression of TLR2 in the synovial 
fibroblasts of RA patients, when compared 
with those of OA patients (15). However, 
since both TLR2 and TLR4 are potenti-
ally critical receptors in the initiation and 
perpetuation of the inflammatory cycle in 
arthritis, and fibroblasts are not the only 
cells considered to be key players in the 
disease, we investigated the expression 
of these TLRs in synovial tissue sections 
from RA patients in comparison with those 
from OA patients and healthy controls. In 
addition, we investigated whether synovial 
expression of TLR2 and TLR4 was asso-
ciated with the pro-inflammatory cytokines 
IL-1β, TNFα, IFNγ, IL-12, and IL-18, and we 
studied the role of IL-12 and IL-18 in the re-
gulation of TLR2 and TLR4 expression on 
monocytes in vitro.
Our results demonstrate clearly higher ex-
pression levels of TLR2 and TLR4 in sy-
novial tissue from RA patients. Moreover, 
the level of TLR2 and TLR4 expression in 
both the lining and sublining from modera-
tely inflamed joints was associated with the 
presence of IL-12 and IL-18 in the lining. 
In addition, IL-12 and IL-18 induced an up-
regulation of TLR2 and TLR4 on monocy-
tes, which was inhibited by the blockade of 
IFNγ. Our findings indicate that IL-12 and 
IL-18, both abundantly present in the sy-
novium of RA patients, are involved in the 
regulation of TLR2 and TLR4, which may 
play a potentially important role in the sy-
novial inflammation during RA.
Methods
Patients.
Twenty-nine consecutive patients with RA 
were enrolled in the study. All patients met 
the American College of Rheumatology (for-
merly, the American Rheumatism Associati-
on) criteria for RA (32). The disease activity 
was calculated by using the Disease Activity 
Score (DAS), and, for the current study only, 
patients with a DAS higher than 3.2 were in-
cluded (33). The therapeutic regimens of all 
patients were recorded before blood sam-
pling. Patients receiving prednisone within 6 
weeks or biologic therapies, including anti-
TNFα or IL-1 receptor antagonist, before the 
study were not included.
Percutaneous biopsies of the knee joint were 
performed with a Parker-Pearson needle, 
following local administration of anesthesia. 
An average of 30 samples was obtained 
at each procedure. Prior to the biopsy, the 
erythrocyte sedimentation rate (ESR) was 
measured and knee joints were scored by 
an experienced rheumatologist for the ab-
sence (score of 0) or presence of local pain, 
swelling, or effusion (score of 1, respectively, 
for each of these). The 3 scores were added 
up and patients were classified as having no 
(score 0), moderate (score 1-2), or severe 
(score 3) knee-joint arthritis. The synovial 
tissue from healthy individuals and patients 
with OA was isolated during arthroscopic 
procedures performed by orthopedic surge-
ons. The Medical Ethics Committee of the 
University Medical Center Nijmegen appro-
ved the study protocol.
Antibodies for detection of TLRs and 
cytokines.
Diaminobenzidine (DAB) and bovine se-
rum albumin were obtained from Sigma (St. 
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Louis, MO). Polyclonal antibodies against 
human TLR2 (H-175) and TLR4 (H-80) were 
obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA). Biotinylated swine anti-
rabbit Ig affinity-isolated F(ab)2 was obtained 
from Dako (Glostrup, Denmark). Dulbecco’s 
modified Eagle’s medium, RPMI-1640 with 
Glutamax, fetal calf serum (FCS), and so-
dium pyruvate were purchased from Gibco 
Invitrogen (Breda, The Netherlands). Mono-
clonal antibodies against human IL-12 p70 
(IgG, MAB 219), human IL-18 (IgG, AF 318), 
recombinant human IL-12, IL-18, and IFNγ 
were obtained from R&D Systems (Minne-
apolis, MN). Antibodies against human CD3 
(A0452), CD14 (M0825), and CD68 (M0718) 
were purchased from Dako. Avidin peroxida-
se (Elite kit) was obtained from Vector (Bur-
lingame, CA). Lipoteichoic acid (LTA; L3140) 
and LPS (L4391) were purchased from Sig-
ma. BioPlex kits for determination of IFNγ, 
IL-6, and TNFα (catalog no. 171-B11921, 
171-B10719, and 171-B12236, respectively), 
using Luminex bead array technology, were 
purchased from Bio-Rad (Hercules, CA).
Immunohistochemical analysis of syno-
vial tissues.
Tissue samples were immediately fixed with 
4% formaldehyde and embedded in paraf-
fin. After dewaxing and dehydration, secti-
ons were blocked with normal swine serum 
followed by 60 minutes of incubation with 
the antibodies against TLR2 and TLR4 at 
a concentration of 10 μg/ml and 17 μg/ml, 
respectively. The secondary antibody, bio-
tinylated swine anti-rabbit Ig, was added to 
the incubation for 30 minutes. Slides were 
stained with streptavidin peroxidase, deve-
loped with DAB, and counterstained with he-
matoxylin for 30 seconds. A similar amount 
of biopsy tissue was embedded in Tissue 
Tek (Miles, Elkart, IN) and then snap-frozen 
and stored in liquid nitrogen until sectioned. 
Snap-frozen material was used to assess 
CD3 and CD68 staining. Control sections 
were stained with irrelevant primary isotype-
specific IgG antibodies.
Sections were coded and randomly ana-
lyzed by 2 blinded observers (YMJ and 
LABJ). Inadequate sections, which lacked 
synovial lining, were left out of the analysis. 
Staining for TLR2 and TLR4 was semiquan-
titatively scored on a 5-point scale (range 
0-4) at 200× magnification; a score of 0 re-
presented no or minimal staining, a score of 
1 indicated 10-20% positive cells, a score of 
2 indicated 30-40% positive cells, a score 
of 3 indicated 50-60% positive cells, and 
a score of 4 represented staining of more 
than 60% of the cells. Staining for IL-1β, IL-
18, and TNFα was performed as described 
previously (8). The number of IL-12-positive 
cells in the sublining was counted manually 
in 5 random high-power fields, and the count 
was then averaged and scored on a 0-4 sca-
le as follows: 0 = 0-1 positive cells, 1 = 2-3 
positive cells, 2 = 4-6 positive cells, 3 = 7-10 
positive cells, and 4 = >10 positive cells.
Monocyte cultures and fluorescence-
activated cell sorter (FACS) analysis.
Monocytes were cultured using standardi-
zed protocols as previously described (3). 
Briefly, peripheral blood mononuclear cells 
(PBMCs) were isolated from heparinized ve-
nous blood using density gradient centrifu-
gation over Ficoll-Hypaque (Amersham Bi-
osciences, Roosendaal, The Netherlands). 
The interphase was collected and washed 
with citrated phosphate buffered saline. 
After washing, PBMCs were adjusted to 
0.5×106 cells/ml in RPMI-1640 supplemen-
ted with antibiotics and 10% heat-inacti-
vated FCS (Life Technologies, Breda, The 
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Netherlands). Monocytes were isolated from 
the PBMCs by incubation with magnetic-ac-
tivated cell sorting beads coated with a mo-
noclonal antibody against human CD14 (Mil-
tenyi Biotec, Bergisch Gladbach, Germany). 
Immunomagnetic separation was performed 
according to the manufacturer’s instructi-
ons. Isolated CD14+ cells were brought to a 
concentration of 0.5×106 cells/ml in RPMI-
1640 (Life Technologies, Grand Island, NY) 
supplemented with 10% FCS and antibiotic-
antimycotic. CD14+ monocytes and PBMCs 
were incubated in medium alone or in me-
dium with either IFNγ (10 ng/ml), IL-12 (10 
ng/ml), IL-18 (50 ng/ml), or a combination of 
IL-12 and IL-18 for 24 hours and 48 hours 
at 37°C. Neutralizing anti-human IFNγ anti-
bodies (Innogenetics, Ghent, Belgium) were 
used at a concentration of 10 μg/ml to neu-
tralize IFNγ during PBMC cultures exposed 
to either IL-12, IL-18, or the combination of 
both cytokines.
The expression of the cell-surface markers 
TLR2 and TLR4 on monocytes was measu-
red by indirect immunofluorescence staining, 
as described in detail previously (3). Briefly, 
the first layer was attached after incubation 
of 1×105 monocytes for 30 minutes at 4°C 
with the monoclonal anti-human antibodies 
against TLR2 (H-175), TLR4 (HTA-125; 
Santa Cruz Biotechnology), and CD14. Af-
ter a washing step, the cells were incubated 
with fluorescein isothiocyanate-conjugated 
goat anti-mouse IgG for 30 minutes at 4°C 
in complete darkness.
Cells were gated according to their forward- 
and side-scattering patterns, using FACS 
analysis. For each marker, 104 cells were 
counted in the gate. For the functional ana-
lysis, PBMCs were preincubated with IL-12 
(10 ng/ml), IL-18 (50 ng/ml), and/or the com-
bination of both for 24 hours. Thereafter, the 
PBMCs were stimulated for 18 hours with 
TLR2-specific ligands (LTA) and TLR4-spe-
cific ligands (LPS).
Statistical analysis.
Results are expressed as the arbitrary sco-
re, with the median (25th, 75th percentile 
[25%, 75%]) or the mean ± SD. Differences 
between experimental groups were tested 
using the Mann-Whitney U test. Correlations 
between the expression of TLRs and cytoki-
nes were calculated using Spearman’s non-
parametric correlation test. Both tests were 
conducted using GraphPad Prism, version 
2.01. Only P values less than 0.05 were con-
sidered significant.
Results
TLR2 and TLR4 expression in synovial 
tissue of RA and OA patients and healthy 
individuals.
Synovial sections obtained from 29 patients 
with RA were stained with antibodies against 
TLR2 and TLR4, or with irrelevant primary 
isotype-specific IgG antibodies as a nega-
tive control. TLR2 was detected in 78% of 
the RA patients, whereas TLR4 was present 
in 70%. TLR2 and TLR4 were detected in 
the lining, the sublining, and the perivascular 
region of the RA synovium (Figure 1). Both 
TLR2 and TLR4 were relatively overexpres-
sed in the lining (mean ± SD scores 1.9 ± 1.5 
and 1.4 ± 1.4, respectively) compared with 
expression in the sublining (1.3 ± 1.3 and 0.8 
± 1.2, respectively) or the endothelial cells 
(0.8 ± 1.1 and 1.1 ± 1.6, respectively). Mo-
reover, in moderately inflamed synovium, 
expression of TLR2 in the lining was higher 
when compared with that of TLR4 (median 
[25%, 75%] score 3 [2, 4] versus 2 [1, 4]). In 
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contrast, the expression of both TLR2 and 
TLR4 was markedly lower in synovial tis-
sue obtained from patients with OA and was 
hardly detectable in synovial tissue samples 
from healthy controls (Figure 1). 
Expression of TLR2 and TLR4 predo-
minantly in moderately inflamed knee 
joints.
Prior to the biopsy, the 29 RA patients were 
classified into 3 groups on the basis of the 
ESR and clinical scoring of the knee, with ca-
tegories as follows: no (n = 5), moderate (n 
= 12), or severe (n = 12) knee-joint arthritis. 
The degree of inflammation along with the 
scores for TLR2 and TLR4 expression are 
shown in Figure 2. In the lining, both TLR2 
(median [25%, 75%] 3 [2, 4] versus 1 [0, 2]; 
P = 0.007) and TLR4 (median 2 [1, 4] versus 
0 [0, 0.5]; P = 0.03) were expressed at sig-
nificantly higher levels in synovial tissue with 
moderate inflammation when compared with 
synovial tissue with no inflammation. In con-
trast, TLR2 and TLR4 were equally distribu-
ted in the sublining and perivascular regions 
of synovial tissue from joints with severe, 
moderate, or no inflammation. 
The predominant expression of TLR2 and 
TLR4 in the synovial tissue of moderately 
inflamed joints was not correlated with the 
presence of T cells (CD3) or macrophages 
(CD68) (data not shown). In contrast, the 
expression of CD3 was lowest in the syno-
vial tissue from moderately inflamed joints, 
whereas CD68 was most abundant in seve-
rely inflamed knee joints (data not shown).
Association of TLR2 and TLR4 expres-
sion with presence of pro-inflammatory 
cytokines.
The biopsy samples used in this study were 
previously used to detect the presence of IL-
1β, IL-12, IL-17, IL-18, and TNFα (6). Since 
we were interested in the potential associ-
ation between the presence of pro-inflam-
matory cytokines and the levels of TLR2 
and TLR4, we studied this relationship. Ex-
pression of the cytokines and receptors was 
scored on a 5-point scale (range 0-4) and 
correlations were determined.
The overall presence of IL-1β, IL-17, and 
TNFα was not associated with either TLR2 
or TLR4. Interestingly, IL-12 levels in the li-
Figure 1. Immunohistochemical detection of Toll-like 
receptor 2 (TLR2) and TLR4 in synovial biopsy tissues 
from patients with rheumatoid arthritis (RA), osteoar-
thritis (OA), and healthy individuals. As a control, staining 
was performed with nonrelevant isotype control antibody 
(A and B). Expression of TLR2 (C and D) and TLR4 (E 
and F) was examined in RA synovial tissue, as compared 
with TLR2 and TLR4 expression in synovial tissue from 
patients with OA (G and H) and healthy individuals (I and 
J). Hematoxylin counterstained; original magnification 
400×.
D
A B
C
E F
G H
I J
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ning were significantly associated with the 
expression of TLR2 (for lining, r = 0.53, P < 
0.005; for sublining, r = 0.60, P = 0.001) and 
TLR4 (for lining, r = 0.46, P = 0.01; for subli-
ning, r = 0.44, P = 0.03) (Table 1). The same 
trend, albeit not significant, was observed 
between the levels of IL-18 and the expres-
sion of TLR2 (for lining,  r = 0.27, P = 0.06; 
for sublining, r = 0.23, P = 0.07) and TLR4 
(for lining, r = 0.24, P = 0.07; for sublining, r = 
0.27, P = 0.08). 
Association of TLR2 and TLR4 expres-
sion on monocytes with indirect regula-
tion by IL-12 and IL-18.
To explore the potential effects of IL-18 and 
IL-12 on the regulation of TLR2 and TLR4 
protein expression on monocytes, purified 
CD14+ monocytes from RA patients and 
healthy individuals were incubated with IL-
12 and IL-18. In contrast to the results in 
monocyte cultures with IFNγ (positive con-
trol), both IL-12 and IL-18 did not affect the 
expression of TLR2 or TLR4 on purified mo-
nocytes (Table 2). 
Because the presence of IL-12, IL-18, and, 
especially, the combination of both cytoki-
nes results in production of IFNγ by T cells, 
we sought evidence to indicate whether IL-
12, IL-18, or both were able to increase the 
expression of TLR2 and TLR4 on monocytes 
in the presence of T cells. We therefore in-
cubated PBMCs with IFNγ, IL-12, IL-18, and 
Figure 2. Expression of TLR2 and TLR4 in relation to the severity of arthritis in synovial tissues from RA patients. On 
macroscopic scoring, synovial samples were categorized as noninflamed, moderately inflamed, or severely inflamed. Mi-
croscopic inflammation and expression of TLR2 in the lining (A) and sublining (B) together with TLR4 in the lining (C) and 
sublining (D) were scored using semiquantitative scales ranging from 0 to 4 (0 = no or minimal staining; 1 = 10-20% po-
sitive cells; 2 = 30-40% positive cells; 3 = 50-60% positive cells; 4 = >60% positive cells). Bars show the mean score for 
synovial sections without inflammation (n=5), with moderate inflammation (n=12), or with severe inflammation (n=12). 
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a combination of IL-12 and IL-18 and studied 
the expression of both receptors on mono-
cytes. Incubation with IFNγ resulted in a 
marked increase of both TLR2 and TLR4 on 
CD14+ monocytes, which was equally distri-
buted among healthy individuals (increase in 
TLR2, 126%; increase in TLR4, 250%) and 
RA patients (increase in TLR2, 127%; incre-
ase in TLR4, 222%), and reached a peak at 
48 hours (Figure 3A). Intriguingly, stimulati-
on with IL-12 and IL-18 and the combination 
of both IL-12 and IL-18 similarly resulted in 
an increase in TLR2 and TLR4 expression; 
however, their peaks were reached within 24 
hours (data not shown). These data suggest 
that IL-12 and IL-18 alone and in combinati-
on promote IFNγ secretion by T cells, which 
in turn induces enhancement of TLR2 and 
TLR4 expression on monocytes. 
To examine whether the IL-12- and/or IL-
18-driven up-regulation of TLR2 and TLR4 
protein expression was dependent on IFNγ, 
we determined IFNγ levels in culture super-
In total, 29 synovial tissue samples from rheumatoid arthritis (RA) patients with active disease were analyzed for IL-12, IL-
18, TLR2, or TLR4 expression. Expression was scored in the lining and sublining by 2 blinded observers (YMJ and LABJ) 
on a scale ranging from 0 to 4 (for details, see Patients and Methods). Correlations were calculated using Spearman’s 
nonparametric correlation test, with GraphPad Prism, version 2.01. Biopsy samples were obtained from noninflamed 
(n=5; patients 4, 12, 19, 25, and 26), moderately inflamed (n=12; patients 1, 2, 6, 7, 14-17, 20, 21, 23, and 24), and seve-
rely inflamed (n=12; patients 3, 5, 8-11, 13, 18, 22, and 27-29) knee joints. ND = not detectable). 
Table 1: Individual scores of IL-12/IL-18 and TLR2/TLR4 expression in synovial tissue samples from RA patients
TLR2 TLR4
PATIENT LINING SUBLINING LINING SUBLINING LINING SUBLINING LINING SUBLINING
1 1.0 2.0 1.0 0.5 4.0 1.0 1.0 0.0
2 0.0 0.0 0.0 0.0 3.0 2.0 2.0 0.0
3 0.0 0.0 0.0 0.0 1.0 1.0 2.0 3.0
4 0.0 0.0 1.0 1.0 0.0 0.0 0.0 0.0
5 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0
6 3.0 4.0 3.0 0.5 4.0 4.0 4.0 2.0
7 0.0 2.0 3.0 0.5 3.0 1.0 4.0 3.0
8 2.0 3.0 1.0 1.0 2.0 2.0 1.0 1.0
9 0.0 0.0 0.0 0.0 3.0 2.0 0.0 3.0
10 0.0 2.0 0.5 0.5 ND ND ND ND
11 0.0 2.0 1.0 3.0 0.0 0.0 3.0 3.0
12 0.0 1.0 0.0 0.0 1.0 ND 2.0 ND
13 0.0 1.0 2.0 1.0 0.0 2.0 0.0 0.0
14 1.0 2.0 2.0 3.0 3.0 3.0 2.0 1.0
15 0.0 1.0 1.0 1.0 3.0 0.0 2.0 2.0
16 0.0 0.0 1.0 1.0 ND ND ND ND
17 0.0 1.0 1.0 0.0 0.0 0.0 0.0 0.0
18 0.0 1.0 1.0 1.0 ND 4.0 ND 0.0
19 0.0 1.0 0.0 0.0 3.0 1.0 1.0 0.0
20 1.0 2.0 2.0 1.0 1.0 1.0 2.0 1.0
21 0.0 0.0 0.0 0.0 2.0 0.0 4.0 0.0
22 0.0 0.0 1.0 4.0 ND ND ND 0.0
23 2.0 4.0 3.0 1.0 4.0 4.0 0.0 1.0
24 1.0 1.0 4.0 2.0 4.0 1.0 2.0 0.0
25 0.0 0.0 1.0 2.0 1.0 1.0 0.0 0.0
26 0.0 0.0 4.0 4.0 0.0 0.0 0.0 0.0
27 0.0 0.0 1.0 3.0 0.0 0.0 2.0 0.0
28 0.0 2.0 1.0 2.0 2.0 2.0 3.0 0.0
29 0.0 0.0 0.0 1.0 2.0 0.0 0.0 0.0
IL-12 IL-18
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natants after exposure to IL-12, IL-18, or the 
combination of both (Figure 3B). Using the 
Luminex bead array system, we found high 
levels of IFNγ in supernatants of PBMCs that 
were incubated with the combination of IL-
12 and IL-18. Interestingly, the in vitro IFNγ 
production induced by the combination of IL-
12 and IL-18 is significantly lower in PBMCs 
from RA patients compared with that in 
PBMCs from healthy controls.
To confirm the finding that IFNγ regulates the 
enhancement of TLR expression, we perfor-
med studies in the presence or absence of 
neutralizing antibodies directed against hu-
man IFNγ. Figure 3C shows clearly that the 
up-regulation of TLR2 and TLR4 was largely 
IFNγ-dependent, since it was almost fully 
inhibited by the neutralization of IFNγ. Re-
markably, although we could not detect IFNγ 
in the culture supernatant after 24 hours of 
stimulation of PBMCs with either IL-12 or 
IL-18, the slight up-regulation of both TLR2 
and TLR4 seen after stimulation with both IL-
12 and IL-18 combined was IFNγ dependent 
(Figure 3C).
IL-12/IL-18-mediated up-regulation of 
TLR2 and TLR4 and TLR-specific trig-
gering of increased production of TNFα 
and IL-6.
For a better understanding of the impact of 
IL-12/IL-18- and TLR2/TLR4-mediated ef-
fects on RA initiation and/or progression, the 
functionality of the increased expression of 
TLR2 and TLR4 after stimulation with IL-12 
and IL-18 was tested. To this aim, we incu-
bated IL-12/IL-18-prestimulated PBMCs with 
TLR2- and TLR4-specific ligands (LTA and 
LPS, respectively) and measured the secre-
tion of TNFα and IL-6; we then compared 
the findings with those in PBMCs stimulated 
with IFNγ alone. As expected, stimulation 
of both PBMC supernatants, preincubated 
with either IL-12/IL-18 or IFNγ together with 
LPS, resulted in a clearly higher secretion of 
TNFα (mean ± SD 3,333 ± 249 pg/ml [P < 
0.001] and 2,582 ± 289 pg/ml [P < 0.001], 
respectively) when compared with PBMCs 
without any preincubation (150 ± 79 pg/ml 
TNFα) (Figure 3D). Similarly, the production 
of IL-6 was higher by PBMCs preincubated 
with IL-12/IL-18 (18,989 ± 3,739 pg/ml) or 
IFNγ (13,767 ± 742 pg/ml) than in PBMCs 
stimulated with LPS alone (6,258 ± 245 pg/
ml); this same phenomenon was observed 
for IL-6 production upon stimulation with 
LPS. The triggering of TLR2-mediated pa-
thways by LTA resulted in the same effects, 
indicating that the increased expression of 
both TLR2 and TLR4 mediated by IL-12 and 
IL-18 was functional.
CD14+ monocytes were isolated from heparinized ve-
nous blood by density-gradient centrifugation over Fi-
coll-Hypaque and positive selection using MACS CD14 
beads (Miltenyi Biotec, Bergisch Gladbach, Germany). 
CD14+ monocytes were cultured for 24 hours with IFNγ 
(10 ng/ml), IL-12 (10 ng/ml), IL-18 (50 ng/ml), or the com-
bination of IL-12/IL-18. Thereafter, TLR2 and TLR4 ex-
pression was determined by fluorescence-activated cell 
sorter analysis (see Patients and Methods). Values are 
the mean ± SD of 3 healthy controls. *P < 0.01 versus 
medium control group, by Mann-Whitney U test.
Table 2: TLR2 and TLR4 expression on purified CD14+ 
monocytes
T IME POINT, STIMULUS TLR2 TLR4
0 63 14 16  6
24 hours
medium 70  4 17  2
IFN 81  23 64  34*
IL-12 55  20 20  10
IL-18 59  19 18  8
IL-12 / IL-18 60  25 19  13
99  10 13  3
149 21* 34  12*
108 12 19  8
107 18 17  7
104 17 20  12
48 hours
medium
IFN
IL-12
IL-18
IL-12 / IL-18
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Figure 3. Cytokine regulation of TLR2 and TLR4 expression and function. A. To measure TLR2 and TLR4 protein ex-
pression on CD14+ monocytes, freshly isolated PBMCs from healthy controls (n=6) or RA patients (n=3) were cultured 
for 48 hours, with either IL-12 (10 ng/ml), IL-18 (50 ng/ml), or the combination of both cytokines. IFNγ (10 ng/ml) was in-
cluded as a positive control. TLR expression on CD14+ cells was examined by fluorescence-activated cell sorter (FACS) 
analysis, using specific antibodies for CD14, TLR2, and TLR4.  *P < 0.05 versus controls, by Mann-Whitney U test. B. To 
demonstrate stimulation of IFNγ production by IL-12 and IL-18, supernatants of cultured PBMCs were analyzed for IFNγ 
levels. Note the slightly enhanced levels of IFNγ after 48 hours of IL-12 exposure, both in PBMC culture supernatants 
from healthy controls (n = 6) and in those from RA patients (n = 3). Remarkably higher levels of IFNγ were found after 
exposure of PBMCs to the IL-12/IL-18 combination. C. To show that blockade of IFNγ prevents IL-12/IL-18-driven up-re-
gulation of TLR2 and TLR4 expression, PBMCs from healthy controls (n=3) were cultured for 24 hours with IFNγ, IL-12, 
IL-18, or the IL-12/IL-18 combination. Previously, neutralizing mouse anti-human IFNγ antibodies (10μg/ml) or control 
IgG1 antibodies were added to the PBMC cultures. TLR expression on CD14+ cells was examined by FACS analysis. 
Note that blockade of IFNγ prevents enhanced TLR2 and TLR4 expression induced by IL-12, IL-18, and the combination 
of both cytokines. D. To show that enhanced TLR2/TLR4 expression by IL-12/IL-18 exposure promotes production of 
cytokines, PBMCs from healthy controls (n=3) were cultured for 24 hours either in medium alone or with IFNγ or with the 
IL-12/IL-18 combination. Thereafter, the cells were cultured for another 24 hours in medium, TLR2 agonist (lipoteichoic 
acid 3μg/ml), or TLR4 agonist (lipopolysaccharide 20 ng/ml). The sensitivity of the Luminex bead array was below 10 
pg/ml for both IL-6 and TNFα.  *P < 0.01 versus medium alone, by Mann-Whitney U test. Bars show the mean and SD. 
MFI = mean fluorescence intensity.
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Discussion
In the present study we demonstrate that 
the expression of both TLR2 and TLR4 in 
synovial tissue from RA patients is signifi-
cantly increased compared with that in sy-
novial tissue from OA patients and their he-
althy counterparts. In addition, we provide 
evidence of a critical role of IL-12 and IL-18 
in the regulation of TLR2 and TLR4 expres-
sion in synovial tissue. The up-regulation 
of TLR2 and TLR4, however, was indirect, 
since monocytes alone were not able to up-
regulate TLR2 and TLR4 when cultured with 
IL-12, IL-18, or the combination of both. In 
contrast, the addition of IFNγ to monocytes 
did result in a clear up-regulation of TLR2 
and TLR4. The indirect role of IL-12 and IL-
18 on TLR expression was shown by the 
fact that stimulation of PBMCs with IL-12 
and IL-18 resulted in an increased expres-
sion of the TLRs. As expected, the concen-
tration of IFNγ was significantly increased in 
these cultures and was most likely produced 
by T cells. Blockade studies with anti-IFNγ 
antibodies confirmed that IL-12/IL-18-indu-
ced TLR expression on CD4+ monocytes 
is IFNγ-dependent. Thus, our data suggest 
that the higher expression of IL-12 and IL-18 
in the synovium might be responsible for the 
increased synovial expression of TLR2 and 
TLR4.
Recently, we and other investigators showed 
that IL-18 was abundantly present in the sy-
novial tissue of RA patients and demonstra-
ted that this pro-inflammatory cytokine was 
related to local and systemic parameters of 
inflammation in patients with RA (6,34). IL-
12, another pro-inflammatory cytokine, is a 
potent stimulator of TNFα and IFNγ. Toge-
ther with IL-18, IL-12 has a unique synergis-
tic effect on the induction of IFNγ secretion 
and Th1 responses (35).
In vitro exposure of PBMCs to IL-12/IL-18 
resulted in synergistic IFNγ production by T 
cells. Consistent with very recent findings, 
PBMCs of RA patients produced remarka-
bly lower levels of INFγ after stimulation with 
the IL-12/IL-18 combination (36). In addition 
to IL-18, IL-12 was found to be highly expres-
sed in synovial tissue from patients with 
RA, suggesting an important role for these 
cytokines in RA (6). Evidence of a critical 
role of both IL-12 and IL-18 in arthritis was 
further substantiated by animal studies. The 
administration of IL-12 accelerated onset of 
disease and increased severity of collagen-
induced arthritis (CIA) (37), whereas mice 
deficient in IL-18 exhibited a clearly reduced 
incidence of CIA, characterized by less in-
flammation and attenuated cartilage des-
truction (38). Although not previously explo-
red, one of the mechanisms by which IL-12 
and IL-18 deploy their effects on the immune 
system might be regulation of TLRs either 
directly or indirectly via secretion of IFNγ.
TLRs have recently emerged as key recep-
tors responsible for the recognition of specific 
bacterial components, including LPS, CpG 
DNA, and flagellin, which are also known as 
PAMPs (13,17). In addition, TLRs recognize 
endogenous ligands, including fragments of 
the cartilage, such as fibronectin fragments, 
and hyaluronic acid and HSPs. It was re-
cently demonstrated that these endogenous 
ligands (natural adjuvants) can activate den-
dritic cells in conditions of cell stress and/or 
structural cell damage, leading to primary 
immune responses and initiation of autoim-
munity (13,39,40). Consistent with this sce-
nario, several pathways of stress-signaling 
molecules are found to be activated in the 
synovial membrane and fluid of RA patients 
(41). It is conceivable that these local endo-
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genous ligands activate TLR2- and TLR4-
bearing dendritic cells, macrophages, and 
fibroblasts, which leads to an increased se-
cretion of pro-inflammatory cytokines such 
as IL-12, IL-18, IL-1β, and TNFα.
The presence of endogenous ligands to-
gether with the up-regulated expression of 
TLR2/TLR4, mediated by IL-12/IL-18, does 
perhaps lead to a vicious circle of inflam-
mation that ultimately leads to irreversible 
joint destruction. A potential role for TLRs 
in RA and experimental models of arthritis 
has recently been suggested by a sequence 
of intriguing findings. First, the identification 
of a critical link with DNA-bound immune 
complexes, which are abundantly present in 
RA and trigger TLRs, sheds new light on the 
potential pathogenic mechanisms involved 
(12,24). Second, the vaccination against ad-
juvant arthritis, using Hsp60, clearly showed 
the importance of TLR4 in the regulation 
of the immune balance (42). Finally, a role 
for TLR2 and TLR4 was suggested by our 
group by the finding that a TLR4 variant was 
associated with RA disease susceptibility 
(14). Furthermore, we found evidence that 
stimulation via TLR ligands leads to distinct 
cytokine patterns produced by dendritic cells 
from RA patients as compared with healthy 
individuals (Radstake RDJ, et al: unpublis-
hed observations).
The enhanced expression of TLR2 and 
TLR4 in RA synovial tissue, together with 
the new regulatory pathway associated with 
IL-12 and IL-18, prompted us to postulate 
the following hypothesis for a new patho-
genic mechanism in RA. Endogenous or 
exogenous ligands, released in RA synovial 
tissue upon cell stress, minor trauma, or un-
determined bacterial or viral infection, lead 
to a TLR-mediated activation of the innate 
immune response. In the absence of an ef-
ficient contraregulatory mechanism, this ini-
tial response might lead to a vicious circle in 
which mass production of pro-inflammatory 
mediators, including cytokines and chemo-
kines, results in influx of inflammatory cells, 
more cartilage damage, and the subse-
quent release of more endogenous ligands. 
When not efficiently counteracted, this reac-
tion leads to the detrimental effect seen in 
sustained RA.
In conclusion, our data support previous 
evidence of an important role of TLR2 and 
TLR4 in the pathogenesis of RA. Further-
more, we present evidence that IL-12 and IL-
18 are indirectly associated with the regula-
tion of TLR2 and TLR4 expression. Detailed 
insight into the precise role of TLRs in RA 
pathogenesis might lead to new therapeutic 
strategies.
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Objective. To evaluate the expression of TLR3 and TLR7 in synovial tissue and to study potential 
differences in the maturation and cytokine production mediated by TLR2, TLR3, TLR4, and TLR7/8 
by dendritic cells (DCs) from rheumatoid arthritis (RA) patients and DCs from healthy controls. 
Methods. Synovial expression of TLR3 and TLR7 in RA synovial biopsies was studied using im-
munohistochemistry. Monocyte-derived DCs from RA patients and healthy controls were cultured 
for 6 days and subsequently stimulated for 48 hours via TLR-mediated pathways (lipoteichoic acid, 
Pam3Cys, and fibroblast-stimulating lipopeptide 1 for TLR2, poly(IC) for TLR3, lipopolysaccharide 
and extra domain A for TLR4, and R848 for TLR7/8). Phenotypic DC maturation was measured 
using flow cytometry. The secretion of TNFα, IL-6, IL-10, and IL-12 was measured using the Bio-
Plex system. Cell lines expressing TLR2 and TLR4 were used for the detection of TLR2 and TLR4 
ligands in serum and synovial fluid from RA patients. 
Results. TLR3 and TLR7 were highly expressed in RA synovial tissue. All TLR ligands elicited 
phenotypic DC maturation equally between DCs from RA patients and those from healthy con-
trols. TLR2- and TLR4-mediated stimulation of DCs from RA patients resulted in markedly higher 
production of inflammatory mediators (TNFα and IL-6) compared to DCs from healthy controls. 
In contrast, upon stimulation of TLR3 and TLR7/8, the level of cytokine production was equal bet-
ween DCs from RA patients and those from healthy controls. Remarkably, both TLR3 and TLR7/8 
stimulation resulted in a skewed balance towards IL-12. Intriguingly, the combined stimulation of 
TLR4 and TLR3-7/8 resulted in a marked synergy with respect to the production of inflammatory 
mediators. As a proof of concept, TLR4 ligands were increased in the serum and synovial fluid of 
RA patients. 
Conclusion. TLRs are involved in the regulation of DC activation and cytokine production. We 
hypothesize that various TLR ligands in the joint trigger multiple TLR simultaneously, favoring the 
breakthrough of tolerance in RA.
Introduction
Rheumatoid arthritis (RA) is an inflamma-
tory autoimmune disease that leads to the 
destruction of synovial joints. Although the 
exact mechanisms that are responsible re-
main obscure, it is generally accepted that 
besides genetic factors, environmental trig-
gers contribute to the disease pathogenesis 
(1,2). An infectious etiology of RA has been 
a longstanding hypothesis, which has been 
examined with greater sophisticated scienti-
fic rigor recently. Currently, evidence points 
towards a potential role of Epstein-Barr virus 
(3-5), parvovirus B19 (6,7), and cytomegalo-
virus (8,9), all of which are found in RA sy-
novial tissue. The potential role of viruses in 
the pathogenesis of RA was further substan-
tiated by the findings that human parvovirus 
B19-transgenic mice are highly susceptible 
to polyarthritis (10), the murine herpesvirus 
induces relapsing experimental autoimmune 
arthritis (11), and that double-stranded (viral) 
RNA (dsRNA) has overt arthritogenic pro-
perties (12). Several mechanisms have been 
attributed to the actual link between the pre-
sence of viral material and the observed im-
munohistopathologic changes during inflam-
matory synovitis; however, the precise mode 
of action has not been elucidated thus far.
Synovial inflammation is characterized by 
a massive influx of numerous inflammatory 
cells, including T cells, B cells, macropha-
ges, and dendritic cells (DCs). Potentially, 
all of these contribute to the progressive 
breakdown of cartilage and destruction of 
the underlying bone (13-15). DCs are pro-
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fessional antigen-presenting cells that are 
highly adept at stimulating T cells and are 
therefore intricately involved in the balance 
between immunity and tolerance (16). DCs 
can produce large quantities of pro-inflam-
matory cytokines, chemokines, and metal-
loproteinases that potentially contribute to 
the detrimental processes during synovial 
inflammation. In fact, several observations 
indicate the potential role of DCs in RA di-
sease pathogenesis. First, DCs are abun-
dantly present at strategic locations in RA 
synovial tissue (17-19). Second, models of 
experimental arthritis have shown that pre-
sentation of collagen-derived peptides by 
mature DCs is sufficient for the induction of 
arthritis (20), and finally, genetically modu-
lated DCs were able to abrogate experimen-
tal arthritis (21).
The function of DCs is time and space de-
pendent. In the immature state, DCs reside 
in the periphery and function as sentinels of 
the immune system, specialized in antigen 
uptake and processing. To execute anti-
gen recognition with utmost efficiency, DCs 
are equipped with several antigen recogni-
tion receptors, including Toll-like receptors 
(TLRs).
TLRs are involved in the detection of envi-
ronmental signals and the regulation of DC 
function and are therefore the subject of 
investigations in autoimmunity. The signals 
that elicit TLRs are often called danger sig-
nals and include both exogenous ligands, 
such as lipopolysaccharide (LPS), lipotei-
choic acid (LTA), flagellin, CpG motifs, and 
dsRNA, often referred to as pathogen-as-
sociated molecular patterns (22,23), and 
endogenous ligands, such as heat-shock 
proteins (24), fibronectin (25), hyaluronic 
acid (26), and messenger RNA (mRNA) 
(27). Endogenous ligands are released 
upon normal cell turnover and stressful 
events and are likely to be abundant in the 
synovial compartment. The pivotal role of 
endogenous ligands was substantiated by 
the finding that such signals lead to primary 
immune responses under conditions of cell 
stress and precipitate autoimmunity in the 
presence of self antigens (28-31). There-
fore, endogenous ligands are considered to 
be natural initiators of autoimmunity.
Evidence of a role of TLRs in the pathoge-
nesis of RA originates from the finding that 
inducible Hsp70, generally accepted as a 
TLR4 ligand, was increased in RA synovial 
fluid and on DCs isolated from RA synovial 
fluid (32). Expression of TLR2 and TLR4 is 
increased and regulated by pro-inflammato-
ry cytokines that are present in the synovial 
compartment (33,34) and by the identificati-
on of the TLR4 (Asp299Gly) functional vari-
ant as a marker for RA disease susceptibility 
(35). In addition, the link between DNA and 
TLRs in RA, as recently demonstrated by 
Leadbetter and colleagues, further substan-
tiated the potential role of TLRs in arthritis 
(36).
Taken together, it is tempting to speculate 
that TLRs play a role in the onset and/or se-
verity of RA. This prompted us to investigate 
the expression of TLRs other than TLR2 
and TLR4 in RA synovial tissue and to study 
potential differences in TLR-mediated DC 
activation between RA patients and healthy 
controls using both exogenous and endo-
genous ligands. Furthermore, we tested the 
hypothesis that simultaneous stimulation of 
different TLRs resulted in a synergistic ef-
fect on cytokine production by DCs.
Here we demonstrate that TLR3 and TLR7 
are increased in the synovial tissue of RA 
patients. Furthermore, we show that the cy-
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tokine repertoire produced by DCs depends 
heavily upon the TLR pathways triggered. 
Simultaneous stimulation of TLR4, in com-
bination with TLR3-7/8 pathways, leads to 
a synergistic effect with regard to cytokine 
production, suggesting that the presence 
of different TLR agonists in the joint com-
partment, including viral RNA, favors a pro-
inflammatory environment that leads to a 
disturbed balance between tolerance and 
immunity.
Methods
Study population
A total of 22 patients with RA and 21 he-
althy volunteers were enrolled in this study. 
Patients attended the Radboud University 
Nijmegen Medical Centre and fulfilled the 
American College of Rheumatology (ACR; 
formerly, the American Rheumatism Asso-
ciation) criteria for RA (37). The treatment 
regimens of all patients were recorded be-
fore blood sampling, and patients who used 
high-dose prednisolone or anticytokine the-
rapies (anti-tumor necrosis factor α  [anti-
TNFα] and/or interleukin-1 receptor anta-
gonist) were excluded. All patients provided 
informed consent. 
For immunohistochemical analysis, percuta-
neous biopsies of the knee joint were perfor-
med with a Parker-Pearson needle following 
administration of local anesthesia. On aver-
age, 30 samples were obtained during each 
procedure. The synovial tissue from healthy 
individuals and from patients with osteoar-
thritis (OA) was isolated during arthroscopic 
procedures performed by the orthopedic 
surgeons. The Medical Ethics Committee of 
Radboud University Nijmegen Medical Cen-
tre approved the study protocol.
Antibodies used for TLR immunohisto-
chemical analysis and cytokine detec-
tion
Antibodies against human TLR2 (H-175), 
TLR4 (H-80), TLR3 (T-17), and TLR7 (V-20) 
were obtained from Santa Cruz Biotechno-
logy (Santa Cruz, CA). Biotinylated swine 
anti-rabbit Ig affinity-isolated F(ab)2 was 
obtained from Dako (Glostrup, Denmark). 
Biotinylated mouse anti-goat IgG was pur-
chased from Jackson ImmunoResearch 
(West Grove, PA). Vectastain ABC reagent 
(Elite kit) was obtained from Vector (Bur-
lingame, CA)-and streptavidin peroxidase 
was obtained from Dako. Diaminobenzidine 
(DAB) was obtained from Sigma (St. Louis, 
MO). Bio-Plex kits using Luminex bead ar-
ray technology for the determination of IL-6, 
TNFα, IL-10, and IL-12 were purchased from 
Bio-Rad (Hercules, CA).
Immunohistochemical analysis of syno-
vial tissue
Tissue samples were immediately fixed with 
4% formaldehyde and embedded in paraffin. 
For TLR2 and TLR4 staining, after dewaxing 
and dehydration, sections were blocked with 
normal swine serum followed by 60 minutes 
of incubation with antibodies against TLR2 
and TLR4 at concentrations of 10 μg/ml and 
17 μg/ml, respectively. After this, endoge-
nous peroxidase was blocked with 3% H2O2 
in methanol for 15 minutes, and the secon-
dary antibody, biotinylated swine anti-rabbit 
IgG, was incubated for 30 minutes. Slides 
were stained with streptavidin-peroxidase, 
developed with DAB, and counterstained 
with hematoxylin for 30 seconds. For TLR3 
and TLR7 staining, sections were incubated 
with antibodies against human TLR3 and 
human TLR7 for 60 minutes. After this, en-
dogenous peroxidase was blocked with 3% 
H2O2 in methanol for 15 minutes, and subse-
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quently, the secondary antibody, biotinylated 
mouse anti-goat IgG, was incubated for 30 
minutes. Vectastain ABC reagent was incu-
bated for 30 minutes, developed with DAB, 
and counterstained with hematoxylin for 30 
seconds. Staining of TLR2, TLR4, TLR3, 
and TLR7 at 200× magnification was sco-
red semiquantitatively on a 5-point scale. A 
score of 0 represented no or minimal stai-
ning, 1 represented 10-20% positive cells, 2 
represented 30-40% positive cells, 3 repre-
sented 50-60% positive cells, and a score of 
4 represented staining of >60% of the cells.
Culture of monocyte-derived DCs
Monocyte-derived DCs were cultured using 
standardized protocols, as previously des-
cribed (18). Briefly, peripheral blood mono-
nuclear cells were isolated from heparinized 
venous blood by density gradient centrifuga-
tion over Ficoll-Paque (Amersham Bioscien-
ces, Roosendaal, The Netherlands). Low-
density cells were collected and washed 
with citrated phosphate buffered saline and 
5% fetal calf serum (FCS), after which the 
cells were allowed to adhere for 1 hour at 
37°C in RPMI 1640 (Dutch modification) (In-
vitrogen, Carlsbad, CA) supplemented with 
2% human serum (PAA Laboratories, Linz, 
Austria) in 6-well culture plates or 25cm2 
cell culture flasks (Corning, Corning, NY). 
Adherent monocytes were cultured in RPMI 
1640 (Dutch modification) supplemented 
with 10% FCS and antibiotic/antimycotic 
(Life Technologies, Gaithersburg, MD) in the 
presence of IL-4 (500 units/ml; Schering-
Plough, Amstelveen, The Netherlands) and 
granulocyte-macrophage colony-stimulating 
factor (800 units/ml; Schering-Plough) for 6 
days. Fresh culture medium with the same 
supplements was added on day 3, and then 
immature DCs were harvested on day 6. To 
generate mature DCs, immature DCs were 
resuspended in fresh cytokine-containing 
culture medium and transferred to new cul-
ture plates at a concentration of 0.5 × 106/
ml. To induce DC maturation, cells were sti-
mulated as described below.
TLR stimulation of monocyte-derived 
DCs
Triggering via TLR-mediated pathways was 
achieved with various TLR-specific ligands. 
To trigger TLR2, 10 μg/ml of LTA (Sigma) 
was used. To correct for potential LPS 
contamination in the LTA, Pam3Cys and fi-
broblast-stimulating lipopeptide 1 (FSL-1), 
which are known to be highly specific for 
the TLR1/TLR2 or TLR2/TLR6 pathways, 
were used. For stimulation of TLR4, we used 
2μg/ml of Escherichia coli LPS (Sigma). As 
a known endogenous TLR4 ligand, we used 
1 M recombinant extra domain A (EDA) pro-
teins. As a control for this, recombinant extra 
domain B and III11 domain proteins (all kindly 
provided by Dr. J. Strauss, University of 
Pennsylvania, Philadelphia, PA) were used, 
which are also fibronectin fragments but lack 
TLR4 binding capacity.
To trigger TLR3 and TLR7/8, we used 
poly(IC) and R848, both obtained from In-
vivoGen (San Diego, CA). All TLR ligands 
that were used were checked for potential 
LPS contamination using a TLR4 antagonist 
(E5564), which was kindly provided by Eisai 
Research Institute, Andover, MA (38). After 
culture for 48 hours at 37°C in the presence 
of 5% CO2, the supernatants were collec-
ted.
Simultaneous stimulation of different 
TLR pathways
To test whether simultaneous stimulation of 
different TLR pathways resulted in syner-
gistic cytokine production, immature DCs 
were generated as described above. On 
45
                            
     Chapter 3 
day 6, cells were stimulated with combina-
tions of TLR2/TLR3, TLR2/TLR4, TLR2/
TLR7/8, TLR3/TLR4, TLR3/TLR7/8, and 
TLR4/TLR7/8 ligands and compared to cells 
stimulated with each of these substances 
alone. Furthermore, the combinations of 
TLR2/TLR3/TLR7 and TLR4/TLR3/TLR7/8 
were used to test a potential additional ef-
fect of 3 TLR pathways. After culture for 24 
hours at 37°C in the presence of 5% CO2, 
the supernatants were collected.
Phenotype analysis of monocyte-derived 
DCs
Flow cytometry was used to determine 
the expression of cell surface markers on 
both immature and mature DCs. First, DCs 
(1 × 105) were incubated with monoclonal 
antibodies against human CD14 (Dako), 
CD80 (Becton Dickinson, Mountain View, 
CA), CD83 (Beckman Coulter, Mijdrecht, 
The Netherlands), CD86 (PharMingen, 
San Diego, CA), type I major histocompa-
tibility complex (MHCI) (clone W6/32), and 
MHCII HLA-DR/DP (clone Q1514) for 30 
minutes at 4°C. Cells were then washed 
and incubated with fluorescein isothiocy-
anate (FITC)-conjugated goat anti-mouse 
IgG (Zymed, South San Francisco, CA) for 
30 minutes at 4°C in complete darkness. 
Subsequently, cells were washed and ana-
lyzed using a fluorescence-activated cell 
sorter (FACSCalibur; Becton Dickinson) to 
determine the proportion of positive cells 
relative to cells stained with relevant IgG 
isotypes. For TLR2 and TLR4 expression, 
cells were incubated with monoclonal an-
tibodies against human TLR2 (H-175) and 
TLR4 (H-80), both obtained from Santa 
Cruz Biotechnology, and subsequently in-
cubated with goat anti-rabbit IgG and goat 
anti-mouse IgG, respectively (both ob-
tained from Zymed).
Measurement of cytokines in culture 
supernatants
TNFα, IL-6, IL-10, and IL-12 levels were 
measured in the supernatants of the DC 
cultures, using commercially available kits 
according to the manufacturer’s instructions 
(Bio-Rad) (39). Cytokine levels were measu-
red and analyzed using the Bio-Plex system 
(Bio-Rad). Data were analyzed using Bio-
Plex Manager software (Bio-Rad).
Stimulation of TLR2 and TLR4 transgenic 
Chinese hamster ovary (CHO) cell lines
The CHO fibroblast CD14 reporter line (clone 
3E10) is a stably transfected CD14-positive 
CHO cell line that expresses inducible mem-
brane CD25 (Tac antigen) under transcrip-
tional control of the human E-selectin pro-
moter (40). The promoter fragment contains 
an essential NF-κB binding site, which, upon 
stimulation with LPS, results in a 3-10-fold 
increase in CD25 surface expression. CHO/
CD14/human TLR2 (HuTLR2) reporter cell 
lines were constructed by stable cotrans-
fection with complementary DNA for the 
human TLR2 and pcDNA3 (Invitrogen). The 
CHO/CD14/HuTLR4 reporter cell lines were 
derived in the same manner. (Both reporter 
cell lines were kindly provided by Dr. R. In-
galls and Dr. D. Golenbock from the Boston 
Medical Center, Boston, MA.) All of the ex-
periments with the CHO cell lines were per-
formed at least twice.
CHO/CD14 cells were cultured in Ham’s 
F12 medium with L-glutamine (BioWhitta-
ker, Walkersville, MD), gentamicin (Cen-
trafarm, Etten-Leur, The Netherlands), 2.5% 
FCS, and 400 units/ml hygromycin B (Cal-
biochem, Amsterdam, The Netherlands). 
G418 sulfate (0.5 mg/ml) and puromycin 
(50 μg/ml) (both obtained from Sigma) were 
added to the CHO/CD14/TLR2 and CHO/
CD14/TLR4 cells, respectively. Cells at a 
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concentration of 1 × 105/ml were stimula-
ted with 10% serum or synovial fluid from 
RA patients, 10% serum from patients with 
systemic sclerosis (SSc) or systemic lupus 
erythematosus (SLE), or 10% normal hu-
man serum (PAA Laboratories). To check 
for potential endotoxin contamination of 
the synovial fluids used, some of the expe-
riments were performed in the presence or 
absence of polymyxin B, a natural LPS anta-
gonist. The synovial fluids were also measu-
red for gram-negative bacterial endotoxins 
using the Limulus amebocyte lysate assay, 
performed according to the manufacturer’s 
instructions (Pyrogent Plus multitest kit; 
BioWhittaker).
Analysis of CD25 surface expression by 
CHO cells
Flow cytometry was performed to determine 
the surface expression of CD25 on the trans-
genic cell lines. First, 1 × 105 cells were in-
cubated with a monoclonal antibody against 
human CD25 (Dako) for 30 minutes at 4°C. 
Cells were then washed and incubated 
with FITC-conjugated goat anti-mouse IgG 
(Zymed) for 30 minutes at 4°C in complete 
darkness. Cells were washed and analyzed 
by FACSCalibur to determine the proportion 
of positive cells relative to cells stained with 
a relevant IgG isotype.
Statistical analysis
Differences in cytokine production between 
cells from healthy volunteers and those from 
RA patients were analyzed using the Mann-
Whitney U test. P values were 2-sided, and 
P values less than 0.05 were considered 
significant.
Results
Increased expression of TLR3 and TLR7 
in RA synovial tissue. 
To study the potential role of viral RNA in 
synovial inflammation, we tested the ex-
pression of TLR3 and TLR7 in RA synovial 
tissue. To this end, we stained synovial tis-
sue sections from 5 RA patients with antibo-
dies against TLR3 and TLR7 and compared 
them with synovial tissue sections from 5 
OA patients and 5 healthy controls (Figure 
1). Intriguingly, both TLR3 and TLR7 were 
abundantly expressed in RA synovial tissue. 
Whereas TLR3 was predominantly located 
in the lining, sublining, and perivascular re-
gions, TLR7 was scattered throughout the 
lining and expressed in the lining of RA sy-
novial tissue (mean ± SEM TLR3 score 0.7 
Figure 1. Immunohistochemical detection of TLR3 (left 
panel) and TLR7 (right panel) in synovial biopsy samples 
from RA patients and healthy controls. Top panel shows 
staining with an isotype control antibody. C, E. TLR3 
expression in synovial tissue from healthy individuals 
and RA patients respectively. D, F. TLR7 expression in 
synovial tissue from healthy individuals and RA patients 
respectively.All tissues were counterstained with hema-
toxylin (original magnification × 400).

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Figure 2. Expression of cell surface markers CD83, CD86, and MHCII on DCs before and after Toll-like receptor (TLR)-
mediated maturation with various TLR ligands. The indicated markers or isotype controls (gray peak) of DCs within the life 
gate were determined using fluorescence-activated cell sorting analysis. Each graph displays data from a representative 
rheumatoid arthritis (RA) patient (dotted line) and a healthy control (solid line). Top panel shows the expression of CD83, 
CD86, and MHCII by immature DCs (iDCs) from a RA patient and a healthy control. Other panels show the expression of 
these markers upon stimulation with the TLR ligands indicated on the y-axis. 
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± 0.4, TLR7 score 1.8 ± 0.7) as compared to 
synovial tissue from OA patients (TLR3 sco-
re 0.2 ± 0.2, TLR7 score 0.5 ± 0.4) and he-
althy controls (TLR3 score 0.2 ± 0.2, TLR7 
score 0.3 ± 0.2). Remarkably, TLR3 and 
TLR7 were hardly detectable in the subli-
ning of synovial tissue from OA patients and 
healthy controls; in contrast, both TLR3 and 
TLR7 were abundant in the sublining of RA 
synovial tissue (TLR3 score 0.8 ± 0.4, TLR7 
score 1.8 ± 0.7). 
Maturation of DCs from RA patients and 
healthy controls upon stimulation with 
TLR2, TLR3, TLR4, and TLR7/8 ago-
nists. 
Since TLR2, TLR3, TLR4, and TLR7 are 
highly expressed in RA synovial tissue 
(33) and important in DC maturation, we 
used monocyte-derived DCs to test the 
capacity of various TLR ligands to induce 
DC maturation. In addition, we studied po-
tential differences between DCs from RA 
patients and those from healthy controls. 
Consistent with the literature, immature 
DCs were characterized by the absence 
of CD14 (data not shown), intermediate 
expression of CD86 and MHCII, and low 
expression of the mature DC marker CD83 
(Figure 2, top panel). TLR-mediated DC 
maturation was reflected by the up regu-
lation of CD83, CD86, and MHCII (Figure 
2) combined with the down-regulation 
of CD14. Stimulation of the TLR2 (LTA), 
TLR3 (poly[IC]), TLR4 (LPS and EDA), 
and TLR7/8 (R848) pathways resulted in 
full DC maturation, which was found to be 
equally efficient for DCs from RA patients 
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Figure 3. Production of pro- and anti-inflammatory cytokines by DCs after incubation for 48 hours with TLR2-, TLR3-, 
TLR4-, and TLR7/8-specific ligands. Production of A. TNFα, B. IL-6, and C. IL-10 and IL-12 by DCs from healthy controls 
(n=8) and from RA patients (n=10) upon stimulation with LTA, poly(IC), LPS, EDA, and R848 is shown. Values represent 
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(n = 10) and healthy controls (n = 8) (Fi-
gure 2). No effect was seen upon stimula-
tion with EDB and III11, which were used as 
negative controls for EDA, which lack the 
capacity to elicit TLR4-mediated triggering 
(data not shown) (25). 
Different cytokine patterns upon DC 
stimulation via TLR2, TLR3, TLR4, and 
TLR7/8 pathways. 
The type of immune response is largely 
dependent on the production of cytokines. 
Therefore, we next investigated the pro-
duction of TNFα, IL-6, IL-10, and IL-12 by 
monocyte-derived DCs from RA patients 
(n = 10) and healthy controls (n = 8) upon 
stimulation via TLR2, TLR3, TLR4, and 
TLR7/8 pathways. The cytokine levels, 
as shown in Figure 3, were corrected for 
cytokine production by unstimulated cells. 
For all stimuli used, cytokine production 
was enhanced compared to unstimulated 
DCs. Intriguingly, the production of TNFα 
by DCs from RA patients upon stimulation 
with the TLR2 ligand LTA (P < 0.01) and 
the TLR4 ligands LPS (P = 0.03) and EDA 
(P = 0.02) was significantly higher than 
that of DCs from healthy controls (Figure 
3A). Similarly, the production of IL-6 was 
significantly increased by DCs from RA pa-
tients upon stimulation with LTA (P = 0.01), 
LPS (P = 0.03), and EDA (P = 0.03) (Fi-
gure 3B). In contrast to TLR2/4 triggering, 
the level of cytokine production upon TLR3 
and TLR7/8 stimulation was equal between 
DCs from RA patients and those from he-
althy controls (Figures 3A and B). 
The balance between IL-10 and IL-12 lar-
gely determined the type of immune res-
ponse. Upon stimulation of the TLR2 and 
TLR4 pathways, the IL-10 levels tended 
to be higher than the IL-12 levels, which 
occurred exclusively in DCs from RA pa-
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Figure 4. Production of A. TNFα, B. IL-10, and C. IL-12 by 
DCs upon triggering of single and multiple TLR pathways. 
DCs were stimulated with TLR3, TLR4, and TLR7/8 ligan-
ds alone (shaded bars; each individual shaded bar repre-
sents 1 TLR ligand as indicated) and with a combination 
of different TLR pathways simultaneously (solid bars). 
These values were compared with the cytokine produc-
tion that would be estimated to occur if the combination 
of TLR ligands had an additive effect over the effect with 
one of the TLR pathways alone (open bars). TNFα, IL-
10, and IL-12 were measured in the supernatants after 24 
hours of coincubation. Each graph displays data from a 
representative RA patient. The sensitivity of the cytokine 
assay was <5 pg/ml for each measured cytokine. See 
Figure 2 for other definitions.
tients. In contrast, TLR3 and TLR7/8 sti-
mulation resulted in a skewed balance to-
wards IL-12, which occurred in DCs from 
RA patients as well as healthy controls. 
Taken together, these data suggested that 
TLR3- and TLR7/8-mediated DC stimu-
lation in RA results in a skewed balance 
towards IL-12 and strongly favors Th1-me-
diated responses.
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Synergistic increase in cytokine produc-
tion upon simultaneous stimulation of 
TLR4 and TLR3-7/8 pathways. 
To test the hypothesis that simultaneous sti-
mulation of different TLR pathways results 
in an augmented DC activation, we stimula-
ted DCs with combinations of several TLR 
ligands. To this end, we cocultured DCs 
from 5 healthy controls and 5 RA patients 
with combinations of TLR3/4, TLR4-7/8, 
TLR3-7/8, and TLR3-4-7/8 for 24 hours. As 
shown in Figure 4 and Table 1, the produc-
tion of TNFα, IL-10, and IL-12 dramatically 
increased in a synergistic manner when 2 or 
more TLR pathways were stimulated simul-
taneously. Similar patterns of cytokine pro-
duction were observed for DCs from RA pa-
tients and healthy controls (data not shown). 
Intriguingly, the highest absolute levels of 
TNFα (mean 10,152 pg/ml), IL-12 (3,089 pg/
ml), and IL-10 (686 pg/ml), and the highest 
percentage increase in synergistic effect on 
TNFα (median 128%), IL-12 (478%), and IL-
10 (428%) were reached upon stimulation 
using the combination of TLR4 and TLR7/8 
agonists. Moreover, the addition of a third 
TLR stimulus resulted in a further increase 
in the absolute levels of TNFα, IL-10, and IL-
12 compared to the combinations of 2 TLRs. 
However, the percentage increase in these 
cytokines was similar, or even lower, when 
DCs were stimulated with a combination of 3 
TLR ligands as compared to 2 TLR ligands. 
Remarkably, the addition of TLR2 ligands 
to any other TLR pathway did not result in 
a clear synergistic effect (data not shown). 
Taken together, these data underscore the 
potential role of simultaneous TLR stimula-
tion in DC activation, with special emphasis 
on synergy between the TLR4 and TLR3-7/8 
pathways. 
Presence of TLR4 ligands in RA serum 
and synovial fluid. 
Since we demonstrated that the combination 
of TLR4 ligands with TLR3 and/or TLR7/8 
resulted in a synergistically elevated produc-
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Figure 5. Expression of CD25 on Chinese hamster ovary 
(CHO) CD14/human TLR4 (HuTLR4) cell lines. CHO 
CD14/HuTLR4 cells were activated upon coculturing with 
serum from patients with inactive RA (n=5) and with se-
rum and synovial fluid from patients with active RA (n=7). 
In contrast, serum from patients with systemic sclerosis 
(SSc) (n=5) and systemic lupus erythematosus (SLE) 
(n=5) failed to induce CHO CD14/HuTLR4 cell activation. 
As expected, LPS, a potent inducer of TLR4, was highly 
capable of activating TLR4-expressing cells. Values re-
present the mean and SEM. 
Table 1. Median level of synergy of TNFα, IL-12, and 
IL-10 production by dendritic cells from rheumatoid ar-
thritis patients upon stimulation with a combination of 
TLR pathways
Synergy is expressed as the median percentage increase 
compared with the value that would be expected when 
the combination of TLR pathways was considered to have 
an additive effect.
TNF
23
128
116
37
IL-12
209
478
116
211
IL-10
5
428
299
210
COMBINATION
TLR4/3
TLR4/7
TLR3/7
TLR3/4/7
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tion of cytokines, we tested whether TLR4 
agonists were present in RA serum and sy-
novial fluid. To this end, we used CHO re-
porter cell lines that were stably transfected 
with CD14 alone (CHO/CD14), with CD14 
and human TLR2 (CHO/CD14/HuTLR2), 
and with CD14 and human TLR4 (CHO/
CD14/HuTLR4). These cells were incubated 
overnight with 10% serum and/or synovial 
fluid from RA patients.
Whereas incubation of the TLR4-expres-
sing CHO cells with normal human serum 
did not result in an up regulation of CD25, 
incubation of the cells with serum from RA 
patients with low levels of disease activity 
(Disease Activity Score <3.0 [41]) (n = 5) 
resulted in increased expression of CD25 
surface expression (18%) (Figure 5). Intri-
guingly, the serum from RA patients with ac-
tive disease (n = 7) even further increased 
the expression of CD25 to 35%, which was 
similar to that found after incubation with sy-
novial fluid (36%) from the same patients. 
A comparison with serum samples from 
patients with SSc (n = 5) and SLE (n = 5) 
demonstrated that, although at a lower level 
than in RA, serum from SSc patients (CD25 
expression level 11%) also contained TLR4 
ligands, whereas SLE serum (1%) did not. 
In contrast, incubation of the CHO/CD14 
and CHO/CD14/HuTLR2 cell lines with the 
same set of sera did not result in increased 
CD25 expression, suggesting that the sti-
mulation was TLR4 specific. The addition 
of polymyxin B in these experiments had 
no effect on CD25 expression, and results 
of the Limulus amebocyte lysate assay 
were negative for all synovial fluid samples 
measured. Stimulation with LPS, included 
as a positive control, resulted in a potent ac-
tivation response, as seen by the increased 
expression of CD25 (66%). 
Discussion
In this study, we present novel data regar-
ding the increased expression of TLR3 and 
TLR7 in synovial tissue from RA patients 
compared to that of healthy individuals. Sin-
ce TLR3 and TLR7 are receptors that recog-
nize single-stranded and double-stranded 
viral mRNA, these findings shed new light 
on the possible involvement of viruses in 
RA pathogenesis. Currently, a large body of 
evidence points towards the involvement of 
DNA viruses in the pathogenesis of RA. In 
the synovial tissue of RA patients, parvovi-
rus B19, Epstein-Barr virus, and cytomega-
lovirus were found to be frequently present 
(3,4,7,42-45). Although not fully investiga-
ted, it is also very likely that RNA viruses 
occur in the synovial compartment. In light 
of this, it is interesting that local TLR3 and 
TLR7 expression is increased in the synovial 
tissue of RA patients. Although the mecha-
nisms behind this increased expression of 
viral recognition molecules have not been 
elucidated thus far, it is tempting to specu-
late that the recognition of viral RNA and/or 
mRNA from the host itself leads to the ac-
tivation of antigen-presenting cells (APCs) 
that are abundant in the RA synovial com-
partment, thereby amplifying the inflamma-
tory reaction.
Moreover, the finding that DC stimulation 
mediated by TLR3 and TLR7/8 results in a 
markedly skewed balance towards IL-12 is 
interesting, since we recently demonstrated 
that IL-12 is indirectly involved in the up re-
gulation of TLR2 and TLR4, both of which 
are highly expressed in RA synovial tissue 
(33). These data suggest that TLR3/7 sig-
naling results in an up regulation of TLR2/4, 
subsequently leading to a higher sensitivity 
for endogenous ligands, favoring a vicious 
inflammatory circle. In addition, we produ-
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ced novel data showing that the stimulation 
of multiple TLR pathways simultaneously 
results in clear synergistic effects with res-
pect to the production of inflammatory medi-
ators. The combination of TLR4 and TLR7/8 
pathways especially resulted in synergistic 
effects, further substantiating the idea that 
the combination of endogenous ligands and 
viral mRNA might contribute to the pro-in-
flammatory environment and propel a chro-
nic inflammatory response in the synovial 
compartment.
Interestingly, we found that DCs from RA pa-
tients secrete higher levels of TNFα and IL-6 
compared to DCs from healthy controls upon 
triggering with specific TLR2 (LTA) and TLR4 
(LPS and EDA) ligands. Since much contro-
versy exists about the specificity of LTA, we 
also tested other TLR1/TLR2 and TLR2/
TLR6 heterodimer-specific ligands (FSL-1 
and Pam3Cys) (46,47). Although the abso-
lute levels of pro-inflammatory cytokines by 
stimulation with FSL-1 and Pam3Cys were 
lower compared to LTA, clear differences 
between RA patients and healthy controls 
remained, indicating that this phenome-
non is specific for TLR2 and TLR4 pa-
thways. The fact that TLR4 ligands were in-
creased in the serum and synovial fluid from 
RA patients further substantiates a potential 
role of TLR4 in the onset and/or perpetua-
tion of this condition. Every reaction that is 
started has to be terminated; the same is 
true for the immune response. Therefore, 
the innate immune system is subjected to 
sophisticated regulation, and there is incre-
asing evidence that an imbalance between 
pro- and antiinflammatory pathways might 
give rise to autoimmunity. Some intracellu-
lar adapters (e.g., TIRAP) (48) and inhibitory 
molecules (e.g., SIGIRR) (49) are involved 
in TLR2 and TLR4 signaling. However, it is 
likely that many more, yet unidentified, mo-
lecules are implicated. Seen in this light, the 
increased TLR2 and TLR4 responses found 
in RA might be caused by an alteration in 
one of these molecules.
DCs are professional APCs that are unri-
valed in their capacity for activating naive 
and effector T cells. DCs initiate immunity 
and uphold tolerance, 2 critical processes 
necessary to successfully combat pathoge-
nic invaders and prevent autoimmunity (16). 
Autoimmunity is attributed to the breakdown 
of tolerance when lymphocyte clones fail to 
discriminate between self and nonself, re-
sulting in destructive responses directed to 
multiple organs. The mechanisms by which 
autoimmunity is triggered are not fully under-
stood, but DCs and TLRs are likely to play a 
role in this process. Recently, Ichikawa and 
colleagues (30) and Waldner and associa-
tes (31) provided a conceptual framework 
demonstrating that TLRs are key molecules 
for the breakthrough of tolerance. Our data 
show that triggering different TLRs at the 
same time resulted in marked synergy with 
respect to the production of pro-inflamma-
tory mediators, indicating that simultaneous 
stimulation of different TLR pathways faci-
litates an environment in which the break-
through of tolerance is likely to occur.
Taken together, these data suggest that 
TLRs are involved in the regulation of in-
flammatory responses in the synovial com-
partment. TLRs recognize many exogenous 
and host-derived molecules; the latter are 
present in RA serum and synovial fluid. In 
this light, it could be envisaged that, upon 
the occurrence of a certain event, a variety 
of TLR ligands that lead to the activation of 
DCs are released in the synovial compart-
ment. Perhaps a trivial joint trauma or viral 
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infection leads to such an event. As a result, 
cell activation and the subsequent release of 
pro-inflammatory mediators results in carti-
lage breakdown and the subsequent release 
of more endogenous TLR ligands. At the 
same time, the abundance of pro-inflamma-
tory cytokines leads to an increased surface 
expression of TLRs and an increased ca-
pability to sense and react to TLR ligands. 
Normally, every pro-inflammatory response 
should lead to the activation of a counterac-
tive mechanism to restore the immunologic 
balance. However, in RA, such a mecha-
nism seems to be insufficient, resulting in 
a vicious circle of cell influx and activation, 
ending up in total joint destruction.
In conclusion, this is the first study to show 
that TLR3 and TLR7 expression is increased 
in RA synovial tissue and that the simulta-
neous triggering of multiple TLR pathways 
results in the augmentation of the pro-in-
flammatory response, favoring a pro-inflam-
matory environment and the breakthrough 
of tolerance in RA.
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Introduction
Dendritic cells (DCs)3 are professional anti-
gen presenting cells (APC) that regulate the 
delicate balance between immunity and to-
lerance. In the absence of inflammation, im-
mature DCs (iDCs) reside in the periphery, 
highly capable for Ag uptake, which is lar-
gely arranged by FcγRs and TLRs. Upon 
ligand binding, DCs undergo maturation, 
which coincides with a down-regulation of 
Ag recognition receptors, up-regulation of 
MHC and costimulatory molecules, and pro-
duction of pro-inflammatory mediators such 
as TNFα and IL-12. To date, a large body 
of evidence points towards the crucial role 
for DCs in the onset and perpetuation of ar-
thritis (1, 2, 3, 4). 
Many signals are able to induce DC activa-
tion, and among the most powerful of these 
are microbial and viral products, also called 
pathogen-associated molecular patterns, 
which are recognized by TLRs. Exogenous 
TLR ligands include lipoteichoic acid, LPS, 
CpG motifs of bacterial DNA, and viral RNA 
(5, 6, 7, 8). More recently, however, many 
studies addressed the role of endogenous 
ligands in the TLR-mediated cell activation 
(9, 10, 11, 12). Intriguingly, such endoge-
nous ligands, including fibronectin, heat 
shock proteins (HSPs), hyluronic acid, and 
host-derived RNA, are released upon tissue 
damage and cell stress, events that are like-
ly to occur during inflammatory conditions. 
The activation of cells by endogenous com-
ponents from distressed or injured cells sup-
ports the so-called “Danger Model” propo-
sed by Matzinger (13). This theory suggests 
that the immune system is more concerned 
with damage than with foreignness and is 
called into action by alarm signals from inju-
red tissues, rather than by the recognition of 
nonself. In this light, it is tempting to specula-
te that an immune response to endogenous 
components plays a role in the initiation of 
autoimmune diseases. Accordingly, TLRs 
are implicated in the breakdown of tolerance 
Dendritic cells (DCs) are specialized antigen presenting cells that can be activated upon pathogen 
recognition as well as recognition of endogenous ligands, which are released during inflammation 
and cell stress. The recognition of exogenous and endogenous ligands depends on TLRs, which 
are abundantly expressed in synovial tissue from rheumatoid arthritis (RA) patients. Furthermore 
TLR ligands are found to be present in RA serum and synovial fluid and are significantly increased, 
compared to serum and synovial fluid from healthy volunteers and patients with systemic sclerosis 
and systemic lupus erythematosus. Identification of novel endogenous TLR ligands might contri-
bute to the elucidation of the role of TLRs in RA and other autoimmune diseases. In this study, we 
investigated whether five members of the small heat shock protein (HSP) family were involved in 
TLR4-mediated DC activation and whether these small HSPs were present in RA synovial tissue. 
In vitro, monocyte-derived DCs were stimulated with recombinant αA crystallin, αB crystallin, 
HSP20, HSPB8, and HSP27. Using flow cytometry and multiplex cytokine assays, we showed that 
both αA crystallin and HSPB8 were able to activate DCs and that this activation was TLR4 depen-
dent. Furthermore, Western blot and immunohistochemistry showed that HSPB8 was abundantly 
expressed in synovial tissue from patients with RA. With these experiments, we identified sHSP 
αA crystallin and HSPB8 as two new endogenous TLR4 ligands from which HSPB8 is abundantly 
expressed in RA synovial tissue. These findings suggest a role for HSPB8 during the inflammatory 
process in autoimmune diseases such as RA. 
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as shown in experimental models of diabe-
tes (14), Crohn’s disease (15), and multiple 
sclerosis (16, 17), and recent research sug-
gested that simultaneous or sequential trig-
gering of different TLR pathways might be 
the event that sets off autoimmunity (18). 
Rheumatoid arthritis (RA) is such an au-
toimmune disease, characterized by chronic 
inflammation of synovial joints leading to 
cartilage damage and ultimately total joint 
destruction. Although the exact pathways 
leading to the initiation and perpetuation of 
synovial inflammation remains obscure, re-
cent evidence addressed the potential role 
of TLRs in arthritis. At first, TLR2, TLR3, 
TLR4, TLR7, and several ligands were found 
to be highly expressed in synovial tissue 
from RA patients, compared to that from 
healthy donors (3, 4, 19). Second, we have 
shown that TLR-mediated activation of DCs 
from RA patients led to significantly higher 
levels of the key pro-inflammatory cytokines 
TNFα and IL-6, compared to DCs from their 
healthy counterparts. Finally, the involve-
ment of various TLRs in the onset and per-
petuation of experimental arthritis has been 
elegantly shown (20, 21, 22). 
These latter findings have sparked the re-
search into the role of several endogenous 
TLR ligands in RA of which HSPs have been 
studied the most thoroughly thus far. HSPs 
constitute a family of proteins that carry out 
housekeeping functions that are important 
for the survival of eukaryotic cells. More re-
cently, evidence emerged on a role for HSPs 
during innate and adaptive immune respon-
ses (23, 24, 25). HSPs can be classified into 
several distinct families from which HSP60 
(HSP60, HSP65, and GROEL) and HSP70 
(HSP72, HSP73, and GRP170) have been 
the subject of extensive studies with regard 
to immunogenetic properties. The small 
HSPs (sHSPs), including αA crystallin, αB 
crystallin, HSP27, HSPB8 (HSP22), and 
HSP20, represent another class of HSPs, 
ranging in size from 12 to 43 kDa (26, 27, 
28). In contrast with HSP60 and HSP70, the 
role of sHSPs in autoimmune diseases have 
not been subjected to similar research. To 
characterize the potential role of sHSPs in 
arthritis, in this study, we investigated the 
ability of five members of the sHSPs (αA 
crystallin, αB crystallin, HSPB8, HSP27, 
and HSP20), to stimulate monocyte-derived 
DCs and the possible role for TLRs in this 
process. In this study, we demonstrate, for 
the first time, that the sHSP αA crystallin and 
B8 (HSP22) clearly induced DC maturation 
and cytokine production, which was TLR4 
dependent. In addition, HSPB8, but not αA 
crystallin, was highly expressed in synovial 
tissue from RA patients, further substanti-
ating a potential role for HSPB8 during the 
inflammatory process in RA. 
Materials & Methods
Patients/study population 
For this study, a total of seven RA patients at-
tending the Department of Rheumatology at 
Radboud University Nijmegen Medical Center 
and seven healthy volunteers were included. 
The patients fulfilled the American College of 
Rheumatology criteria for RA (29), and they 
all gave their informed consent. Patients using 
high-dose prednisolone (>10 mg/day) or anti-
cytokine therapies (anti-TNFα and/or IL-1Ra) 
were excluded from this study. For immu-
nohistochemical analysis, synovial biopsies 
from RA patients (n = 5) were obtained using 
small needle arthroscopy. On average, 20 bi-
opsy samples were obtained from the medial 
and lateral suprapattelar pouch on each oc-
casion. The local Medical Ethics Committee 
approved the study protocol. 
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Expression and purification of the 
sHSPs 
For the expression of the different sHSPs, 
pET16b constructs were used containing 
the coding sequence of human αA crystallin, 
αB crystallin, HSPB8, HSP27, or rat HSP20. 
Expression of each protein was induced in 
Rosetta (DE3)pLysS cells (Novagen) for 3 h 
at 37°C with 0.4 mM isopropyl  -D-1-thioga-
lactopyranoside. Cells were spun down from 
four cultures of 450 ml and resuspended 
in 20 ml of 25 mM Tris-HCl, 2 mM EDTA, 
and 50 mM glucose) (TEG50), pH 8.0, con-
taining protease inhibitors (one complete 
protease inhibitor mixture tablet; Roche). 
The cell suspension was frozen, thawed, 
and sonicated three times for 30 s. The sus-
pension was cleared by centrifugation, and 
the supernatant was desalted with a HiTrap 
26/10 column (Amersham Biosciences) in 
25 mM Tris-HCl and 2 mM EDTA) (TE), pH 
7.0. The different sHSPs were purified over 
a DEAE-Sepharose fast-flow column and 
Source 15Q column (Amersham Bioscien-
ces) at room temperature and a flow rate of 
2 ml/min, using a gradient from 0 to 1000 
mM NaCl in TE (pH 7.0). 
Culture of monocyte-derived DCs 
Monocyte-derived DCs were cultured es-
sentially the same as described previously 
(30). Briefly, PBMC were isolated from he-
parinized venous blood by using density-
gradient centrifugation over Ficoll-Paque 
(Amersham Biosciences). Low-density cells 
were collected and washed with citrated 
PBS 5% FCS, whereafter the cells were 
allowed to adhere for 1 h at 37°C in RPMI 
1640 Dutch modification (Invitrogen Life 
Technologies) supplemented with 2% hu-
man serum (PAA Laboratories) in 25-cm2 
cell culture flasks (Corning). Adherent mo-
nocytes were cultured in RPMI 1640 Dutch 
modification supplemented with 10% FCS 
and antibiotic-antimycotic (Invitrogen Life 
Technologies) in the presence of IL-4 (500 
U/ml; Schering-Plough) and GM-CSF (800 
U/ml; Schering-Plough) for 6 days. Fresh 
culture medium with the same supplements 
was added at day 3 where after iDCs were 
harvested at day 6. The iDCs were resus-
pended in fresh cytokine-containing culture 
medium and transferred to culture plates 
in a concentration of 0.5 x 106 cells/ml and 
stimulated as described in the subsequent 
section. 
Stimulation of monocyte-derived DCs 
with sHSPs 
Monocyte-derived iDCs were stimulated 
with 1 and 10 μg/ml each of these five 
members of the sHSP family; αA crystallin, 
αB crystallin, HSPB8, HSP27, HSP20. LPS 
(Sigma-Aldrich) stimulation (2 μg/ml) was 
used as a positive control for inducing DC 
maturation. To correct for potential endo-
toxin contamination 10 μg/ml polymyxin B 
(PMB) was added. Furthermore, the sHSPs 
in the presence of PMB were also tested 
for the presence of Gram-negative bacte-
rial endotoxin by the Limulus amebocyte ly-
sate (LAL) test, performed according to the 
manufacturer’s instructions (Multitest LAL 
Pyrogen Plus; BioWhittaker). Moreover, 
we also performed experiments with heat-
inactivated HSPB8 and αA crystallin. To 
test the involvement of TLR4 in stimulation 
with these sHSPs, 100 nM TLR4 antagonist 
(E5564; provided by the Eisai Research In-
stitute, Andover, MA) was added to the cul-
ture (31). After 24 h of culture at 37°C in the 
presence of 5% CO2, culture supernatants 
were collected. Supernatants were stored 
at –20°C until cytokine measurement was 
performed. 
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Stimulation of peritoneal macrophages 
from TLR4 knock-out mice with αA cry-
stallin and HSPB8 
BALB/c TLR4-deficient (TLR4–/–) mice were 
provided by S. Akira (Osaka University, Os-
aka, Japan). Peritoneal macrophages from 
TLR4–/– and wild-type mice (both BALB/cA 
background) were isolated by peritoneal la-
vage using ice-cold DMEM/10% FCS. Cells 
were put into 24-well-plates (Corning) at a 
concentration of 1 x 106 cells/ml. After a 4-
day adjustment period, culture medium was 
changed to one containing 10 μg/ml HSPB8 
or control medium. To correct for potential 
endotoxin contamination, medium contained 
10 μg/ml PMB. After 24 h, the culture me-
dium was collected and stored at –20°C until 
cytokine measurement was performed. 
Phenotypical analysis of monocyte-
derived DCs 
The phenotypical analysis of mono-
cyte-derived DCs was performed using 
standardized flow cytometry protocols as 
described previously (30). Briefly, a num-
ber of 1 x 105 DCs were incubated with 
mAbs against human CD14 (DakoCyto-
mation), CD80 (BD Biosciences), CD83 
(Beckman Coulter), CD86 (BD Pharmin-
gen), MHC class I (MHC-I) (clone W6/32), 
and MHC-II DR/DP (clone Q1514) for 30 
min at 4°C. Cells were then washed and 
incubated with FITC-conjugated goat 
anti-mouse IgG (Zymed Laboratories) for 
30 min at 4°C in complete darkness. Sub-
sequently, cells were washed and ana-
lyzed with a fluorescence-activated cell 
sorter (FACSCalibur; BD Biosciences) for 
the proportion of positive cells relative to 
cells stained with relevant IgG isotypes. 
Cells were gated according to their for-
ward- and side-scattering patterns. For 
each marker, 104 cells were counted in 
the gate. 
Figure 1. Expression of cell surface markers CD83 and CD86 after stimulation with several small heat-shock proteins. 
FACS® analysis of the indicated markers (bold line) or isotype controls (thin line) from DC within the life gate. Human 
monocyte-derived DCs were stimulated with 10 mg/ml αA crystallin, αB crystallin, HSPB8, HSP27, HSP20, 2 mg/ml 
LPS or medium for 48 hours. 
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CD14 CD80 CD83 CD86 MHCI DR/DP
Immature DC 6 (1) 21 (8) 21 (7) 165 (53) 152 (40) 462 (111)
LPS 4 (1) 111 (17) 41 (7) 294 (23) 218 (68) 770 (237)
HSPB8 5 (2) 65 (12) 38 (11) 238 (57) 262 (21) 610 (197)
Table 1. Mean fluoresence intensity of the DC surface molecules CD14, CD83, CD83, CD86, MHCI and MHCII
The values shown represent the mean and SEM (between brackets) of all DCs used in the experiments
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Measurement of cytokines in culture 
supernatant 
Human TNFα, IL-6, IL-10, IL-12p70, and 
mice IL-6 levels were measured in the su-
pernatants of the DC cultures and the pe-
ritoneal macrophage cultures, respectively, 
using commercially available kits (Bio-Rad) 
according to the manufacturer’s instructions 
(32). Cytokine levels were measured and 
analyzed with the Bio-Plex system and its 
software (Bio-Rad). The sensitivity of the 
cytokine assay was <5 pg/ml for all cytoki-
nes measured. 
SDS-PAGE and Western blotting of αA 
crystallin and HSPB8 in synovial tissue 
Synovial tissue samples containing 50 μg 
of synovium proteins together with 10 ng 
αA crystallin or HSPB8 were subjected to 
SDS-PAGE and transferred to nitrocellulose 
membranes (Hybond; Amersham Bioscien-
ces). Membranes were then blocked with 5% 
nonfat dried milk in TBST (15 mM Tris-HCL 
(pH 8.0), 150 mM NaCl, 0.1% Tween 20) 
and probed with primary rabbit anti-HSPB8 
serum or rabbit anti- A-serum and secon-
dary swine-anti-rabbit peroxidase-coupled 
Abs. Immunoreactive bands were visualized 
by the ECL Western blotting detection kit 
(Pierce). 
Immunohistochemical analysis of human 
synovial biopsies 
Synovial tissue samples were embedded in 
Tissue Tek OCT (Sakura) and snap-frozen 
in liquid nitrogen. Cryostat sections (5 μm) 
were mounted on superfrost slides and sto-
red at –80°C until processing. For HSPB8 
Figure 2. Cytokine production by DCs from RA patients and healthy controls after stimulation with several small heat-
shock proteins. Mean production of IL-6 (A), TNFα (B), IL-10 (C) and IL-12p70 (D) by DC from RA patients (black bars) 
and healthy controls (grey bars) upon stimulation with 10 mg/ml αA crystallin, αB crystallin, HSPB8, HSP27, HSP20, 2 
mg/ml LPS or medium for 24 hours (n=7 for αA crystallin and HSPB8, for other small HSP n=3). Error bars represent the 
SEM. The sensitivity of the cytokine assay was below 5 pg/ml for each measured cytokine.
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staining, sections were incubated with 2 
μg/ml goat anti-human HSPB8 (Abcam) for 
60 min. After this, endogenous peroxidase 
was blocked with 0.3% H2O2 in methanol for 
15 min, and the secondary Ab, biotinylated 
mouse anti-goat IgG (Jackson ImmunoRe-
search Laboratories), was incubated for 30 
min. Vectastain ABC reagent (Vector Labo-
ratories) was incubated for 30 min, develo-
ped with diaminobenzidine (Sigma-Aldrich), 
and counterstained with hematoxylin for 
30s. 
For αA crystallin staining, sections were in-
cubated with rabbit anti-human αA crystal-
lin serum (50x diluted) for 60 min. After this, 
endogenous peroxidase was blocked with 
0.3% H2O2 in methanol for 15 min and the 
secondary Ab, biotinylated swine anti-rabbit 
IgG (Dako), was incubated for 30 min. Sub-
sequently, slides were incubated with strep-
tavidin-HRP (Dako) for 30 min, developed 
with diaminobenzidine (Sigma-Aldrich), and 
counterstained with hematoxylin for 30 s. 
Results
αA crystallin and HSPB8 selectively 
induce DC maturation 
To study the potency of sHSPs to induce DC 
maturation, we compared iDC stimulation 
using 5 different sHSPs (αA crystallin, αB cry-
stallin, HSPB8, HSP27, and HSP20) to TLR4-
mediated DC maturation using LPS. The iDCs 
are characterized by the absence of CD14, low 
levels of CD83, and intermediate levels of the 
costimulatory molecules CD80 and CD86 and 
MHC molecules. LPS-mediated DC matura-
tion is characterized by a clear up-regulation 
of CD83, the costimulatory molecules CD80 
and CD86, and MHC molecules (Table I). In 
our experiments, stimulation with αA crystallin 
and HSPB8 induced a clear DC maturation as 
seen by the absence of CD14 and high mean 
levels of CD80, CD83, CD86, and MHC-II, 
which was comparable to LPS-mediated sti-
mulation (CD83 and CD86 expression from 
a representative healthy individual; Figure 1) 
In contrast, stimulation with the sHSP αB 
crystallin, HSP20, and HSP27 did not affect 
the phenotype of iDCs at all (Figure 1). 
In addition, we studied whether differences 
between RA DCs and DCs from healthy con-
trols exist. The sHSP αA crystallin and HSPB8 
induced maturation of RA DCs to an equal 
extent, compared with that seen in control 
DCs (data not shown). To correct for potential 
endotoxin contamination, experiments were 
performed in the presence of PMB. Only small 
Figure 3. Expression of cell surface markers CD80, 
CD83, CD86 and MCHII after stimulation with HSPB8 or 
αA crystallin in the presence and absence of a TLR4 an-
tagonist. FACS® analysis of the indicated markers (bold 
line) or isotype controls (thin line) from DCs within the 
life gate. Human monocyte-derived DCs were stimulated 
with 10 mg/ml HSPB8 or αA crystallin for 48 hours in the 
presence or absence of a TLR4 antagonist (E5564).
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differences in FACS results were observed 
when cultured with or without PMB (data not 
shown). 
Increased cytokine production upon 
DC stimulation with αA crystallin and 
HSPB8 
DC maturation by TLR ligands is known to 
be accompanied by an increased production 
of pro-inflammatory cytokines. Therefore, 
we investigated whether phenotypic matu-
ration of DCs induced by αA crystallin and 
HSPB8 coincided with an increased produc-
tion of the inflammatory mediators TNFα, IL-
6, IL-10, and IL-12p70 as seen in LPS-me-
diated DC maturation (3, 33). As shown in 
Figure 2, 10 μg/ml αA crystallin and HSPB8 
clearly induced secretion of IL-6, TNFα, and 
to a lesser extent, IL-10 and IL-12p70, and 
resembled the cytokine pattern induced by 
LPS stimulation. In contrast with this, but in 
line with the results of the FACS® analysis, 
αB crystallin, HSP27, and HSP20 hardly in-
duced cytokines. 
Interestingly, although not statistically signi-
ficant, cytokine levels produced by RA cells 
Figure 4. Cytokine production by DCs from RA patients and healthy controls after stimulation with αA crystallin and 
HSPB8 in the presence or absence of a TLR4 antagonist. Mean production of IL-6 (A), TNFα (B), IL-10 (C), and IL-12p70 
(D) by DCs from RA patients and healthy controls upon stimulation with 10 μg/ml αA crystallin or HSPB8 for 24 h (n=5). 
Cells were cultured in the presence (shaded bars) or absence (filled bars) of 100 nM TLR4 antagonist (E5564). The 
values shown are corrected for the cytokine production by unstimulated DCs. Error bars represent SEM. The sensitivity 
of the cytokine assay was <5 pg/ml for each measured cytokine.
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were markedly increased, compared to the 
cytokine levels produced by DCs from he-
althy controls upon stimulation with αA cry-
stallin and HSPB8 (IL-6  13,000 pg/ml; TNFα 
8,500 pg/ml). Although the absolute cytoki-
ne levels produced by RA cells were mar-
kedly increased, the shape of the TLR-sHSP 
dose-response curves were similar for RA 
cells as well as cells from healthy controls. 
These results exclude that the differences in 
cytokine production are a result of different 
shapes of dose-response curves. 
As tested by dose-response experiments, 
both HSPs were able to activate DCs in a 
concentration as from 50 ng HSP/ml, resul-
ting in production of IL-6 (data not shown). 
To correct for potential endotoxin contamina-
tion, we performed all the cell stimulation ex-
periments in the presence of PMB; however, 
addition of PMB only slightly decreased the 
sHSP-mediated cytokine production, indica-
ting that hardly any endotoxins were present 
in our sHSP preparations. In addition, we 
performed experiments with heat-inactiva-
ted HSPB8 and αA crystallin, which showed 
a significant reduction in TNFα  production 
(98% reduction), excluding that endotoxin 
contamination played a role in our experi-
ments. 
αA crystallin- and HSPB8-mediated 
stimulation of DCs is largely TLR4 
dependent 
Many studies refer to the potential role 
of TLR4 in the recognition of HSPs, their 
role in DC maturation, and the potential 
implication for TLRs in the pathogenesis 
of arthritis. Therefore, we studied whether 
TLR4 was involved in DC activation by 
HSP αA crystallin and HSPB8. To this 
aim, we stimulated DCs with αA crystallin 
and HSPB8 in the presence and absence 
of a TLR4 antagonist (E5564) (31). With 
respect to DC maturation, adding a TLR4 
antagonist clearly inhibited DC matura-
tion, as seen by a clear decrease in the 
expression of CD80, CD83, CD86, and 
MHC-II (Figure 3). In line with this finding, 
the production of IL-6 ( 80% decrease), 
TNFα ( 85% decrease), IL-10 ( 70% de-
crease), and IL-12p70 ( 80% decrease) 
by DCs from healthy individuals was mar-
kedly reduced by the addition of a TLR4 
antagonist (Figure 4). Although somewhat 
less clear, this effect was demonstrated 
Figure 5. IL-6 production by peritoneal macrophages 
from TLR4–/– mice and wild-type mice upon stimula-
tion with HSPB8. Mean IL-6 production by peritoneal 
macrophages from TLR4–/– (n=7) and wild-type (n=7) 
mice after incubation with 10 μg/ml HSPB8 for 24 h. The 
sensitivity of the cytokine assay was <5 pg/ml.
Figure 6. Western blot detection of HSPB8 and αA 
crystallin in synovial tissue from RA patients. Synovial 
tissue samples (n= 3) were analyzed for the expres-
sion of HSPB8 and αA crystallin (open arrows). As 
a positive control, rHSPB8 and rαA crystallin were 
used. The black arrow indicates a modified form of 
HSPB8.
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for DCs from RA patients as well (IL-6, 
60% decrease; TNFα,  65% decrease; IL-
10,  80% decrease; and IL-12p70,  85% 
decrease). 
TLR4–/– macrophages do not respond 
to HSPB8 stimulation 
To further confirm the TLR4 dependency of 
HSPB8 stimulation, we stimulated perito-
neal macrophages of wild-type and TLR4–
/– mice with HSPB8-containing medium 
or medium alone. In both wild-type macro-
phages as well as TLR4–/– macrophages, 
medium did not induce the production of 
IL-6. As expected, and confirming our pre-
vious data, HSPB8 stimulation of wild-type 
macrophages resulted in a markedly incre-
ased production of IL-6 The production of 
other cytokines (TNFα and IL-10) was be-
low detection level. The almost complete 
abrogation of IL-6 production by peritoneal 
macrophages from TLR4–/– mice further 
confirms the TLR4 dependency of HSPB8-
mediated cell activation (Figure 5). 
HSPB8 is abundantly expressed in sy-
novial tissue from RA patients 
Thus far, the main expression of αA crystallin 
Figure 7. Immunohistochemical detection of HSPB8 in synovial tissue from RA patients. A. Staining of the synovial 
lining with an isotype control Ab (magnification x200). B. Staining of the synovial lining with a specific Ab against HSPB8 
(magnification x200). C. Staining of synovial vascular endothelial cells with an isotype control Ab (magnification x400). D. 
Staining of synovial vascular endothelial cells with a specific Ab against HSPB8 (magnification x400). All synovial tissue 
sections were counterstained with hematoxylin.
A
C
B
D
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and HSPB8 in human tissues was confined 
to the eye lens, skeletal muscle, heart, and 
placenta (34). To study the potential role for 
sHSPs in synovial inflammation, we tested 
the expression of αA crystallin and HSPB8 
in RA synovium using Western blotting and 
immunohistochemistry techniques. 
Interestingly, Western blotting showed clear 
staining for of HSPB8 in RA synovial tissue, 
whereas αA crystallin staining was comple-
tely absent (Figure 6).  
Additional immunohistochemistry showed 
that the expression of HSPB8 was particu-
larly present in the lining (Figure 7B) and 
the vascular endothelial (Figure 7D) cells. 
HSPB8 also was expressed in the subli-
ning, albeit to a lesser extent. 
Discussion
Antigen recognition by TLRs results in ac-
tivation of the innate immune system and 
leads to the secretion of many inflamma-
tory mediators such as TNFα, IL-6, and 
several chemokines. Therefore, the innate 
immune response is likely to play a consi-
derable role both in the initiation and per-
petuation of the inflammatory processes 
during RA. In this study, we demonstrated 
that two members of the sHSP family, αA 
crystallin and HSPB8, were able to activa-
te DCs by inducing maturation and cyto-
kine production. Blockade of TLR4, using 
a selective TLR4 antagonist (E5564) (31), 
clearly abrogated this effect, demonstra-
ting the TLR4 dependency of this HSP 
stimulation. In line with this finding, incu-
bation of peritoneal macrophages from 
TLR4–/– mice, with HSPB8 and αA cry-
stallin, did barely lead to the production 
of inflammatory cytokines, whereas wild-
type mice clearly did show an increased 
cytokine production. Finally, we provided 
evidence for a role of HSPB8 in the pa-
thogenesis of RA by demonstrating that 
HSPB8, but not αA crystallin, was highly 
present in RA synovial tissue. 
Lately, an increasing amount of literature 
points to a role for TLRs in the recogni-
tion of host-derived molecules, such as 
hyaluronan, fibronectin fragments, HSPs, 
mRNA from necrotic cells, and mammali-
an chromatin (9, 10, 11, 12, 35). However, 
recently it has been shown that the stimu-
lating effect some of these endogenous 
TLR ligands is caused by endotoxin con-
tamination and not by the ligand itself (36, 
37). To exclude the possibility that LPS 
contamination interfered with our experi-
ments, we performed all the stimulation 
experiments in the presence and absence 
of PMB, a natural LPS binding protein. 
Second, we tested the presence of LPS 
using the LAL test, which showed to be 
negative for all five HSP samples tested. 
Furthermore, experiments with heat-inac-
tivated HSPB8 and αA crystallin showed a 
significant decrease in TNFα production, 
excluding the involvement of endotoxins in 
the TLR4-mediated DC activation. Finally, 
all five HSPs tested were simultaneously 
prepared using the same protocols. The 
fact that DC maturation and activation 
could be achieved only by incubation with 
HSPB8 and αA crystallin underscores the 
fact that an effect of endotoxins could be 
ruled out. 
The ability of HSPB8 and αA crystallin 
to activate cells using TLR4 is intriguing 
because we and others found that TLRs 
are highly expressed in RA synovial tissue 
(3, 4, 19, 38). We also found that, upon 
stimulation of TLR2 and TLR4, DCs from 
RA patients produce significantly higher 
amounts of pro-inflammatory cytokines, 
compared to DCs from healthy controls 
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(3). Additionally, models of experimental 
arthritis support the role for TLRs in this 
inflammatory disease (20, 39). Further-
more, the involvement of TLRs in tole-
rance breakthrough has been demonstra-
ted in experimental models of diabetes 
and multiple sclerosis (14, 16, 17). 
Therefore, our finding that HSPB8 is abun-
dantly expressed in the synovial tissue 
of RA patients underscores that HSPB8 
could act as a TLR4 ligand during RA, 
thereby amplifying the inflammatory loop. 
Because recent literature shows that si-
multaneous stimulation of TLRs might be 
the event that sets of autoimmunity, it is 
tempting to speculate that HSPB8, toge-
ther with other endogenous TLR ligands, 
which are released in the synovial com-
partment, are involved in this process (3, 
40). 
The expression of HSPB8 in human tis-
sues, particularly in skeletal and smooth 
muscles, heart, and brain, has been 
described well (34, 41). The finding that 
HSPB8 also is expressed in synovial tis-
sue is new and could be explained by the 
fact that synovial tissue is normally not 
part of the tissue data bank used to screen 
the tissue distribution of new proteins. 
In conclusion, we identified two new 
TLR4 agonists, HSPB8 and αA crystal-
lin. HSPB8 is highly expressed in RA sy-
novial tissue and is likely to be released 
during synovial inflammation. The release 
of this protein in the synovial joint could 
potentially lead to an ungoing activation 
of inflammatory cells, thereby amplifying 
the inflammatory loop of synovial inflam-
mation. Further research is necessary to 
elucidate the precise role of HSPB8 in the 
pathogenesis of RA. 
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Introduction
Rheumatoid arthritis (RA) is a systemic au-
toimmune disease, which mainly affects the 
synovial joints. The synovial inflammation 
is characterized by a massive infiltration 
of cells including T-cells, B-cells, macro-
phages and dendritic cells (DCs), resulting 
in destruction of the joints. Since DCs are 
abundantly present at strategic locations in 
RA synovial tissue (1), increasing evidence 
addressed a role for DCs in the pathogene-
sis of RA (1-4). 
Many external stimuli are able to induce DC 
activation, and among the most powerfull of 
these are microbial and viral products such 
as lipoteichoic acid, LPS, and viral RNA. 
These components, also called pathogen-
associated molecular patterns, can be re-
cognized by pattern recognition receptors 
(PRR), including Toll-like receptors (TLRs) 
(1;5-8). More recently, however, many stu-
dies provided evidence for TLR-mediated 
immune activation by “self molecules”, in-
cluding heat-shock proteins, fibronectin, 
hyaluronic acid and host derived RNA (9-
12). These so called endogenous ligands 
can be released upon tissue damage and 
cell stress, events that are likely to occur 
during inflammatory conditions. In vivo evi-
dence for TLR-mediated signaling that was 
induced by endogenous ligands comes 
from studies of acute tissue injury, as in 
trauma or hemorrhagic shock (13;14). The 
possible involvement of TLRs in the patho-
genesis of RA has been studied intensively 
in the last few years, resulting in an incre-
asing body of evidence. First, TLRs are 
abundantly expressed in RA synovial tissue 
and this expression is markedly increased 
compared to synovial tissue from patients 
with osteoarthritis and healthy controls 
(15;16). Moreover, the endogenous TLR 
ligand heat-shock protein B8 (HSPB8) 
was expressed in synovial tissue. In vitro 
Rheumatoid Arthritis (RA) is a chronic autoimmune disease that is characterized by inflammation 
of the synovial joints, which ultimately leads to joint destruction. Although the exact cause still has 
to be identified, many evidence addressed a role for Toll-like receptors (TLRs) in the pathogenesis 
of this disease. Since it has been shown that TLR4 stimulation of dendritic cells (DCs) from RA 
patients results in much higher production of pro-inflammatory cytokines compared to DCs from 
healthy individuals, we here tried to identify potential factors that are involved in the TLR4 hyper-
responsiveness during RA.
Using array-based gene expression profiling, expression of allograft-inflammatory 1 (AIF-1) was 
found to be significantly enhanced in DCs from RA patients. This enhanced expression was con-
firmed using real-time PCR, in DCs as well as in monocytes. Furthermore we found the enhanced 
expression of all AIF-1 isoforms  in cells from RA patients using real-time PCR. In vitro stimulation 
experiments showed that the expression of total AIF-1 as well as its separate isoforms  strongly 
correlated with the TLR4-induced production of IL-6 and TNFα in cells from RA patients as well 
as in cells from healthy controls. Therefore it is highly likely that the enhanced expression of AIF-1 
determines hyperresponsiveness towards TLR4.
In conclusion, using a gene expression approach, we identified AIF-1 as a potential factor to be 
involved in the TLR4 hyperresponsiveness in RA, although the exact function of the several AIF-1 
isoforms has not been elucidated thus far. Therefore, further investigation into the specific function 
of the separate AIF-1 isoforms might provide additional evidence with respect to the exact role of 
AIF-1 in the pathogenesis or chronicity of RA.
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studies have demonstrated that TLRs are 
under strong regulation of several cytoki-
nes, such as TNFα, IL-1β and IFNγ, which 
play key roles in RA (15;17-19). The invol-
vement of TLRs in the pathogenesis of RA 
was also recently underscored by some 
clinical research, as treatment of RA using 
anti-TNFα therapy resulted in significantly 
decreased levels of TLR4 (20) and inhibi-
tion of the TLR4 signaling pathway in RA 
patients using Chaperonin 10 (heat shock 
protein 10, XToll™) was shown to be well 
tolerated and efficacious (21). Recently 
we demonstrated that upon stimulation of 
TLR2 and TLR4, DCs from RA patients 
produced much higher cytokine levels 
compared to DCs from healthy controls, 
whereas the cytokine responses upon 
stimulation of other TLRs did not differ 
(16). Interestingly, the expression levels 
of TLR2 and TLR4 were not significantly 
different between cells from RA patients 
and healthy volunteers, excluding that 
the enhanced cytokine production resul-
ted from increased TLR expression. The 
fact that TLR2 as well as TLR4 stimulation 
showed an enhanced cytokine produc-
tion by RA cells, also excludes a role for 
CD14 in this process. The purpose of this 
study was to investigate the factors that 
are differentially expressed at basal level 
in DCs from RA patients  compared to he-
althy controls, which might be associated 
with enhanced responses upon TLR4 sti-
mulation. Therefore, we performed gene 
expression profiling and subsequent real-
time PCR. We found that basal mRNA ex-
pression of allograft inflammatory factor I 
(AIF-1) was significantly increased in DCs 
from RA patients and this expression cor-
related with the cytokine levels produced 
upon TLR4 stimulation. 
Materials & methods
Patients / study population
A total of 17 RA patients and 17 healthy vo-
lunteers were included in this study. RA pa-
tients were attending the Radboud Univer-
sity Nijmegen Medical Centre, fulfilled the 
American College of Rheumatology criteria 
for RA (22) and all gave informed consent. 
Patients using high dose prednisolone 
(>10mg/day) or anti-cytokine therapies 
(anti-TNFα and/or IL-1Ra) were excluded 
from this study. The local Medical Ethics 
Committee approved the study protocol.
Isolation, generation and stimulation of 
monocytes and monocyte-derived DCs
Peripheral blood mononuclear cells 
(PBMCs) were isolated from heparinized 
venous blood using density gradient cen-
trifugation over Ficoll-Paque (Amersham 
Biosciences, Roosendaal, The Nether-
lands). Low-density cells were collected 
and washed with citrated PBS 5% FCS. 
For monocytes, CD14+ cell fraction was 
isolated using MACS® cell separation, ac-
cording to the manufacturer’s instructions. 
Briefly, PBMC were incubated with anti-
human CD14 MicroBeads (Miltenyi Bio-
tec, Bergisch Gladbach, Germany) for 30 
minutes, subsequently cells were washed 
and CD14+ fraction was separated from 
the CD14- fraction over a MACS® MS se-
paration column (Miltenyi Biotec, Bergisch 
Gladbach, Germany).  
For monocyte-derived DCs, PBMCs were 
allowed to adhere for 1 hour at 37°C in 
RPMI-1640 Dutch Modification (Invitrogen 
Corporation, Carlsbad, CA, USA supple-
mented with 2% human serum (PAA Labo-
ratories, Pasching, Austria) in 25cm2 cell 
culture flasks (Corning Incorporated, NY, 
USA). Adherent monocytes were cultured 
81
                            
     Chapter 5 
in RPMI-1640 Dutch modification supple-
mented with 10% fetal calf serum (FCS) 
and antibiotic-antimycotic (Life Techno-
logies) in the presence of IL-4 (500 U/ml, 
R&D Systems, Minneapolis, MN, USA) and 
GM-CSF (800 U/ml, R&D Systems, Minne-
apolis, MN, USA) for 6 days. Fresh culture 
medium with the same supplements was 
added at day 3 where after immature DCs 
were harvested at day 6.
Monocytes and immature DCs, in a con-
centration of 0.5x106 cells/ml were stimula-
ted with 1mg/ml LPS. Subsequently, culture 
supernatants were removed and 1ml TRIzol 
reagent (Sigma St. Louis, MO, USA) was 
added to the cells and stored at –20°C until 
RNA isolation was performed. 
RNA isolation
For array-based gene expression profiling 
RNA from 5 RA patients and 5 healthy con-
trols was isolated from unstimulated DCs 
using RNAeasy (Qiagen Benelux, Venlo), 
according to the manufacturers instruction. 
RNA was quantified by RiboGreen assay 
(Molecular Probes Europe BV, Leiden) 
adjusted for a crystal 96-well microtiter-
plate (Thermo Labsystems, Vantaa) using 
FluoStar Galaxy (BMG Labtechnologies, 
Toronto). RNA integrity was assessed on 
1% SeaKem® gold agarose gel. All sam-
ples passed the quality control, and were 
subjected to the subsequent labeling and 
hybridization. RNA samples from 3 repre-
sentative RA patients and 2 representative 
healthy controls were used for array-based 
gene expression profiling.  
For real-time PCR analysis, total RNA from 
12 RA patients and 12 healthy controls was 
extracted in 1 ml of TRIzol reagent, an im-
proved single-step RNA isolation method 
based on the method described by Chomc-
zynski et al. (23).
Oligonucleotide array analysis.
One microgram of total RNA was used as 
starting material for cDNA preparation. Ge-
neration of biotinylated cRNA target and 
subsequent hybridization, washing and 
staining of HG_U133 Plus2.0 oligonucle-
otide arrays (Affymetrix, Santa Clara, CA) 
were performed according to Affymetrix 
Expression Analysis Technical Manual for 
one-cycle amplification (24). The arrays 
were then scanned using a laser scanner 
GeneChip®Scanner (Affymetrix) accor-
ding to the manufacturers instruction and 
analyzed by using Affymetrix Gene Chip 
Operating Software (GCOS) version 1.4. 
Normalization, model-fitting, and filtering 
were performed using DNA-Chip Analyzer 
(dChip) version 1.3 (Harvard) (25). Subse-
quently, pair-wise comparisons were perfor-
med by dChip applying the criteria: >2 fold 
change and p<0.05 by t-statistics. Functio-
nal cluster analysis was performed by dChip 
incorporating gene ontology (GO) terms for 
biological process, molecular function, cel-
lular localization and protein domain (http://
www.geneontology.org) as well as pathways 
collection from GenMAPP (http://www.gen-
mapp.org) and Kyoto Encyclopedia of Genes 
and Genomes (KEGG: http://www.genome.
ad.jp/kegg). P<0.001 was considered statis-
tically significant.  
Real-time PCR
Quantitative real-time PCR was performed 
using the ABI/Prism 7000 sequence detection 
system (Applied Biosystems, Foster City, CA). 
PCR conditions were as follows: 2 min at 50°C 
and 10 min at 95°C followed by 40 cycles of 
15 seconds at 95°C and 1 min at 60°C, with 
data collection in the last 30 seconds. All PCR 
were performed with SYBR Green Master mix 
(Applied Biosystems), 10ng cDNA, and primer 
concentration of 300 nmol/L in a total volume 
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of 25 μl. Quantification of the PCR signals was 
performed by comparing the cycle threshold 
value (Ct) of the gene of interest of each sam-
ple with the Ct values of the reference gene 
GAPDH (δCt). Relative expression is calcula-
ted as 2-δCtx10,000. Primers sequences for 
gene expression analysis for hGAPDH total 
hAIF-1 and the AIF-1 isoforms are depicted 
in Table I.
Measurement of cytokines in culture 
supernatant
TNFα and IL-6 levels were measured in the 
supernatant of the cell cultures, using com-
mercially available kits (Bio-Rad Laborato-
ries, Hercules, USA) according to the manu-
facturer’s instructions (26). Cytokine levels 
were measured and analyzed with the Bio-
Plex system (Bio-Rad Laboratories). Data 
analysis was done with Bio-Plex Manager 
software (Bio-Rad Laboratories). 
Statistical analysis
Statistical analysis for array-based gene ex-
pression was performed using dChip. The 
t-statistic is computed as (mean1 – mean2) / 
sqrt(SE(mean1)2 + SE(mean2) 2), and its p-
value is computed based on the t-distribution, 
and the degree of freedom is set according to 
Welch modified two-sample t-test (25). 
Differences in AIF-1 mRNA expression, de-
termined by real-time PCR, and LPS-induced 
cytokine production, were calculated using 
Student’s T-test or Mann-Whitney U test as 
appropriate. P values were two sided and the 
level of significance was set at P<0,05. Cor-
Table 1. Oligonucleotide primers for quantitatiave PCR analysis
Software package Primer Express Version 2.0 (applied Biosystems) was used to select appropriate primer sets. All 
sequences are presented in the 5->3’ direction
Table 2. Overview microarray analysis results (functional clusters)
cDNA FORWARD PRIMER REVERSE PRIMER
hGAPDH
hAIF-1 total
hAIF-1 isoform 1
hAIF-1 isoform 2
ATC TTC TTT TGC GTC GCC AG
GGA AAA AGC GAG AGA AAA GGA AA
TGG TGT GCA GGC CTA AGA AGA
CTC AGT CCC CTG CTG AAA ACC
GGA GAG CCT GCA GAC AGA GG
TTC CCC ATG GTG TCT GAG C
AAT CAG GGC AAC TCA GAG ATA GCT
CTT CCG CAT CCC CAT TCT C
GAG AGC AGA AGG GAT AAG CGC
GGC TCA TAG CTC AGC AGA TGChAIF-1 isoform 3
The enrichmnts in GO/protein domain/pathway are assesed by using dCHIP. P-values were calculated base on the num-
ber of genes belonging to GO/protein domain/pathwas withing the selected group of genes ( RA vs. healthy controls).
FUNCTIONAL CLUSTERS P VALUE
Gene Ontology
Immune response
Complement activation, classical pathway
innate immune response
Protein domain
Pathway
Complement Activation Classical
Complement C1q protein
0.000031
0.000125
0.000782
0.000045
0.000034
NUMBER
IN LIST
9
3
3
3
3
NUMBER
ON ARRAY
974
58
108
33
29
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relation between the real-time PCR values 
and cytokine levels were evaluated by Pear-
son’s linear regression model and p<0.05 
was considered statistically significant.
Results
Microarray analysis of DCs derived from 
RA patients. 
The RNA isolated from DCs derived from 
3 RA patients (RA) and 2 healthy controls 
was used for the array-based gene expres-
sion study. All RNA samples were of suffi-
cient quality and integrity as determined by 
RNA gel, and were subsequently analyzed 
by using human genome array U130 plus 
2.0. (Affymetrix, Santa Clara) as described 
in the materials and methods section. After 
normalization, model-based expression fit-
ting and filtering by using dChip, total filte-
red genes were further analyzed and clus-
tered. We have identified 104 differentially 
expressed genes; 33 up regulated genes 
(subcluster 1) and 71 down regulated  ge-
nes (subcluster 2) between DCs derived 
from RA and healthy controls by applying 
criteria of more than 2 fold change and sta-
tistical significance (p<0.05; Figure 1). Re-
markably, in this group of genes statistically 
significant enrichment of genes involved in 
immune response, complement activation, 
Complement component 1, Q subcomponent, beta polypeptide
Myeloid cell nuclear differentiation antigen
Immunoglobulin lambda joining 3
Membrane-spanning 4-domains, subfamily A, member 1
Secreted and transmembrane 1
Immunoglobulin lambda locus
Immunoglobulin heavy locus
Complement component 1, Q subcomponent, alpha polypeptide
Complement component 1, Q subcomponent, gamma polypeptide
5
3
-4
-4
5
-4
-4
5
3
5
5
3
5
5
3
GENE NAME IMMUNERESPONSE
COMPLEMENT
ACTIVATION
INNATE IMMUNE
RESPONSE
FUNCTIONAL CLUSTERS
(FOLD CHANGE)
Table 3. Gene list belonging to the functional clusters
Table 4. RA genes with highest fold change difference compared to healthy controls
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
C-type lectin domain family 12, member A
Epithelial membrane protein 1
Allograft inflammatory factor 1
Purinergic receptor P2Y, G-protein coupled, 12
C-type lectin superfamily 4, member G
Membrane-spanning 4-domains, subfamily A, member 6A
Secreted and transmembrane 1
Complement component 1, Q subcomponent, alpha polypeptide
cAMP responsive element binding protein 5
Complement component 1, Q subcomponent, beta polypeptide
MOB1, Mps one binder kinase activator-like 2B
Ras-induced senescence 1
Myeloid cell nuclear differentiation antigen
Complement component 1, Q subcomponent, gamma polypeptide
Reticulon 1
Chromosome 9 open reading frame 28
EST
Carboxypeptidase, vitellogenic-like
Potassium voltage-gated chanel, Isk-related family, member 3
Calpain 2, (m/II) large subunit
11.
8.
8.
8.
8.
7.
5.
5.
5.
5.
5.
4.
3.
3.
3.
3.
3.
3.
3.
3.
FOLD CHANGE
NM_138337
NM_001423
AF299327
AA810452
BC039679
AA045175
BF939675
NM_015991
AI819043
NM_000491
AI692878
BF_062629
NM_002432
AI184968
NM_021136.
BC000122
AA047234
NM_031311
AI692703
M23254
ACCESSION
CLEC12A
EMP1
AIF-1
P2RY12
CLEC4G
MS4A6A
SECTM1
C1QA
CREB5
C1QB
MOBKL2B
TMEM158
MNDA
C1QC
RTN1.
FAM125B
CPVL
KCNE3
CAPN2
GENE SYMBOL
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Figure 1. Hierarchical cluster analysis of differentially ex-
pressed genes. RNA were isolated from DCs derived from 
three RA patients (RA) and two healthy donors (HE). The 
individual samples were coded by donor origin and the 
number. The gene expression profiling was performed as 
described in Materials and Methods. Hierarchical cluster 
analysis was performed on genes (vertical dendrogram) 
and samples (horizontal dendrogram) according to the 
algorithm described in Materials and Method. The mag-
nified view in the box shows sample information in color 
blocks (1st row :individual sample color code, 2nd row: 
blue for HE, green for RA). The colors represent relative 
expression level. Red: up regulation, Blue: down regula-
tion, White: avarage. 
and innate immune response were found. 
In agreement with gene function, protein do-
main of complement c1q protein as well as 
pathway signature of classical complement 
activation were found. These results are 
summarized in Table 2. There was a large 
overlap among the genes belonging to these 
biological processes, and three subcompo-
nents of complement component 1q (C1q) 
were the common element complying these 
gene categories (Table 3). These results de-
monstrate that DCs from RA patients have 
a gene expression signature very different 
from healthy controls (Figure 1 box), althou-
gh they can mature and differentiate similar 
to DCs from healthy controls. The most pro-
nounced signature is the activation of clas-
sical complement pathway.  
We then analyzed the genes with highest 
fold change difference compared to healthy 
controls. Table 4 enlists the top 20 genes, 
in which the redundant genes are elimina-
ted. The values derived from different probe 
sets against the same gene were very simi-
lar, demonstrating the accuracy of analysis. 
We identified allograft inflammatory factor 1 
(AIF-1) as one of the genes with the highest 
magnitude of differential expression. Inte-
restingly, AIF-1 is located at chromosomal 
position 6p21, a region that is associated 
with various autoimmune disorders, inclu-
ding RA (40). 
Real-time PCR analysis of AIF-1 expression
At least three alternatively spliced variants 
of AIF-1 are described thus far, which might 
exert different functions. Since array-based 
microarray analysis did not discriminate 
between the separate isoforms, we deter-
mined the expression of the alternatively 
spliced AIF-1 variants using real-time PCR. 
As shown in Figure 2A, the expression of to-
tal AIF-1 was significantly enhanced in DCs 
from RA patients (relative expression he-
althy controls 2906 vs. RA 17900; p value = 
0.04), which was a comparable to the results 
of the microarray analysis. The separate 
AIF-1 isoforms also showed clearly enhan-
ced expression in DCs from RA patients (Fi-
gure 2B – 2D), however this difference was 
not statistically significant for all of the AIF-1 
H
E
1
H
E
2
R
A
1
R
A
2
R
A
3
I
II
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Figure 2. Relative mRNA expression (2-δCT x 10,000) of the total AIF-1 expression (A) and the separate isoforms, isoform 
1 (B), isoform 2 (C) and isoform 3 (D) on dendritic cells and on monocytes (E-H) from healthy controls (N = 5) and RA 
patients (N = 5). Error bars represent SEM.
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isoforms (relative expression isoform 1 he-
althy controls 44 vs. RA 238; NS, isoform 2 
healthy controls 8 vs. RA 65; p value = 0.01, 
isoform 3 healthy controls 197 vs. RA 899; 
NS). In addition, we determined the AIF-1 
expression on LPS-stimulated (mature) DC. 
Here we found that although the expression 
of AIF-1 on DCs was clearly down-regula-
ted by LPS, expression on mature DCs from 
RA patients was still significantly enhanced 
compared to mature DCs from healthy indi-
viduals.
To examine whether the difference in AIF-
1 expression between healthy controls and 
RA patients was specific for DCs or whether 
this was already present on monocytes, we 
determined the expression of total AIF-1 and 
the separate AIF-1 isoforms on monocytes 
also (Figure 2E– 2H). Although not statisti-
cally significant, just as in DCs, the expres-
sion of total AIF-1 was enhanced in mono-
cytes from RA patients (relative expression 
healthy controls 34560 vs. RA 75580; NS). 
Furthermore, the expression of the AIF-1 
Figure 3. Correlation between relative mRNA expression of total AIF-1 and its separate isoforms  and TLR-induced 
production of IL-6 and TNFα in dendritic cells. In this figure, values of healthy individuals (filled checks) as well as RA 
patients (open checks) are depicted. *P<0.05, statistically significant.
Figure 4. Correlation between relative mRNA expression of total AIF-1 and its separate isoforms  and TLR-induced pro-
duction of IL-6 and TNFα in monocytes. In this figure, values of healthy individuals (filled checks) as well as RA patients 
(open checks) are depicted. *P<0.05, statistically significant.
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isoforms was enhanced in RA patients com-
pared to healthy controls as well (relative 
expression isoform 1 healthy controls 729 
vs. RA 1890; NS, isoform 2 healthy controls 
158 vs. RA 623; p value = 0.02, isoform 3 
healthy controls 15550 vs. RA 33450; p va-
lue = 0.03). 
Correlation of AIF-1 expression and 
TLR4-induced cytokine production
Since DCs from RA patients express higher 
levels of AIF-1 mRNA and it is known that 
cells from RA patients produce higher levels 
of IL-6 and TNFα upon TLR4-mediated sti-
mulation, we investigated whether the basal 
AIF-1 expression on immature DCs was 
correlated with the TLR4-induced cytokine 
production. As shown in Figure 3, the ex-
pression of total AIF-1 in DCs is strongly cor-
related with the TLR4-induced production of 
IL-6 (pearson r = 0.84, p value = 0.04) and to 
a lesser extent with TNFα (pearson r = 0.77, 
NS). Furthermore, the separate AIF-1 iso-
forms were also correlated with the produc-
tion of IL-6 (isoform 1: pearson r = 0.85, NS; 
isoform 2: pearson r = 0.90, p value 0.04; 
isoform 3: pearson r = 0.74, NS) and TNFα 
(isoform 1: pearson r = 0.93, p value = 0.02; 
isoform 2: pearson r = 0.92, p value 0.01; 
isoform 3: pearson r = 0.70, NS).
To check whether the correlation between 
AIF-1 expression and TLR4-induced cy-
tokine production was specific for DCs we 
determined the correlation between to-
tal AIF-1 and the separate AIF-1 isoforms 
TLR4-induced IL-6 and TNFα production 
on monocytes as well. As shown in Figure 
4, the expression of total AIF-1 in DCs is 
strongly correlated with the TLR4-induced 
production of IL-6 (pearson r = 0.86, p value 
= 0.003) and TNFα (pearson r = 0.83, p va-
lue = 0.02). Furthermore, the separate AIF-1 
isoforms were also correlated with the pro-
duction of IL-6 (isoform 1: pearson r = 0.86, 
p value = 0.003; isoform 2: pearson r = 0.67, 
p value 0.04; isoform 3: pearson r = 0.66, 
NS) and TNFα (isoform 1: pearson r = 0.87, 
p value = 0.01; isoform 2: pearson r = 0.66, 
NS; isoform 3: pearson r = 0.66, NS).
Discussion
In the present study, using an array-based 
gene expression approach and real-time 
PCR, we tried to identify factors that were 
differentially expressed in cells from RA 
patients compared to healthy controls. Stri-
kingly, among the 20 genes with the highest 
fold upregulation in RA patients we found 5 
genes which all are involved in the innate 
immunity; two C-type lectins and three com-
plement components. We also indentified 
the AIF-1 gene among the 20 genes with 
highest fold upregulation. Interestingly, AIF-
1  is located at chromosomal position 6p21, 
a region that is associated with various au-
toimmune disorders, including RA (40).
In this study we demonstrated that AIF-1 
expression in monocytes and DCs from 
RA patients was strongly enhanced com-
pared to monocytes and DCs from healthy 
controls. Furthermore, the expression of 
total AIF-1 as well as its separate isoforms 
strongly correlated with the TLR4-induced 
cytokine production on DCs as well as on 
monocytes. 
AIF-1 (allograft inflammatory factor 1) was 
first identified in rat cardiac allografts under-
going chronic rejection (27). The expression 
was confined to macrophages and neutrop-
hils and was strongly regulated by the T-cell 
derived cytokine IFNγ. Ever since, AIF-1 ex-
pression was studied in several pathological 
conditions such as autoimmune encepha-
lomyelitis, diabetes and cerebral infarction 
(28-30). Overexpression of AIF-1 augmen-
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ted lipopolysaccharide-induced production 
of IL-6, IL-10 and IL-12 in a mouse macro-
phage cell line, suggesting a role for AIF-1 in 
inflammatory processes (31).  However, the 
exact role of AIF-1 in inflammation and im-
mune regulation is still not fully understood.
There are several alternatively spiced vari-
ants of AIF-1 and at least 3 isoforms enco-
ded by different exons have been described 
(32). AIF-1 transcript 2 and 3 have a spe-
cific domain, whereas AIF-isoform 1 is just 
a common fragment of AIF-1 isoform 2 and 
isoform 3 (33). 
Recently, it was demonstrated that AIF-1 
protein was markedly increased in affected 
skin from patients with systemic sclerosis 
compared to normal skin and that the AIF-1 
positive cells include T-cells, macrophages 
and endothelial cells (33). It is very interes-
ting that we demonstrated here that the ex-
pression of all AIF-1 isoforms was increased 
in monocytes and DCs from RA patients, 
which is, like systemic sclerosis, classified 
as a rheumatic autoimmune disease as 
well. 
The fact that the increased AIF-1 expression 
was not specific for DCs, but also seen in 
freshly isolated monocytes, suggests that its 
expression was under regulation of systemic 
inflammatory factors. For example, IL-1β 
and TNFα, which are increased in serum of 
RA patients and are considered as key cy-
tokines in the pathogenesis of RA (34-36), 
are both known to promote the expression 
of AIF-1 in macrophage cell lines (37). The-
refore it is quite conceivable that AIF-1 ex-
pression in RA patients is enhanced due to 
increased serum levels of IL-1β and TNFα. 
In this context, it would be of great interest 
to investigate whether anti-TNFα therapy, 
which is now successfully used in the clinic 
to treat RA, would decrease the expression 
of AIF-1 on peripheral blood monocytes in 
turn. However, no research has been con-
ducted to investigate this subject thus far. 
Previously, we described that DCs from RA 
patients produce much higher amounts of 
cytokines upon stimulation of TLR4 (16). In 
the present study we found that the expres-
sion of total AIF-1 as well as some of the se-
parate isoforms was strongly correlated with 
the TLR4-induced production of IL-6 and 
TNFα. These findings suggest that AIF-1 is 
involved in the TLR4 hyperresponsiveness 
during rheumatoid arthritis. There are some 
indications that AIF-1 isoform 2 and isoform 
3 could have opposite effects on cell activa-
tion as it was reported that overexpression 
of isoform 3 caused proliferation of vascu-
lar smooth muscle cells (VSMC), whereas 
overexpression of isoform 2 inhibited proli-
feration (38). However, our study does not 
indicate different functions of AIF-1 isoform 
2 and isoform 3 thusfar. Further studies into 
the function of the AIF-1 isoforms are re-
quired to elucidate the exact role of the AIF-
1 isoforms.
Very recently, an independent article that 
did not use an array-based gene expres-
sion approach, also suggested a role for 
AIF-1 in the pathogenesis of RA (39). Here, 
expression of AIF-1 was found to be higher 
in synovial tissue and synovial fluid from RA 
patients compared to patients with osteo-
arthritis (OA) and AIF-1 levels in synovial 
fluid correlated with the IL-6 concentration. 
These results seem to be in line with our fin-
dings, although this study did not address a 
role for the separate AIF-1 isoforms. These 
results further indicate the potential involve-
ment of AIF-1 in the pathogenesis or chroni-
city of RA. 
In conclusion, using an array-based gene 
expression analysis, we identified AIF-1 as 
a potential factor to be involved in the TLR4 
hyperresponsiveness in RA. We showed en-
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hanced expression of total AIF-1 and its se-
parate isoforms in monocytes and DCs from 
RA patients. The strong correlation between 
AIF-1 and TLR4-mediated cytokine produc-
tion, further substantiates a role for AIF-1 in 
this process.  However, further investigation 
into the specific function of the separate AIF-
1 isoforms might provide additional evidence 
with respect to the exact role of AIF-1 in the 
TLR4 hyperresponsiveness as well as the 
pathogenesis of RA. 
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by so-called pattern recognition receptors 
(PRR), from which the Toll-like receptor fa-
mily (TLR) has been studied most intensively. 
While TLR2 and TLR4 were identified to re-
cognize ligands from bacterial origin, TLR3, 
TLR7 and TLR9 serve as receptors for viral 
nucleic acids and therefore would have a key 
role in antiviral immunity (5-8) (9;10), by ef-
fective production of type I IFNs. Production 
of type I IFNs by TLR-mediated immune ac-
tivation requires activation of IRF-3 and IRF-
7 (11); TRIF appeared to be the key adaptor 
molecule that enables TLR3 to trigger pro-
duction of type I IFNs, whereas TLR7 and 
TLR9 induce production of type I IFNs TRIF-
independently, via MYD88 (12). In addition, 
to induce an appropriate antiviral response, 
production of type I IFNs was also found to 
be involved in the immune response against 
ligands from bacterial origin, as autocrine 
production of type I IFNs upon TLR4-media-
ted lipopolysaccharide (LPS) stimulation was 
Objective. To investigate whether the synovial expression of TLR3 and TLR7 was associated with 
the expression of the pro-inflammatory cytokines IFNα, TNFα, IL-1β, IL-12, IL-17 and IL-18 and to 
study whether the expression of these receptors and cytokines were related to each other in vitro. 
Methods. Using immunohistochemistry, TLR3, TLR7 IFNα, TNFα, IL-1β, IL-12, IL-17 and IL-18 
expression was determined on synovial specimens from 34 RA patients with active disease. In 
vitro, monocytes, monocyte-derived dendritic cells and RA synovial fibroblasts were stimulated via 
TLR3 and TLR7 and IL-1β production was measured by real-time PCR and Luminex bead array 
technology. TLR3 and TLR7 mRNA expression upon IFNα, IL-1β and IL-18 stimulated cells was 
assessed using real-time PCR. Functional experiments were performed by IFNα pre-incubation 
and subsequent TLR3 and TLR7 stimulation. 
Results. Synovial TLR3 and TLR7 expression was associated with the presence of IFNα, IL-1β 
and IL-18, but not with TNFα, IL-12 and IL-17. High amounts of TLR3 and TLR7-induced IL-1β mRNA 
were produced, however no biologically active IL-1β was released. Whereas both IL-1β and IL-18 
were not able to regulate TLR expression, IFNα incubation led to significantly enhanced TLR3 and 
TLR7 mRNA expression levels, which was functional in terms of TNFα and IL-6 production. 
Conclusion. In this study we showed that the expression of TLR3 and TLR7 was associated with 
IL-1β, IL-18 and IFNα in RA synovial tissue. Furthermore, we demonstrated a role for IFNα in the 
in vitro regulation of TLR3 and TLR7. These results suggest the involvement of anti-viral immune 
responses in RA and IFNα as a key player in chronic inflammation
Introduction
Rheumatoid arthritis (RA) is a systemic au-
toimmune disease, which is characterized by 
chronic inflammation of the synovial joints. 
Although the cause of RA is still unknown, 
the role of viruses has been brought forward 
many times in the past as a factor implicated 
in the pathogenesis of RA. For example, cy-
tomegalovirus (1), Epstein-Barr virus (2) and 
parvovirus B19 (3) are all frequently present 
in synovial tissue and synovial fluid from RA 
patients. Furthermore it was demonstrated 
that dsRNA, has clear arthritogenic proper-
ties (4), a finding that further substantiated 
the potential role of viruses in RA. 
Although type I interferons (IFNα/IFNβ) are 
considered as products of the antiviral im-
mune response, the precise pathways that 
underlie such a response is complex and not 
elucidated to a full extent. However, it is ge-
nerally accepted that the first inflammatory 
response against virus infections is mediated 
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required for optimal secretion of IL-12 and 
TNFα by dendritic cells (DCs) (13). The role 
of type I IFNs in RA was recently elegantly 
shown by Pouw-Kraan and collegues, who 
demonstrated that RA patients had a signi-
ficantly elevated expression of genes which 
were regulated by type I IFNs compared to 
healthy individuals (14).
Recently, it was demonstrated that TLR3 
and TLR7 are abundantly expressed in sy-
novial tissue from RA patients (15) and that 
RA synovial fibroblasts could be activated 
by endogenous RNA released from necrotic 
RA synovial fluid cells via TLR3 (16). TLR7, 
on the other hand, can be activated by highly 
conserved RNA sequences, which are for 
example present in sera from patients with 
systemic lupus erythematosus (17;18). For-
merly, it has already been demonstrated that 
host-derived heat-shock proteins, fibronec-
tin and hyaluronic acid, which are likely to be 
abundant in the RA synovial compartment, 
are able to induce an immune response via 
TLR4 (19-21). The finding that tissue-dama-
ge-induced release of endogenous factors 
can stimulate an immune response against 
self antigens, could lead to the development 
of autoimmune diseases, such as RA. 
Besides type I IFNs, other cytokines have 
been studied for their role in the pathoge-
nesis of RA. IL-1β, for example, was one 
of the first cytokines of interest in the field 
of RA, because of its biological role in joint 
destruction, shown in models of experimen-
tal arthritis, followed by TNFα, which acts 
strongly synergistic with IL-1β (22;23). In 
particular for TNFα, its role in RA has been 
further emphasized by the success of anti-
TNFα therapy in RA patients. IL-12 and IL-
18, known as Th1-directing cytokines, are 
alone or in combination strong inducers of 
IFNγ and have shown to be important in the 
development of arthritis in murine models 
(24;25). Furthermore, both cytokines are 
present in synovial tissue from RA patients 
and cause strong upregulation of TLR2 and 
TLR4, mainly driven by production of IFNγ 
(26). A more recent cytokine of interest in 
the area of RA is IL-17, a strong inducer of 
IL-1β and TNFα, which has shown to be 
involved in joint inflammation during expe-
rimental arthritis (27;28). In the upcoming 
years, phase III clinical trials will establish 
whether these cytokines will be useful as 
therapeutic targets in RA. 
The complex mechanisms that underlie the 
pathogenesis of RA and the involvement of 
various cytokines in these processes raised 
the question if these cytokines played a role 
in the expression and regulation of specific 
TLRs during the disease. Therefore we in-
vestigated whether the synovial expression 
of TLR3 and TLR7 was associated with the 
degree of inflammation and the expression 
of the pro-inflammatory cytokines IFNα, 
TNFα, IL-1β, IL-12, IL-17 and IL-18. Further-
more we studied whether these cytokines 
were able to regulate TLR3 and TLR7 ex-
pression in cells which are present in RA 
synovial tissue. 
Methods
Patients / study population
For immunohistochemistry, synovial biop-
sies from RA patients (n=34) were obtained, 
using small needle arthroscopy, from the 
medial and lateral suprapatellar pouch on 
each occasion. For in vitro experiments, he-
parinized venous blood was collected from 
5 RA patients and 12 healthy volunteers. 
Patients were attending the department of 
Rheumatology of the Radboud University 
Nijmegen Medical Centre, fulfilled the Ame-
rican College of Rheumatology criteria for 
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RA (29) and they all gave their informed 
consent. Patients using high dose predniso-
lone (>10mg/day) or anti-cytokine therapies 
(anti-TNFα and/or IL-1Ra) were excluded 
from this study. The local Medical Ethics 
Committee approved the study protocol.
Immunohistochemical staining of synovial 
biopsies
Tissue samples were immediately fixed with 
4% formaldehyde and embedded in paraf-
fin. Staining of IL-1β, IL-12, IL-17, IL-18 and 
TNFα was performed as described previ-
ously (30). For TLR3, TLR7 and IFNα stai-
ning, sections were incubated for 60 minutes 
with antibodies against human TLR3 (T-17), 
human TLR7 (V-20) or IFNα (FL-198), which 
were all obtained from Santa Cruz, Califor-
nia, USA. After this, endogenous peroxidase 
was blocked with 3% H2O2 in methanol for 
15 minutes and subsequently the appropri-
ate biotinylated secondary antibody (mouse 
anti-goat: Jackson ImmunoResearch, West 
Grove, PA, USA / swine anti-rabbit: Dako-
Cytomation, Glostrup, Denmark) was incu-
bated for 30 minutes. For TLR3 and TLR7 
staining, Vectastain® ABC (Vector Laborato-
ries, Burlingame, CA, USA) reagent was in-
cubated for 30 minutes, developed with DAB 
(Sigma, St. Louis, MO, USA), and counter-
stained with hematoxilin for 30 seconds. For 
IFNα staining, sections were incubated with 
streptavidin-PO (DakoCytomation, Glostrup, 
Denmark), developed with DAB (Sigma, St. 
Louis, MO, USA), and counterstained with 
hematoxilin for 30 seconds. 
Staining was semi quantitatively scored on 
a 5-point scale (scores 0-4) at 200x magni-
fication; a score of 0 represented no or mi-
nimal staining, score 1 stands for 10%-20% 
positive cells, 2 for 30%-40%, 3 for 50%-
60%, and a score of 4 represented staining 
of a more that 60% of the cells. 
Isolation and culturing of monocytes 
and monocyte-derived DCs
PBMCs were isolated from heparinized 
venous blood using density gradient cen-
trifugation over Ficoll-Paque (Amersham 
Biosciences, Roosendaal, The Nether-
lands). Low-density cells were collected 
and washed with citrated PBS 5% FCS. For 
monocytes, CD14+ cell fraction was isolated 
using MACS® cell separation, according 
to the manufacturer’s instructions. Briefly, 
PBMCs were incubated with anti-human 
CD14 MicroBeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany) for 30 minutes, subse-
quently cells were washed and CD14+ frac-
tion was separated from the CD14- fraction 
over a MACS® MS separation column (Mil-
tenyi Biotec, Bergisch Gladbach, Germany). 
CD14+ cell fraction was eluted from the co-
lumn, washed again and resuspended in a 
concentration of 0,5x106 cells/ml in RPMI 
1640 Dutch Modification (Invitrogen Corpo-
ration, Carlsbad, CA, USA), supplemented 
with 10% FCS, plated in 6-well plates and 
O/N cultured at 37°C and 5% CO2.
For monocyte-derived dendritic cells, 
PBMCs were allowed to adhere for 1 hour 
at 37°C in RPMI-1640 Dutch Modification 
(Invitrogen Corporation, Carlsbad, CA, USA 
supplemented with 2% human serum (PAA 
Laboratories, Pasching, Austria) in 25cm2 
cell culture flasks (Corning Incorporated, NY, 
USA). Adherent monocytes were cultured in 
RPMI-1640 Dutch modification supplemen-
ted with 10% fetal calf serum (FCS) and 
antibiotic-antimycotic (Life Technologies) 
in the presence of IL-4 (500 U/ml, R&D sy-
stems, Minneapolis, MN, USA) and GM-CSF 
(800 U/ml, R&D systems, Minneapolis, MN, 
USA) for 6 days. Fresh culture medium with 
the same supplements was added at day 3 
where after immature DCs were harvested 
at day 6. Immature DCs were resuspended 
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in fresh cytokine-containing culture medium, 
transferred to 6-well culture plates (Corning 
Incorporated, NY, USA) in a concentration of 
0,5´106 cells/ml and incubated at 37°C and 
5% CO2 for 24 hours.
Isolation and culturing of RA synovial 
fibroblasts
Immediately after surgery, the synovial tis-
sue was minced and digested with Dispa-
se at 37°C for 60 minutes. After washing, 
the cells were grown in Dulbecco’s mini-
mum essential medium (Gibco Invitrogen, 
Basel, Switzerland) supplemented with 
10% FCS, 50 IU/ml penicillin/streptomy-
cin, 2 mM L-glutamine, 10 mM HEPES, and 
0.2% Fungizone (all from Gibco Invitrogen). 
Cell cultures were maintained at 37°C in a 
humidified incubator in an atmosphere of 5% 
CO2. For the experiments, cultured synovial 
fibroblasts, between passages 4 and 8, were 
grown in 12-well culture plates (6 × 104 RA 
synovial fibroblasts/well) and O/N cultured 
at 37°C and 5% CO2.
Stimulation of monocytes, monocyte-
derived dendritic cells and RA synovial 
fibroblasts
To study TLR mRNA expression upon cy-
tokine stimulation, monocytes (which ex-
press TLR7), monocyte-derived DCs and 
RA synovial fibroblasts (which both express 
TLR3) were, after a 24 hour resting period, 
stimulated for 8 hours with 20 ng/ml TNFα, 
IL-1β, IL-12, IL-17, IL-18 and 100 IU/ml IFNα 
(all R&D systems, Minneapolis, MN, USA). 
Subsequently, culture supernatants were re-
moved and 1ml TRIzol reagent (Sigma St. 
Louis, MO, USA) was added to the cells and 
stored at –20°C until RNA isolation was per-
formed. 
To study functional upregulation of TLRs, 
monocytes, monocyte-derived DCs and RA 
synovial fibroblasts were, after an O/N res-
ting period, stimulated IFNα with (R&D sy-
stems, Minneapolis, MN, USA) for 24 hours 
and subsequently stimulated with the TLR3 
and TLR7 agonists poly(I:C) and loxoribin 
respectively (25mg/ml; both Invivogen, San 
Diego, USA) or medium. After another 24 
hours, culture supernatants were collected 
and stored at -20°C until cytokine measure-
ment was performed. 
RNA isolation and real-time PCR
Total RNA was extracted in 1ml of TRIzol 
reagent (Sigma St. Louis, MO, USA), an 
improved single-step RNA isolation method 
based on the method described by Chomc-
zynski et al (31). Quantitative real-time PCR 
was performed using the ABI/Prism 7000 
sequence detection system (Applied Bio-
systems, Foster City, CA). PCR conditions 
were as followed: 2 min at 50°C and 10 min 
cDNA FORWARD PRIMER REVERSE PRIMER
hGAPDH
hTLR3
hTLR7
hIL-1
ATC TTC TTT TGC GTC GCC AG
AGA GTT GTC ATC GAA TCA AAT TAA AGA G
AAT CTG TAC CTG TCC TGC GTG TT
TGC CAT CAA GAA AGT TGA TGC T
ATG ACC AAC AAG TGT CTC CTC C
TTC CCC ATG GTG TCT GAG C
CAT TGT TCA GAA AGA GGC CAA AT
TGG GTA ATT TTT GGG ATC TAC ACT CT
GGA ATG TAG AGG TCT GGT TGA AGA G
GCT CAT GGA AAG AGC TGT AGT GhIFN
Table 1. Oligonucleotide primers for quantitatiave PCR analysis
Software package Primer Express Version 2.0 (applied Biosystems) was used to identify appropriate primer sets. All 
sequences are presented in the 5->3’ direction
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at 95°C followed by 40 cycles of 15 s at 95°C 
and 1 min at 60°C, with data collection in the 
last 30 seconds. All PCRs were performed 
with SYBR Green Master mix (Applied Bio-
systems), 10 ng cDNA, and primer concen-
tration of 300 nmol/L in a total volume of 25 
μl. Quantification of the PCR signals was 
performed by comparing the cycle threshold 
value (Ct) of the gene of interest of each 
sample with the Ct values of the reference 
gene GAPDH. Primers sequences for gene 
expression analysis for hGAPDH, hTLR3, 
hTLR7 and IL-1β are depicted in Table 1.    
Measurement of cytokines in culture 
supernatants
TNFα, IL-1β and  IL-6 levels were measu-
red in the supernatants of the cell cultures, 
using commercially available kits (Bio-Rad 
Laboratories, Hercules, USA) according to 
the manufacturer’s instructions (32). Cytoki-
ne levels were measured and analyzed with 
the Bio-Plex system (Bio-Rad Laborato-
ries). Data analysis was done with Bio-Plex 
Manager software (Bio-Rad Laboratories). 
IFNα production was analyzed with murine 
monoclonal capture and HRP-conjugated 
anti-IFNα antibodies (Bender MedSystems, 
Vienna, Austria) using standard ELISA pro-
cedures.
Statistical analysis
Correlations of the expression of TLRs and 
cytokines in human synovial biopsies were 
calculated using the Pearson’s linear regres-
sion model. Differences in mRNA expres-
sion and cytokine production, upon cell sti-
mulation with cytokines and TLR agonists, 
were calculated using Mann-Whitney U test. 
P values were two sided and the level of sig-
nificance was set at P<0,05.
Results
Synovial TLR3/7 expression and asso-
ciation with IL-1β and IL-18, and IFNα
Synovial biopsies from 24 active RA patients 
were used to detect TLR3, TLR7 and IFNα 
expression. Previously, these biopsies were 
also used to detect the presence of TNFα, 
IL-1β, IL-12, IL-17 and IL-18 (30). Since we 
are interested in the regulation of TLR3 and 
TLR7 in RA synovial tissue, we examined 
whether the expression of these TLRs was 
associated with the expression levels of 
A B
Figure 1. Staining of synovial tissue with an isotpe control antibody (A) or with a specific antibody against IFNα. Synovial 
tissue sections were counterstained with hematoxylin, magnification 200x.
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IFNα, TNFα, IL-1β, IL-12, IL-17 and IL-18. 
IFNα, which is known as a mediator produ-
ced upon TLR3 and TLR7 stimulation, was 
highly expressed in the lining as well as the 
sublining from RA synovial biopsies (Figure 
1). Its expression was strongly associated 
with the expression of TLR3 and TLR7 in the 
lining (Figure 2A and 2D) as well as the subli-
ning (TLR3 lining Pearson r = 0.76, P=0.02 
/ TLR3 sublining Pearson r = 0.77, P=0.01 / 
TLR7 lining Pearson r = 0.70, P=0.04 / TLR7 
sublining Pearson r = 0.84, P=0.01).
Moreover, both IL-1β and IL-18 were asso-
ciated with the expression of TLR3 in the 
lining (Figure 2B and 2C) (IL-1 lining Pear-
son r = 0.54, P=0.02 / IL-18 lining Pearson 
r = 0.48, P=0.04), although the correlation 
was much weaker than the correlation 
between IFNα and TLR3. In addition, IL-18 
expression was also associated with the ex-
pression of TLR7 in the lining (Pearson r = 
0.48, P=0.04) and although not statistically 
significant, the same trend was observed for 
the level of IL-1β and the TLR7 expression 
in the lining (Figure 2E and 2F). In contrast, 
nor IL1β or IL-18 were associated with either 
TLR3 or TLR7 expression in the sublining. 
Neither TNFα, nor IL-12, nor IL-17 was cor-
related with the TLR expression levels.
Cytokine production by monocytes, 
monocyte-derived dendritic cells and 
synovial fibroblasts
As we demonstrated that the synovial ex-
pression of TLR3/7 was associated with 
the expression of IFNα, IL-1β and IL-18, 
we further investigated the relation bet-
ween IL-1β and TLR3/TLR7 expression. 
It is generally accepted that stimulation 
of TLR3 or TLR7 leads to the production 
of type I IFNs. In line with this, in our ex-
periments we found that TLR3 or TLR7 
stimulation resulted in clearly enhanced 
mRNA expression levels of IFNβ, and low 
levels of IFNα protein could be detected in 
culture supernatants (data not shown). In 
contrast, much less is known about IL-1β 
production induced by TLR3 or TLR7 ac-
Figure 2. Correlation between TLR3/7 expression and IFNα, IL-1β, and IL-18 in synovial  biopsies from RA patients. 
Expression of TLR and cytokines were semi quantitatively scored on a 5-point scale. Expression of TLR3 was associated 
with the expression of IFNα (A), IL-1β (B) and IL-18 (C). Expression of TLR7 was also associated with the expression of 
IFNα, (D) IL-1β (E) and IL-18 (F).  
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tivation. In order to investigate this poten-
tial relation between TLR3/TLR7 and IL-1β 
we stimulated TLR3-expressing monocyte-
derived DCs and synovial fibroblasts with 
poly(IC) and TLR7-expressing monocytes 
with loxoribine. After 8 hours of stimulation 
we analyzed the IL-1β mRNA expression 
using real-time PCR. All cell types inves-
tigated showed markedly increased ex-
pression of IL-1β mRNA upon stimulation 
of either TLR3 or TLR7 (data not shown). 
Subsequently, we determined culture su-
pernatant levels of IL-1β after 24 hours of 
TLR3 or TLR7 stimulation. In contrast with 
what is known about TLR4-mediated mo-
nocyte stimulation, neither TLR7-induced 
stimulation of monocytes nor TLR3-induced 
stimulation of monocyte-derived DCs or RA 
synovial fibroblasts resulted in secretion of 
IL-1β. 
TLR regulation by cytokines
We demonstrated that TLR3/TLR7 stimulation 
could result in the production of IFNα, but not 
in the production of IL-1β, at least not on pro-
tein level. Therefore, we investigated whether 
the synovial association between TLR3/TLR7 
and IFNα, IL-1β and IL-18 could be caused 
as IFNα, IL-1β and IL-18 regulate the ex-
pression of TLR3/TLR7. For this, we cul-
tured monocytes (TLR7-expressing cells), 
monocyte-derived dendritic cells (TLR3-ex-
pressing cells) and RA synovial fibroblasts 
(TLR3 expressing cells) in the presence of 
IFNα, IL-1β and IL-18. After 8 hours of incu-
bation, TLR3 and TLR7 mRNA expression 
was determined by real-time PCR. Interes-
tingly, IFNα did significantly enhance the 
TLR3 mRNA expression on RA synovial 
fibroblasts and monocyte-derived DCs. In 
addition TLR7 mRNA expression on mono-
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cytes, was also strongly increased upon in-
cubation with IFNα (Figure 3). The increased 
IFNα-induced TLR expression was equal 
between RA patients and healthy volunteers 
and was specific for TLR3 and TLR7, since 
the expression of TLR2 as well as TLR4 was 
not regulated upon IFNα incubation (data 
not shown). In contrast to IFNα, IL-1β and 
IL-18 did not lead to up regulation of TLR3 or 
TLR7 mRNA. In addition we tested whether 
other RA-associated cytokines, which were 
not associated with TLR3/TLR7 in RA sy-
novial tissue, were able to regulate the ex-
pression of TLR3 and TLR7. However, none 
of the cytokines investigated, namely IL-12, 
IL-17 and TNFα, did lead to up regulation of 
TLR3 or TLR7 mRNA.
Functional effects of IFNα on TLR-
mediated cytokine production
As we demonstrated that expression of TLR3 
and TLR7 was strongly up regulated by IFNα, 
we also wanted to know whether this enhan-
ced TLR expression was functional, in terms of 
increased TLR-mediated cytokine production. 
For this we incubated TLR7-expressing mo-
nocytes and TLR3-expressing monocyte-
derived DCs and RA synovial fibroblasts 
with IFNα or medium for 16 hours and sub-
sequently stimulated TLR3 or TLR7 with 
poly(IC) and loxoribine as appropriate. As 
expected TLR3 stimulation on monocytes, 
as well as TLR7 stimulation on monocyte-
derived DCs did not lead to any cytokine 
production, because these receptors were 
not expressed on protein level by these cells, 
even after incubation of IFNα. In contrast, 
TLR7 stimulation on monocytes and TLR3 
stimulation on monocyte-derived DCs and 
RA synovial fibroblasts led to production of 
IL-6 (data not shown) and TNFα, which was 
significantly enhanced when the cells were 
preincubated with IFNα, compared to cells 
that were stimulated with TLR3/7 ligands in 
the absence of IFNα preincubation  (Figure 
4). 
Discussion
In this study we demonstrated that TLR3 
and TLR7 in synovial tissue from RA pa-
tients were associated with the presence of 
IFNα, IL-1β and IL-18. IFNα in turn, was able 
to induce upregulation of TLR3 and TLR7, 
whereas IL-1β and IL-18 were not. Pre-in-
cubation of monocytes, monocyte-derived 
DCs and RA synovial fibroblasts with IFNα, 
resulted in enhanced cell activation in terms 
of cytokine production upon TLR3 and TLR7 
stimulation. 
Type I IFNs are the key cytokines that regu-
lates the innate immune response against 
viruses (33). Type I IFNs are released upon 
transcription of IRF-3 or IRF-7 which can 
be induced following TLR3- or TLR7-me-
diated cell activation. TLR3 and TLR7 are 
highly expressed in synovial tissue from RA 
patients (15) and TLR3 and TLR7 ligands, 
such as cytomegalovirus, Epstein-Barr virus 
and parvovirus B19 have been demonstra-
ted in the synovial joints from RA patients 
also (1-3). 
Besides being produced after TLR3 and 
TLR7 activation, type I IFNs are able to in-
crease the cellular expression of TLR3 and 
TLR7 in turn. Therefore type I IFNs might 
act as key regulators in maintaining the 
inflammation processes during RA. Very 
recently, it was demonstrated that a type I 
IFN signature was present in RA patients, 
as large-scale expression profiling by mi-
croarray analysis showed markedly eleva-
ted expression of IFN type I regulated ge-
nes in pheripheral blood cells of RA patients 
(14). Type I IFNs are known to inhibit TNFα 
and IL-1β production, whereas it enhances 
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the production of IL-10 and IL-1Ra (34) and 
therefore quite promising in suppressing ar-
thritis activity. Although IFNβ therapy was 
shown to be effective in animal models of 
collagen-induced arthritis (CIA), several cli-
nical trials of IFNβ in patients with RA have 
not shown to be effective so far (35-37). 
The fact that type I IFNs type I strongly up 
regulate TLR3 and TLR7, which in turn are 
continuously stimulated by ligands present 
in the synovial joints, might in fact maintain 
the inflammatory processes and therefore 
lead to IFNβ therapy failure. However, the 
actual role for TLRs in the failure of IFNβ 
therapy in RA should be subject of further 
studies in the future.
Identification of endogenous TLR agonists 
is of great interest in terms of autoimmune 
disorders. In particular for TLR4 several 
endogenous agonist have been described 
thus far. For example hyaluronan frag-
ments, heparan sulfate, fibronectin and 
(small) heat-shock proteins (19-21;38) can 
all be released in RA joints as a result of 
inflammation-induced tissue injury and cell 
stress. In addition, Brentano et al described 
an endogenous ligand for TLR3, as endoge-
nous RNA, released from necrotic synovial 
fluid cells, was able to TLR3-mediated acti-
vation of RA synovial fibroblasts (16). High-
ly conserved RNA sequences within small 
nuclear ribonucleoprotein particles are 
able to activate immune cells via TLR7 and 
could act as an endogenous auto antigen 
in systemic lupus erythematosus (17;18). 
TLR-mediated immune responses in the 
synovial joints might result in the release of 
endogenous TLR ligands, originating from 
cells under stress or tissue damage. The-
refore is not unlikely that a self sustaining 
loop of TLR-activation and generation of 
new endogenous TLR ligands might lead to 
a chronic inflammatory process as occurs 
during RA. 
Expression of TLR3 and TLR7 in RA sy-
novial tissue was, besides the association 
with IFNα, also associated with the ex-
pression of IL-1β and IL-18. Furthermore, 
stimulation of TLR3 and TLR7 resulted in 
markedly enhanced expression of IL-1β 
and IL-18 mRNA, although no active IL-1β 
protein could be detected in the culture su-
pernatants. It is known that production of 
the active IL-1β and IL-18 proteins requires 
cleavage of the proIL-1β and proIL-18 mole-
cules by activation of caspase-1. A lack of 
caspase-1 activating capacity of TLR3 and 
TLR7 might explain why those TLRs do not 
directly induce active IL-1β and IL-18, even 
though high levels of IL-1β and IL-18 mRNA 
were present.
It is generally believed that bacterial lipopo-
lysaccharides are activators of caspase-1 
through stimulation of TLR4 (39).  Recently 
it was described that cells from RA patients 
showed enhanced activity, in terms of cy-
tokine production, upon TLR4-mediated 
stimulation compared to cells from healthy 
controls (15). Since TLR4 stimulation could 
induce the production of type I IFNs by the 
TRIF-IRF3-mediated pathway (40), we spe-
culate that the enhanced TLR4-mediated 
cell activation in RA patients, leads to en-
hanced levels of type I FNs, which in turn 
results in up regulation of TLR3 and TLR7. 
So TLR4 seems to be able to induce IFNα-
mediated TLR3 and TLR7 upregulation as 
well as production of active IL-1β and IL-18. 
In this light, it is conceivable that TLR3 and 
TLR7 do not directly relate to IL-1β and IL-
18, but that correlation of these TLRs and 
IL-1β/IL-18 in RA synovial tissue results 
from the fact that they are both regulated 
after TLR4 activation.
Lately, it has been demonstrated that stimu-
lation of several different TLRs at the same 
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time, leads to synergistically induced levels 
of pro-inflammatory mediators (15;41). Pre-
liminary experiments of our group showed 
that synergistically induced cytokine levels, 
produced upon co-stimulation of TLR3 and 
TLR4, were even more enhanced when cells 
were preincubated with IFNα (unpublished 
results). In this light, it is tempting to specu-
late that the presence of type I IFNs in the 
synovial joint of RA patients, at least partly, 
contributed to the breakthrough of tolerance 
and the development of autoimmunity.    
In contrast to our findings, Severa and col-
leagues recently demonstrated that priming 
of immature DCs, that usually do not ex-
press TLR7, with exogenous IFNβ induced 
a functionally active TLR7. These differen-
ces in experimental outcome might be ex-
plained by dissimilarities in the experimental 
setup. For example, Severa et al., cultured 
monocyte-dendritic cells in the absence of 
IL-4 and GM-CSF for 20 hours before incu-
bation with IFNβ. In the past, we have seen 
that monocyte derived dendritic cells, which 
were not fully matured, show some sort of 
re-differentiation, resulting in monocyte-like 
cells (unpublished results). Since monocy-
tes, in contrast to monocyte-derived dendri-
tic cells, do express TLR7, this might explain 
why Severa and colleagues demonstrate 
IFN-induced TLR7 regulation.  
In conclusion, in this study we showed that 
the expression of TLR3 and TLR7 was as-
sociated with IFNα, IL-1β and IL-18 in RA 
synovial tissue. Furthermore, we demon-
strated the involvement of IFNα in the regu-
lation of TLR3/TLR7 in vitro, a mechanism 
that might underlie the associated synovial 
expression. These results suggest the in-
volvement of anti-viral immuneresponses in 
RA and type I interferons as a key player in 
chronic inflammation.
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Objective. To investigate whether the genetic TLR4 variant, Asp299Gly, has consequences with 
respect to TLR4 mRNA and protein expression. In addition, cytokine production upon stimulation 
of RA mononuclear cells with exogenous and endogenous TLR4 ligands was studied. 
Methods. PBMCs from 28 RA patients carrying (AG; N=14) or not carrying (AA; N=14) the genetic 
TLR4 variant, Asp299Gly, were incubated with LPS (exogenous TLR4 ligand), HSPB8 (endoge-
nous TLR4 ligand) or medium. After 24 hours of incubation, levels of IL-6, TNFα and IL-10 were 
determined in the culture supernatants. Baseline TLR4 expression was determined by real-time 
PCR and flowcytometry. 
Results. Baseline TLR4 mRNA and protein expression were not significantly different in cells from 
RA patients carrying the genetic AG TLR4 variant, compared to the patients who were homozy-
gous for the wild type allele. In contrast, the relative expression of TLR4-bearing CD14+ cells in 
PBMCs from patients with the Asp299Gly TLR4 variant was significantly higher than in PBMCs 
from patients without the polymorphism. Upon exogenous TLR4 stimulation production of IL-6 and 
TNFα and IL-10 were clearly decreased (61%, 66% and 56% decrease respectively) by PBMCs 
from patients carrying the TLR4 variant, just as the production of IL-6, TNFα and IL-10 (54%, 69% 
and 41% decrease respectively) upon endogenous TLR4 stimulation.  
Conclusion. These experiments showed that, while TLR4 expression was not reduced in PBMCs 
from RA patients carrying the TLR4 variant, exogenous as well as endogenous TLR4 stimulation 
did lead to impaired pro- and anti-inflammatory cytokine production by these cells.
Introduction
The innate immune system provides an 
essential defense mechanism against mi-
crobial pathogens. Microbial components, 
known as pathogen-associated molecular 
patterns, can be recognized by Toll-like 
receptors (TLRs), which belong to the fa-
mily of pattern-recognition receptors. No-
wadays, 11 TLRs have been identified in 
humans; they are expressed by numerous 
cell types and tissues, where they detect 
pathogens leading to the induction of an 
immune response. Besides being involved 
in the recognition of microbial pathogens, 
recent research shows that TLRs are also 
implicated in the recognition of “self” mole-
cules such as fibronectin, heat-shock pro-
teins, hyaluronic acid and host derived RNA 
[1-4]. These so called endogenous ligands 
are released upon tissue damage and cell 
stress, events that are likely to occur during 
inflammatory conditions, including rheuma-
toid arthritis (RA).
RA is an inflammatory autoimmune disease, 
which is characterized by a massive infil-
tration of inflammatory cells into the joint 
resulting in chronic inflammation, eventually 
leading to destruction of the synovial joints. 
Although the exact mechanisms that are res-
ponsible for the initiation and perpetuation 
of the disease remain obscure, recent evi-
dence addressed a role for TLRs. TLRs are 
significantly higher expressed in synovial tis-
sue from RA patients compared to patients 
with osteoarthritis (OA) and healthy controls 
[5-7]. Furthermore, monocyte-derived den-
dritic cells from RA patients produce much 
higher amounts of the pro-inflammatory 
cytokines IL-6 and TNFα upon TLR2- and 
TLR4-mediated stimulation than cells from 
healthy controls, whereas cytokine produc-
tion upon TLR3 and TLR7 stimulation is not 
enhanced [6]. The role of TLRs in RA has 
recently been underscored by the finding 
that HSPB8, identified as an endogenous 
ligand for TLR4, is abundantly expressed in 
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RA synovial tissue [8]. Finally, the involve-
ment of TLRs in arthritis has been demon-
strated in several animal models of experi-
mental arthritis [9, 10] and very recently in a 
double-blind ramdomised trial [11].
Several years ago, Arbour et al described 
two common co-segregating missense mu-
tations (Asp299Gly and Thr399Ile) affecting 
the extracellular domain of TLR4, thatwere 
associated with hyporesponsiveness to bac-
terial lipopolysaccharide (LPS). In addition, 
transfection of THP-1 cells with either wild-
type or mutant alleles of TLR4 demonstrated 
that cells transfected with the Asp299Gly al-
lele showed a decreased response to LPS, 
whereas cells transfected with the Thr399Ille 
allele did not [12]. Ever since, many studies 
were performed that investigated the poten-
tial association of the TLR4 polymorphisms 
with the susceptibility to infectious disea-
ses, such as respiratory virus infections and 
septic shock [13, 14],  and  non-infectious 
disorders, such as Crohn’s disease, acute 
allograft rejection and asthma [15-17]. More-
over, research was performed to investigate 
the potential association between the TLR4 
polymorphisms and the susceptibility to and 
severity of RA. Whereas two studies descri-
bed that the Asp299Gly variant in the TLR4 
gene was not associated with susceptibility 
to RA, our group found that this variant did 
associate with decreased susceptibility, but 
not with disease severity [18-20]. The diver-
se results of these studies might result from 
the limited size and clinical characteristics of 
the study population, which makes it hard to 
draw definite conclusions. 
Following the results described by Arbour 
et al, several groups conducted research to 
investigate the functional consequences of 
the Asp299Gly variant in individuals during 
health and disease, with respect to cytokine 
production upon exogenous TLR stimulation 
[21-25]. However, due to conflicting results 
these studies had led to controversy regar-
ding this issue. Since TLR4 seems to be in-
volved in the pathogenesis of RA, and might 
be a promising therapeutic target for the fu-
ture, further research into the role of TLR4 
in cell activation seems warranted. Here we 
investigated the potential differences bet-
ween mononuclear cells (PBMCs) from RA 
patients carrying and not carrying the ge-
netic Asp299Gly TLR4 variant with respect 
to TLR4 mRNA expression, TLR4 protein 
expression and cytokine production upon 
TLR stimulation with exogenous as well as 
endogenous TLR4 agonists. We demon-
strate that, cytokine production by cells from 
patients with the genetic TLR4 variant was 
significantly diminished upon exogenous as 
well as endogenous TLR4 stimulation, des-
pite the fact that the TLR4 expression was 
unaffected. 
Materials & Methods
Patients / study population
A total of 14 RA patients heterozygous for 
the Asp299Gly TLR4 variant (AG) and 14 
RA patients without this variant (AA), at-
tending the Radboud University Nijmegen 
Medical Centre were included in this study. 
Patients fulfilled the American College of 
Rheumatology criteria for RA [26] and gave 
informed consent. Patients using high dose 
prednisolone (>10mg/day) or anti-cytokine 
therapies (anti-TNFα and/or IL-1Ra) were 
excluded from this study. Demographic and 
clinical data, such as age, gender, mean 
DAS28 from the last 6 months of disease fol-
low up, rheumatoid factor, age at the onset 
of the disease, duration of the disease and 
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DMARD use, were determined to characte-
rize the groups of patients with and without 
the variant. The local Medical Ethics Com-
mittee approved the study protocol. Since 
only 0.1% of the RA patients is homozygous 
for the Asp299Gly TLR4 variant, no patients 
with the GG phenotype were included in this 
study.
Genotyping of the TLR4 Asp299Gly vari-
ant
Genomic DNA was isolated from whole 
blood using salt extraction [27]. Geno-
typing of the TLR4 Asp299Gly polymor-
phism (869A>G; rs4986790)  was based 
on restriction fragment length polymor-
phism (RFLP) analysis. PCR amplification 
of TLR4 gene was performed in 50μl re-
action volume containing 50ng genomic 
DNA, 0.4 pmol of each primer (forward 
5’-ATACTTAGACTACTACCTCCATG-3’ 
reverse 5’-AGCCTTTTGAGAGATTT-
GAGT-3’), 10  mM Tris-HCl pH 9.0, 50 mM 
KCl, 1.5 mM MgCl2, 0.01% (w/v) gelatin, 
0.001% (v/v) Triton X-100, 0.35 mM dNTPs 
and 2 U Taq DNA polymerase (Invitrogen, 
Breda, The Netherlands). PCR conditions 
were 5 min denaturation at 94°C, followed 
by 37 cycles (94 C for 1 min, 48 C for 1 min, 
and 72 C for 1 min) and a final extension at 
72°C for 10 min. The product was purified 
on MultiscreenTM PCR plates (Millipore, Bil-
lerica, MA, USA) and genotyped by RFLP 
analysis using NcoI (Invitrogen, Breda, The 
Netherlands). RFLP analysis was validated 
by using several sequenced control sam-
ples of each genotype (AA, AG and GG). 
Digested products were separated on a 4% 
agarose gel resulting in the following frag-
ments: homozygotes common variant (AA; 
195 bp), heterozygote (AG; 195 + 172 + 
23 bp). Since the Asp299Gly TLR4 variant 
shows strong linkage disequilibrium with 
the Thr399Ile polymorphism, all patients 
with the genetic variant selected for this 
study carry both TLR4 polymorphisms.
Generation and culture of PBMCs
PBMCs were isolated from heparinized 
venous blood using density gradient cen-
trifugation over Ficoll-Paque (Amersham 
Biosciences, Roosendaal, The Nether-
lands). Low-density cells were collected 
and washed with citrated PBS 5% FCS, 
where after the cells were resuspended in 
a concentration of 0,5x106 cells/ml in RPMI 
1640 Dutch Modification (Invitrogen Corpo-
ration, Carlsbad, CA, USA), supplemented 
with 10% FCS, plated in 6-well plates and 
cultured by 37°C and 5% CO2 for 16 hours. 
Subsequently, 200ng/ml LPS (exogenous 
TLR4 agonist; Sigma, St. Louis, MO, USA) 
or 10mg/ml HSPB8 (endogenous TLR4 
agonist; kindly provided by W. Boelens, 
Dept. of Biochemistry, Nijmegen Center for 
Molecular Life Sciences, the Netherlands) 
was added to the culture. After 24 hours of 
stimulation culture supernatants were col-
lected and stored at -20°C until cytokine 
measurement was performed.
Table 1: Oligonucleotide primers for real-time PCR analysis.
Software package Primer Express Version 2.0 (Applied Biosystems) was used to identify appropriate primer sets. All 
sequences are presented in the 5->3’ direction.
CDNA FORWARD PRIMER REVERSE PRIMER
hGAPDH ATC TTC TTT TGC GTCGCC AG TTC CCC ATG GTG TCT GAG C
hTLR4 GGC ATG CCT GTG CTG AGT T CTG CTA CAA CAG ATA CTA CAA GCA CAC T
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RNA isolation and real-time PCR
Total RNA was extracted in 1 ml of TRIzol 
reagent, an improved single-step RNA iso-
lation method based on the method descri-
bed by Chomczynski et al [28]. Quantitative 
real-time PCR was performed using the 
ABI/Prism 7000 sequence detection system 
(Applied Biosystems, Foster City, CA). PCR 
conditions were as follows: 2 minutes at 
50°C and 10 minutes at 95°C followed by 40 
cycles of 15 seconds at 95°C and 1 minute 
at 60°C, with data collection in the last 30 se-
conds. All PCRs were performed with SYBR 
Green Master mix (Applied Biosystems), 
10ng cDNA, and primer concentration of 
300nmol/L in a total volume of 25μl. Quan-
tification of the PCR signals was performed 
by comparing the cycle threshold value (Ct) 
of the gene of interest of each sample with 
the Ct values of the reference gene GAPDH 
(ΔCt). Primer sequences for gene expres-
sion analysis for hGAPDH and hTLR4 are 
depicted in Table 1. 
Flowcytometry  
Flowcytometry was performed to deter-
mine the cell surface expression of TLR4 
on PBMCs. First, 1x105 PBMCs were incu-
bated with antibodies against human CD14 
(DakoCytomation, Glostrup, Denmark), CD3 
(Becton-Dickinson, San Jose, USA), TLR4 
(HTA125; Santa Cruz, California, USA) and 
the appropriate (isotype) control antibo-
dies for 30 minutes at 4°C. Cells were then 
washed and subsequently incubated with 
the appropriate goat anti-mouse fluorescein 
isothiocyanate-conjugated IgG (both from 
Zymed Laboratories, South San Francisco, 
USA) in complete darkness. Cells were 
then washed again, fixed in PBS 1% para-
formaldehyde (Sigma, St. Louis, MO, USA) 
and analyzed with a fluorescence activated 
cell sorter (FACSCalibur, Becton-Dickinson, 
San Jose, USA) for the mean fluorescence 
intensity (MFI) relative to cells stained with 
relevant IgG isotypes. 
Measurement of cytokines in culture 
supernatants
TNFα, IL-6 and IL-10 levels were measured 
in the supernatants of the PBMC cultures, 
using commercially available kits (Bio-Rad 
Laboratories, Hercules, USA) according to 
the manufacturer’s instructions [29]. Cytoki-
ne levels were measured and analyzed with 
the Bio-Plex system (Bio-Rad Laboratories). 
Data analysis was done with Bio-Plex Mana-
ger software (Bio-Rad Laboratories). 
Statistical analysis
Differences in TLR expression (mRNA and 
protein) and cytokine production were ana-
lyzed using the Mann-Whitney U test. Dif-
ferences in demographic and clinical cha-
racteristics were calculated using Student 
t-test, Mann-Whitney U test or Chi-square 
test as appropriate. P values were two si-
ded and the level of significance was set at 
P<0.05.
Results
Patient characterization
A total of 14 RA patients with the 
Asp299Gly TLR4 variant (AG) and 14 RA 
patients without this variant (AA), were 
included in this study. No significant diffe-
rences in demographic and clinical disease 
characteristics between patients with diffe-
rent genotypes were observed (Table 2).  
TLR4 expression in cells from RA patients 
with the Asp299Gly TLR4 variant was not 
affected 
To investigate whether the Asp299Gly TLR4 
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variant has an effect on the expression of 
this receptor on PBMCs from RA patients, 
we determined TLR4 mRNA expression le-
vels in freshly isolated PBMCs. As expec-
ted, TLR4 mRNA was present in PBMCs 
from RA patients. Real-time PCR analysis 
showed that TLR4 mRNA expression levels 
were not statistically different between cells 
from RA patients with the Asp299Gly variant 
(ΔCt ± SEM: TLR4 = 4.2 ± 0.3) compared to 
patients without the variant (TLR4 = 4.5 ± 
0.3) (Figure 1). Even 24hr after TLR stimu-
lation, the expression of TLR4 was not diffe-
rent between the two groups of RA patients 
(data not shown), excluding a secondary ef-
fect on TLR expression of the stimuli used.
To confirm our real-time PCR results of 
TLR4 expression, we performed FACS ana-
lysis to study the cell surface expression of 
TLR4 on the CD14+ and CD3+ cell fraction 
of PBMCs. First, TLR4 was present on the 
CD14+ cell fraction. In line with the real-
time PCR results, there was no statistically 
significant difference in protein expression 
levels between cells from RA patients with 
the Asp299Gly variant (MFI ± SEM: TLR4 = 
16.7 ± 3.4) compared to patients without the 
variant (TLR4 = 13.9 ± 3.5) (Figure 2). TLR4 
expression on the CD3+ fraction of PBMCs 
was not detectable using FACS analysis. 
Since TLR4 expression was only detec-
table on the CD14+ fraction of PBMCs, we 
also investigated whether the Asp299Gly 
TLR4 variant has an effect on the amount 
of CD14+ cells in PBMCs from RA patients. 
Table 2: Demographic and clinical characteristics of RA patients with (AG) and without (AA) genetic TLR4 variant.
* None of the RA patients was using more than 1 DMARD at the same time. NS: not significant.
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Figure 1. Relative mRNA expression (2-δCt) of human 
TLR4 on freshly isolated PBMCs from RA patients (N=9) 
with the Asp299Gly TLR4 variant (gray bars) and patients 
(N=9) without the polymorphism (black bars). Error bars 
represent the SEM.
CHARACTERISTIC A/G ( N=14) A/A (N=14) P
Age (years) 66 (SD = 10) 63 (SD = 11) NS
% women 55% 62% NS
Mean DAS28 3.3 (SD = 1.3 ) 3.2 (SD = 1.3) NS
% RF positive 78% 87% NS
Age at onset (years) 54.3 (SD = 8.7) 55.7 (SD = 12.3) NS
Disease duration (years) 11.8 (SD = 6.3) 10.0 (SD = 5.6) NS
% patients using DMARD* 89% 78% NS
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FACS analysis showed that the percentage 
of CD14+ cells in PBMCs from patients with 
the Asp299Gly variant was significantly hi-
gher than in PBMCs from patients without 
the variant (mean ± SEM: 7.5% ± 1.0 vs. 
14.4% ± 2.8) (Figure 3).
Decreased cytokine production upon 
TLR4 stimulation by PBMCs from 
patients with the TLR4 variant
To investigate the functional consequences 
of the Asp299Gly variant in the TLR4 gene, 
we stimulated PBMCs from RA patients with 
and without the variant with an exogenous 
(LPS) as well as endogenous (HSPB8) 
TLR4 agonist for 24 hours and subsequently 
analyzed the presence of IL-6, TNFα and 
IL-10 in the culture supernatants. As we de-
monstrated that the amount of TLR4-bearing 
CD14+ cells in PBMCs from the RA patients 
was different between patients with and wit-
hout the Asp299Gly TLR4 variant, we cor-
rected the levels of IL-6, TNFα and IL-10 for 
the amount of CD14+ cells in the wells. We 
found that cytokine production upon TLR4 
mediated stimulation of PBMCs from RA pa-
tients with the TLR4 variant was significantly 
decreased compared to RA patients without 
the variant. As depicted in Figure 4, levels 
of the pro-inflammatory cytokine IL-6 were 
61% decreased upon stimulation with the 
exogenous TLR4 agonist LPS (mean ± SEM 
AA: 7684pg/ml ± 1324pg/ml; AG: 3012pg/ml 
± 454pg/ml), whereas stimulation with the 
endogenous TLR4 agonist HSPB8 resulted 
in a 54% decrease in cytokine production 
by cells from patients with the TLR4 variant 
(AA: 4376pg/ml ± 916pg/ml; AG: 2022pg/ml 
± 512pg/ml). Production of the pro-inflam-
matory cytokine TNFα by cells from patients 
with the TLR4 variant was also significantly 
decreased; 66% decrease upon LPS sti-
mulation (AA: 5790pg/ml ± 1592pg/ml; AG: 
1987pg/ml ± 330pg/ml) and 69% decrease 
upon HSPB8 stimulation (AA: 4268pg/ml 
± 1191pg/ml; AG: 1338pg/ml ± 386pg/ml). 
Also, levels of the Th2 directing cytokine IL-
10 were significantly decreased upon TLR4 
stimulation of PBMCs from RA patients with 

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Figure 2. FACS analysis for human TLR4. CD14 expres-
sing cells, within life gate, from one representative RA 
patient with the Asp299Gly TLR4 variant (bold line) and 
one representative patient without the polymorphism 
(dotted line) are shown. The thin grey peak represents 
the appropriate isotype control.
Figure 3. Percentage of CD14+ cells in PBMCs from 
RA patients with the Asp299Gly TLR4 variant (gray 
squares) and RA patients without the polymorphism 
(black squares). The horizontal line represents the 
median; * P < 0.05.
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the variant, (56% decrease upon LPS sti-
mulation; AA: 3070pg/ml ± 638pg/ml; AG: 
1360pg/ml ± 162pg/ml and 41% decrease 
upon HSPB8 stimulation; AA: 1834pg/ml ± 
185pg/ml; AG: 1090pg/ml ± 168pg/ml).
Discussion
In the present study, we demonstrated that 
the Asp299Gly TLR4 polymorphism had no 
influence on the mRNA and protein expres-
sion of TLR4, but in contrast cell stimulation 
via this receptor with either exogenous or 
endogenous TLR4 agonists led to a clea-
rly decreased secretion of IL-6, TNFα and 
IL-10.  In the last few years, several groups 
already investigated the functional conse-
quences of the Asp299Gly TLR4 polymor-
phism in health and disease, resulting in 
conflicting conclusions. For example, Schip-
pers et al and Rittersma et al found that the 
TLR4 variant had no functional consequen-
ces in terms of cytokine release upon TLR4 
stimulation of whole blood from patients 
undergoing elective cardiopulmonary by-
pass surgery and patients who underwent 
successful elective stent placement respec-
tively [23,24]. In contrast, Arbour et al des-
cribed that the TLR4 variant was associated 
with hyporesponsiveness to LPS and that 
THP-1 cells transfected with this mutant al-
lele showed a decreased response to LPS 
[12]. Furthermore, Kinane et al demonstra-
ted that epithelial cells from subjects hete-
rozygous for the Asp299Gly TLR4 polymor-
phism were functionally hypo-responsive, 
evidenced by mRNA and protein response 
profiles of pro-inflammatory cytokines and 
chemokines [25]. Interestingly, all studies 
mentioned above, which concluded that 
the Asp299Gly TLR4 polymorphism did not 
lead to impaired cytokine responses upon 
in vitro LPS challenge, did not correct for 
Figure 4. Mean cytokine production by PBMCs from 
RA patients (N=14) with the Asp299Gly variant and RA 
patients (N=14) without the polymorphism after stimu-
lation with LPS (200ng/ml) and HSPB8 (10mg/ml) for 
24 h. Error bars represent the SEM. The sensitivity of 
the cytokine assay was <5 pg/ml for each measured 
cytokine; * P < 0.05; ** P< 0.01.
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the amount of monocytes. In 2002, Sabroe 
et al demonstrated that neutrophils, which 
are abundantly present in whole blood, are 
hardly involved in TLR4-induced cytokine 
production, although they do express low 
levels of TLR4 [30]. However, indirectly, 
these neutrophils are likely to be activated 
by inflammatory mediators from TLR4-sti-
mulated monocytes, leading to the produc-
tion of pro-inflammatory cytokines such as 
TNFα and IL-6 [31]. Therefore, it is concei-
vable that cytokine production by indirectly 
activated neutrophils might veil the effects 
of the Asp299Gly polymorphism on TLR4-
bearing mononuclear cells, explaining the 
discrepancy between the results of various 
groups who studied the functional conse-
quences of the TLR4 variant. Furthermore, 
we demonstrated that the relative amount of 
C14+ cells in PBMCs from patients with the 
Asp299Gly variant was significantly higher 
than in PBMCs from patients without the va-
riant, a phenomenon that might veil the ef-
fects of the Asp299Gly polymorphism in RA 
patients as well. Based on these findings, 
in our study we chose to correct cytokine 
responses for the amount of, TLR4-bearing, 
CD14+ cells. Very recently, Rallabhandi et al 
described that HEK293T cells transfected 
with the polymorphic TLR4 variant showed 
decreased sensitivity to Gram-negative 
LPS and two structurally unrelated TLR4 
agonists, compared to cells transfected 
with the wild type TLR4, under conditions of 
comparable TLR4 surface expression [32]. 
These results are in line with our findings 
and further emphasize the functionality of 
genetic TLR4 variants. 
The finding that the relative amount of 
CD14+ cells in PBMCs from RA patients 
with the Asp299Gly variant was signifi-
cantly higher than in PBMCs from patients 
without the variant is very interesting and 
should be subjected to further research 
into RA and other (autoimmune) diseases. 
Recently, Ferwerda and colleagues inves-
tigated whether the Asp299Gly TLR4 poly-
morphism was associated with the develop-
ment of active tuberculosis in HIV-infected 
patients [33]. Interestingly, they showed an 
increased prevalence of the Asp299Gly va-
riant in all subgroups of patients having low 
T-cell counts, suggesting an effect of the 
Asp299Gly variant on the relative amount of 
CD4+ T-cells as well. 
In terms of autoimmunity it is very interes-
ting that cells from RA patients are known 
to produce much higher levels of cytoki-
nes upon TLR2 and TLR4 stimulation than 
cells from healthy controls [6]. During RA, 
tissue damage and cell stress leads to the 
release of endogenous TLR agonists, in-
cluding fibronectin, heat-shock proteins, 
hyaluronic acid and host-derived RNA into 
the inflamed joint. It is tempting to speculate 
that these tissue-damage-induced endoge-
nous components could risk the initiation of 
autoimmunity. This reasoning supports the 
so called ‘danger theory’ which suggests 
that the immune system is more concerned 
with damage than with foreignness and is 
called into action by alarm signals from in-
jured tissues rather than by the recognition 
of non-self [34]. The role of TLRs in RA is 
recently further underscored by the finding 
that inhibition of the TLR4 signaling pathway 
using Chaperonin 10 (heat shock protein 
10, XToll™), seemed to be efficacious in 
treatment of the symptoms of rheumatoid 
arthritis [11]. 
Presence of the Asp299Gly TLR4 variant 
in patients with RA results in less serious 
immune responses upon TLR4 stimulation 
using either exogenous or endogenous ago-
nists, but as we showed here, these patients 
have significantly higher levels of CD14+ 
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cells. This phenomenon could possibly be 
the reason that, although the Asp299Gly 
TLR4 polymorphism is associated with an 
impaired immune response, RA patients 
do not show remarkable effects of the poly-
morphism in terms of disease severity [19]. 
Furthermore, especially cells from RA pa-
tients with active disease, release such high 
levels of pro-inflammatory cytokines that 
even in the presence of the genetic TLR4 
variant, TLR4 stimulation results in enhan-
ced cytokine production compared to he-
althy individuals. Moreover, Chaperonin 10, 
which seems to be a promising treatment 
for RA, leads to markedly decreased levels 
of LPS-induced TNFα, whereas in contrast 
production of the anti-inflammatory IL-10 ra-
pidly increases [35]. From this, one might 
conclude that the balance between Th1 and 
Th2 cytokines is evenly important in the pa-
thogenesis of RA than the absolute pro- and 
anti-inflammatory cytokine levels present. 
Effective treatment of RA using anti-cytoki-
ne therapies such as anti-TNFα and IL-1Ra 
might also be a result of altered Th1/Th2 
balances caused by selectively diminished 
levels of TNFα and IL-1 respectively. In 
this light, it is plausible that the Asp299Gly 
TLR4 polymorphism is not associated with 
disease severity, as this polymorphism af-
fects the IL-10 production as well.
In conclusion, here we provide evidence 
that the presence of the Asp299Gly TLR4 
variant has a clear impact on the functional 
level despite the fact that the TLR4 expres-
sion level is unaffected. However, since the 
Asp299Gly polymorphism also affects re-
lative expression of TLR4-bearing, CD14+ 
cells and since the polymorphism only dimi-
nishes absolute cytokine levels but does not 
interfere in the balance between Th1 and 
Th2-directing cytokines, this might explain 
why presence of the polymorphism does not 
affect the disease severity.
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Toll-like receptors in rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic, in-
flammatory autoimmune disease, which 
mainly affects the synovial joints with a pre-
ference for the small joints of the hands and 
feet. Synovial inflammation is characterized 
by massive influx of T cells, B cells, fibro-
blast-like synoviocytes, macrophages, and 
dendritic cells (DC) in the synovial tissue. 
Although the exact pathways leading to the 
initiation and perpetuation of synovial inflam-
mation remains obscure, recent evidence 
addressed the potential role of Toll-like re-
ceptors (TLRs) in arthritis. 
Toll-like receptors belong to the family of 
pattern recognition receptors (PRRs), and 
are constitutively expressed by numerous 
cell types and tissues (1-6). TLRs can be 
activated upon recognition of microbial and 
viral products, such as lipoteichoic acid 
(LTA), lipopolysaccharide (LPS), CpG motifs 
of bacterial DNA and viral RNA (7-10). More 
recently however, many studies addressed 
the role of endogenous ligands in the TLR- 
mediated cell activation (11-14). Intriguingly, 
such endogenous ligands, including fibron-
ectin, heat-shock proteins, hyaluronic acid 
and host derived RNA, are released upon 
tissue damage and cell stress, events that 
are likely to occur during inflammatory con-
ditions. The activation of cells by endoge-
nous components from distressed or injured 
cells supports the so-called ‘Danger Mo-
del’, proposed by Matzinger et al. (15). This 
theory suggests that the immune system is 
more concerned with damage than with fo-
reignness, and is called into action by alarm 
signals from injured tissues, rather than by 
the recognition of non-self. 
In terms of autoimmunity, it is very interes-
ting that endogenous components released 
upon tissue damage and cell stress could 
bring an immune response. This thesis pos-
tulated evidence that further substantiates a 
role for TLRs in the initiation and the chroni-
city of RA.   
TLR expression
First it was shown that TLR2, TLR3, TLR4 
and TLR7 were all expressed in RA synovial 
tissue and that the expression was clearly 
enhanced compared to synovial tissue from 
patients suffering from osteoarthritis (OA) 
or healthy controls (chapter 2 and chapter 
3). Furthermore, elevated levels of endo-
genous TLR4 ligands were described to be 
present in serum and synovial fluid from RA 
patients compared to serum from patients 
with systemic sclerosis and systemic lupus 
erythematosus (chapter 3). In addition, a 
new endogenous TLR4 ligand, the so-called 
heat-shock protein B8 (HSPB8), was descri-
bed and this protein was demonstrated to be 
present in synovial tissue from RA patients 
as well (chapter 4). Although both TLRs and 
TLR ligands are present in RA synovial tis-
sue, at this moment it is unclear whether 
they indeed lead to chronic inflammation 
of the innate immune response. In this the-
sis, it was hypothesized that exogenous as 
well as endogenous TLR ligands, which are 
both shown to be present in the synovial 
joints of RA patients (16-20), induce a first 
immune response mediated via TLRs. This 
leads to the production of pro-inflammatory 
mediators such as cytokines, chemokines 
and metalloproteinases. These inflamma-
tory mediators can, in turn, cause damage 
to the tissue, leading to the release of en-
dogenous factors such as heat-shock pro-
teins, fibronectin and hyaluronan, resulting 
in a self-sustaining loop of TLR activation 
and TLR-mediated tissue damage (Figure 
1). Furthermore, another important factor in 
sustaining the inflammatory processes du-
ring RA might be that simultaneous stimula-
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tion of specific TLRs results in a synergistic 
production of pro-inflammatory mediators 
(chapter 3). It is generally believed that si-
multaneous TLR stimulation acts as a sort 
of “combinatorial code’ by which DC discri-
minate pathogens resulting in a more effec-
tive immune response. On the other hand, 
unwanted release of endogenous ligands, 
due to tissue damage and cell stress, could 
synergistically induce an immune response 
as well, favouring an environment in which 
breakthrough of tolerance is likely to occur. 
This idea was underscored by Waldner and 
collegues, who demonstrated that expe-
rimental autoimmune encephalomyelitis, 
which is an experimental model of multiple 
sclerosis, was determined, at least partly, by 
the endogenous activation state of antigen-
presenting cells, such as DC (21).
TLR regulation
Besides direct stimulation of TLRs in the 
synovial joint, TLR-induced immune respon-
ses can also be regulated by cytokines such 
as TNFα, IL-12 and IL-18. TNFα, which was 
one of the first cytokines of interest in the 
field of RA (22;23), is able to up regulate 
expression of TLR4 in vitro (3). In line with 
this, it was demonstrated that anti-TNFα 
therapy in RA patients clearly down-modu-
Figure 1. Schematic overview of self-sustaining loop of TLR activation and TLR-mediated tissue damage as a conceptual 
framework for the chronic inflammation during RA. This figure shows that exogenous as well as endogenous TLR ligands, 
which are both shown to be present in the synovial joints of RA patients, induce a first immune response mediated via 
TLR [1]. Single TLR stimulation leads to the production of pro-inflammatory mediators such as cytokines, chemokines 
and metalloproteinases, however simultaneous stimulation of several TLR results in a synergistically induced immune 
response characterized by extremely high levels of pro-inflammtory mediators [2]. These inflammatory mediators can, 
in turn, cause damage to the tissue, leading to the release of endogenous TLR ligands such as heat-shock proteins, 
fibronectin and hyaluronan [3], resulting in a self-sustaining loop [4] of TLR activation and TLR-mediated tissue damage. 
Furthermore, endogenous TLR stimulation of B-lymphocytes, for example by stimulation with self-DNA, also results in 
the production of rheumatoid factor [5]. In addition, the inflammatory mediators, mainly cytokines, are able to induce TLR 
up regulation [6], which could result in a more serious immune response as well. 
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lated the increased expression of TLR2 and 
TLR4 (24). IL-12 and IL-18, known as Th1-
directing cytokines, are alone or in combi-
nation strong inducers of IFNγ and have 
shown to be important in the development of 
arthritis in murine models (25;26). Further-
more, both cytokines are present in synovial 
tissue from RA patients and cause strong up 
regulation of TLR2 and TLR4, mainly driven 
by production of IFNγ (chapter 2). For TLR3 
and TLR7, it was demonstrated that IFNα 
strongly upregulates expression, which was 
functional in terms of cytokine production, 
since subsequent stimulation resulted in 
enhanced production of inflammatory medi-
ators (chapter 6).
TLR stimulation
In vitro stimulation of the TLRs that were 
highly expressed in RA synovial tissue reve-
aled interesting differences between TLRs 
recognizing pathogens from bacterial or vi-
ral origin (chapter 3). Monocyte-derived DC 
from RA patients produced highly elevated 
levels of the cytokines TNFα, IL-6 and IL-10 
upon stimulation with exogenous and endo-
genous TLR2 and TLR4 ligands, whereas 
stimulation of TLR3 and TLR7 did not lead 
to enhanced cytokine production. Using 
microarray analysis, allograft-inflammatory 
factor 1 (AIF-1) was identified as a factor that 
might be involved in the enhanced TLR2/4-
mediated immune response in RA patients 
(chapter 5), since expression of AIF-1 was 
significantly enhanced in RA patients and 
correlated with the TLR4-induced cytokine 
levels. Finally, the Asp299Gly polymorphism 
in the TLR4 gene of RA patients was shown 
to be functional since stimulation with exo-
genous and endogenous TLR4 ligands 
resulted in clearly diminished cytokine pro-
duction, despite the fact that the TLR4 ex-
pression was unaffected (chapter 7).
TLR4 as the most crucial TLR in the 
pathogenesis of rheumatoid arthritis
In this thesis we mainly focussed on TLR2, 
TLR3, TLR4 and TLR7, which could be divi-
ded into two categories based on their dif-
ferential subcellular localization. Whereas 
TLR2 and TLR4 are present on the plasma 
membrane, TLR3 and TLR7 reside mainly 
within the endosomal/lysosomal compart-
ment. The different location of the TLRs 
relates to the nature of the ligands that are 
recognized; TLRs at the cell surface mainly 
respond to extracellular pathogens, while 
intracellular TLRs are triggered by viral nu-
cleic acids, following the internalization of a 
virus. This intracellular localization avoids 
the recognition of, for example, extracellular 
endogenous mRNA released from necrotic 
cells, therefore preventing the induction of 
an immune response against self-antigens. 
Nowadays, many endogenous ligands for 
TLR4 have been identified, such as heat-
shock proteins, fibronectin and hyaluronic 
acid (12-14). In physiological conditions the-
se ligands are present within a cell or em-
bedded in the extracellular matrix and there-
fore are not able to activate TLR4. However, 
these endogenous ligands could be released 
upon tissue damage and cell stress, events 
that constantly occur during RA. Based on 
the fact that most endogenous TLR ligands 
identified can be recognized by TLR4 and 
the fact that these ligands are very likely to 
be present in the RA synovial joints, at this 
moment TLR4 is considered as the most cru-
cial TLR in the pathogenesis of RA. In line 
with this, it was recently demonstrated that 
a naturally occurring TLR4 antagonist was 
able to suppress the clinical and histological 
characteristics of arthritis as demonstrated 
in several models of experimental arthritis 
(27). Although the exact mechanism of this 
TLR4 antagonist in RA suppresion has not 
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been identified yet, it is quite conceivable 
that blocking of TLR4 stimuli in an arthritic 
environment prevents simultaneous stimula-
tion of TLR4 with one or more other TLRs, 
resulting in a clear reduction of the clinical 
and histological characteristics of arthritis.
Non-TLR pathogen recognition receptors
Nod-like receptors
Although the role of TLRs in the innate immune 
response is well established nowadays, other 
members of the PRR family are supposed to 
be involved in the host response to pathogens 
as well. Where TLRs are membrane-bound 
proteins, expressed on the cellular membrane 
or in the endosomal compartment, Nod-like 
receptors (NLRs) are considered as the cyto-
plasmic counterparts of TLRs. Mammals have 
more than 20 NOD family members, including 
NOD1 (CARD4) and NOD2 (CARD15), which 
are both able to detect distinct substructures 
from bacterial peptidoglycan (28;29). Another 
member of the NLR family, NALP3, is involved 
in the activation of caspase-1, resulting in 
the secretion of IL-1β and IL-18 upon bacte-
ria-induced triggers (30). Interestingly, it was 
demonstrated that NALP3 was also capable 
of caspase-1 activation in response to uric 
acid (31), which is released by necrotic cells. 
In terms of arthritic disorders it is interesting 
that a disturbed uric acid metabolism could 
cause gout, where monosodium urate crystals 
are deposited on the articular cartilage of the 
joints and in the particular tissue-like tendons. 
These results indicate that, just as for TLRs, 
NLRs are able to detect endogenous danger 
signals, although the evidence is very limited 
thus far.   
Lectins
Besides TLRs and NLRs, also lectins are 
involved in the direct recognition of specific 
pathogens. While the main function of TLRs 
is to induce the production of pro-inflam-
matory cytokines and T-cell activation upon 
pathogen recognition, lectins are involved 
in antigen internalization and degradation 
in order to enhance antigen processing and 
presentation (54). Lectins are able to recog-
nize carbohydrate structures and currently 
there is no evidence that they can discri-
minate between self and non-self. Most of 
these carbohydrate-binding proteins belong 
to the C-type lectin superfamily, because 
of their calcium (Ca2+) dependency. There 
are some indications that lectins participate 
in the prevention of autoimmunity as Ga-
lectin-1 had a potent suppressive effect on 
the induction of experimental autoimmune 
encephalomyelitis (33). On the other hand, 
a number of lectins have been identified as 
auto-antigens, including Galectin-3 which is 
associated with Crohn’s disease and cere-
bellar soluble lectins, which are associated 
with multiple sclerosis (34;35). In rheuma-
toid arthritis, lectins have been put forward 
as a possible contributing pathogenetic 
factor also. For example, the C-type lectin 
DC-SIGN was strongly upregulated in the 
synovial joints of RA patients compared to 
synovial expression in patients with osteoar-
thritis or healthy controls (55). A lot of inde-
pendent studies, investigating the possible 
involvement of mannan-binding lectin (MBL) 
in RA, showed that low MBL concentrations 
were correlated with a poor prognosis, but 
were not correlated with disease suscepti-
bility (37). 
RNA helicases
With respect to the recognition of single 
stranded and double stranded RNA, besi-
des TLR3, TLR7 and TLR8, the so-called 
RNA helicases, such as RIG-I (retinoic acid 
inducible gene-I), are involved. Whereas 
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TLRs are activated by the recognition of nu-
cleic acids in the endosomal compartments, 
RIG-I detects viral RNA within the cyto-
plasm, which also leads to activation of NF-
κB and IRF-3 and subsequently secretion of 
type-I IFNs. Recently, it was demonstrated 
that RA patients had a significantly elevated 
expression of genes which were regulated 
by type I IFNs compared to healthy indivi-
duals (38). Therefore it is quite conceivable 
that RIG-I plays a role in RA as well, although 
no data confirming this hypothesis have been 
published thus far. 
All together, besides TLRs, other non-TLR 
members of the PRR family, such as NLRs, 
lectins and RNA helicases, are involved in 
pathogen recognition as well. The co-exi-
stence of these receptors and their diverse 
cellular localization, suggests that the an-
tigen recognition is a complex network of 
interacting receptors and that the outcome 
of the immune response will depend on the 
type of receptors involved (Figure 2). In this 
thesis it was described that co-stimulation of 
two or more TLRs at the same time, results 
in synergistically enhanced cytokine levels 
(chapter 3). Regarding the close functio-
nal similarity between TLRs and the other 
PRRs, it is likely that also synergistic effects 
could be induced by co-stimulation of one 
TLR and one or more other members of the 
PRR family. Few data into the synergistic 
effects between TLRs and non-TLRs have 
turned up so far, mainly about TLRs and 
NLRs (39;40), however the exact interac-
tion between TLRs and non-TLRs should be 
subjected to further research in the future. 
TLRs as a therapeutic target in rheuma-
toid arthritis
Chaperonin 10
As an increasing body of evidence now un-
derscores a role for TLRs in the pathogene-
sis of rheumatoid arthritis, these data could 
provide opportunities for new therapeutic 
approaches to modulate the innate immuni-
ty. Very recently, chaperonin 10, also known 
as heat-shock protein 10 (HSP10) and Xtoll, 
was tested with respect to safety and clinical 
efficacy in patients with rheumatoid arthritis. 
Primary results of this small, randomised trial 
suggested that HSP10 is well tolerated and 
efficacious in, at least, short-term treatment 
of the symptoms of rheumatoid arthritis (41). 
HSP10 was originally identified as a factor 
present in sera during early pregnancy and 
has shown to be immunosuppressive in ex-
perimental autoimmune encephalomyelitis, 
delayed type hypersensitivity, and allograft 
rejection models (42-44). Later on, it was 
demonstrated that purified recombinant hu-
man HSP10 incubated with human periphe-
ral blood mononuclear cells reduced LPS-
induced NF-κB activation and secretion of 
TNFα, RANTES and IL-6 (45). Interestingly, 
reduced secretion of TNFα, RANTES and 
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Figure 2. The co-existence of TLR and non-TLR pa-
thogen recognition receptors and their diverse cellular 
localization, suggests that the antigen recognition is a 
complex network of interacting receptors and that the 
outcome of the immune response will depend on the type 
of receptors involved.  
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IL-6 went together with an increased pro-
duction of IL-10, which is known as a potent 
immunosuppressive cytokine able to inhibit 
TLR4 signaling (46). It is thought that HSP10 
may inhibit pro-inflammatory responses by 
interacting with extracellular HSP60, since 
anti-HSP60 antibodies prevented and mi-
micked HSP10 inhibitory activity (45). In this 
light, HSP10 could be a promising target for 
the treatment of rheumatoid arthritis since, 
in addition to current anti-TNFα treatment, 
effective removal of TNFα is accompanied 
by the induction of an anti-inflammatory 
immune response accomplished by IL-10. 
Nowadays, anti-TNFα therapy is successfully 
used to treat a substantial number of pa-
tients with various indications including 
rheumatoid arthritis, junvenile rheumatoid 
arthritis, inflammatory bowel disease, pso-
riatic arthritis and ankylosing spondylitis. 
However, this therapy is associated with rare 
but severe adverse events such as serious 
infections, lymphoma, or chronic heart failure 
(47;48). Since HSP10 does only suppress 
TNFα levels, but does not completely re-
move all the TNFα from the circulation, the 
risk of serious side effects might be redu-
ced. Nonetheless, at this moment only a small 
randomised trial, with substantial limitations of 
the study design, prove the efficacy of TLR 
blockade in the treatment of RA. Therefore, 
supplementary trials for HSP10 and other 
TLR inhibitors should be performed to further 
investigate the safety and efficacy of these 
promising therapeutic agents. 
Soluble decoy receptors
The inhibition of TLR activation can also be 
achieved in several other ways, for example 
by suppressing the interaction between 
TLRs and its specific ligands using soluble 
decoy receptors. It is known that a constant 
amount of soluble TLR2 is released by hu-
man blood monocytes and that several so-
luble TLR2 isoforms are naturally present in 
human milk and plasma (49). Although no 
soluble TLR4 has been described in humans 
thus far, multiple TLR4 mRNAs have been 
detected, indicating that soluble TLR4 might 
functionally exist in humans. In mice it was 
already demonstrated that soluble TLR4 
significantly inhibited the LPS-mediated 
TNFα production and NF-κB activation (50), 
however no experiments have been perfor-
med in models of experimental arthritis thus 
far. Another way to block the TLR – TLR 
ligand interaction is by using monoclonal 
antibodies against specific TLRs. Although 
this technique might work perfectly for the 
extracellular TLRs, preventing ligation to in-
tracellular TLRs might even be more chal-
lenging. Recently, it was demonstrated that 
a naturally occurring TLR4 antagonist was 
able to suppress the clinical and histological 
characteristics of arthritis as demonstrated 
in several models of experimental arthritis 
(27), suggesting TLR4 blockade as a promi-
sing strategy for the treatment of RA. 
Inhibition of TLR signaling molecules
Furthermore, interference with the TLR 
signaling cascade could be an attractive 
strategy to suppress TLR-induced immune 
activation, for example by the inhibition of 
activating components or activation of inhi-
bitory components. For example inhibition 
of the adaptor molecule Mal, which provides 
signaling specificity for TLR2 and TLR4, 
might suppress the enhanced TLR4 res-
ponse during RA, without interfering in other 
biologically important pathways, such as IL-
1 signaling. Recently, it was shown that  so-
luble ST2 could effectively suppress murine 
collagen-induced arthritis, as demonstrated 
by reduced RA pathology and decreased 
serum levels of IL-6, TNFα and IL-12 (51). 
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Though it is known that the other member 
of the ST2 family, ST2L, suppressed TLR 
signaling by sequestration of MyD88 and 
Mal (52), the mechanism of action of soluble 
ST2 is not fully elucidated yet. However, it is 
demonstrated that soluble ST2 significantly 
down regulated the mRNA expression of 
TLR4 in LPS-activated macrophages in vitro 
(53), a mechanism that could be effective 
in the suppression of TLR-induced immune 
responses as well. 
TLR downregulation
Besides soluble ST2, the expression of 
TLRs can also be downregulated by anti-in-
flammatory cytokines, especially TGFβ and 
IL-10, or by degradation of TLRs through 
ubiquitylation, for example by TRIAD3A. 
Down modulation of TLR expression would 
decrease the sensibility for exogenous as 
well as endogenous TLR ligands and might 
therefore be a strategy for the treatment 
of RA as well. However, in our experience 
(unpublished results) even very low levels 
of TLR expression can lead to full cell ac-
tivation upon triggering with TLR specific 
ligands, suggesting that this strategy might 
only be successful when full ablation of TLR 
expression can be achieved. 
All together, many approaches, with respect 
to TLRs, are conceivable as therapeutic 
strategies for RA, although none of these 
approaches have been tested extensively 
so far.
Conclusion
In summary, in this thesis we provided sub-
stantial data that demonstrated a potential 
role for TLRs in the pathogenesis of RA. 
However it cannot be excluded that other, 
more recently described, non-TLRs contri-
bute to these processes as well, as it is very 
likely that these PRRs act via very complex 
interactions with each other to regulate the 
delicate balance between immunity and to-
lerance. Furthermore, based on the fact that 
most endogenous TLR ligands identified 
can be recognized by TLR4 and the fact that 
these ligands are very likely to be present in 
the RA synovial joints, at this moment TLR4 
is considered as the most crucial TLR in the 
pathogenesis of RA. Although preventing 
TLR stimulation, using HSP10, seems to be 
a successful target for the treatment of RA, 
other strategies to reduce or abolish TLR-in-
duced immune responses should be subjec-
ted to further investigation henceforth.
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Nederlandse samenvatting
Reumatoïde artritis (RA), in de volksmond reuma genoemd, is een chronische, auto-immuun 
aandoening die gekenmerkt wordt door gewrichtsontstekingen die uiteindelijk kunnen leiden 
tot schade aan het kraakbeen en aan het bot. Deze gewrichtsontstekingen worden gekenmerkt 
door verdikking van de slijmvliezen die de gewrichtsholten bekleden (synovium) en grote aan-
tallen ontstekingscellen zoals T-cellen, B-cellen, fibroblast-achtige synoviocyten, macrofagen 
en dendritische cellen. De exacte oorzaak van het ontstaan van RA is nog onbekend, maar 
recent onderzoek wijst erop dat de zgn. Toll-like receptors (TLRs) hierbij betrokken zijn.
TLRs behoren tot de familie van ‘pattern recognition receptors’ en komen voor op en in ver-
scheidene celtypen en weefsels. Vandaag de dag zijn er 11 verschillende TLRs beschreven 
en deze TLRs worden geactiveerd na herkenning van microbiële en virale producten (exogene 
liganden), zoals ‘lipoteichoic acid’ (LTA), ‘lipopolisaccharide’ (LPS), bacterieel DNA en viraal 
RNA. Recentelijk is echter ook aangetoond dat lichaamseigen (endogene) liganden in staat 
zijn om TLRs te activeren, enkele voorbeelden hiervan zijn fibronectine, heat-shock eiwitten, 
hyaluronzuren en endogeen RNA. Tijdens ontstekingsprocessen, zoals bij RA, vindt weefsel-
schade en celstress plaats. Hierdoor komen deze endogene producten vrij komen wat kan 
leiden tot een ontstekingsreactie. Dit verschijnsel is, in het bijzonder bij auto-immuun aandoe-
ningen zoals RA, erg interessant.
In dit proefschrift wordt de rol van TLRs in het ontstaan en de chroniciteit van RA beschreven. 
In hoofdstuk 2 en hoofdstuk 3 wordt beschreven dat TLR2, TLR3, TLR4 en TLR7 voorkomen 
(expressie) in synoviaal weefsel van RA patiënten en dat deze sterk verhoogd aanwezig zijn 
in vergelijking met synoviaal weefsel van patiënten met osteoartritis (artrose) en gezonde vrij-
willigers. Daarnaast zijn verhoogde spiegels van endogene TLR4 liganden aangetoond in het 
serum en synoviaal vocht van RA patiënten in vergelijking met patiënten die lijden aan scle-
rodermie of systemische lupus erythematodes (hoofdstuk 3). Bovendien wordt een nieuwe 
endogene TLR4 ligand, het zgn. heat-shock eiwit B8 (HSPB8) beschreven; dit eiwit komt ook 
voor in synoviaal weefsel van RA patiënten (hoofdstuk 4). 
Hoewel zowel TLRs en TLR liganden aanwezig zijn in synoviaal weefsel van RA patiënten is 
het op dit moment onduidelijk of zij ook daadwerkelijk kunnen leiden tot een chronische ontste-
king. In dit proefschrift is aangenomen dat zowel exogene als endogene TLR liganden, welke 
beide aanwezig zijn in de synoviale gewrichten van RA patiënten, een afweerreactie kunnen 
veroorzaken via TLR activatie. Dit leidt tot de productie van ontstekingsmediatoren zoals cy-
tokines, chemokines en methalloproteinases en deze mediatoren veroorzaken op hun beurt 
weefselschade. Hierdoor komen endogene liganden, zoals heat-shock eiwitten, fibronectine 
en hyaluronzuren vrij waardoor er een vicieuze cirkel ontstaat van TLR activatie en TLR-ge-
medieerde weefselschade.
Een andere belangrijke factor in het in stand houden van de ontsteking bij RA, is de bevinding 
dat gelijktijdige (simultane) stimulatie van verschillende TLRs leidt tot een sterkere productie 
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van ontstekingsmediatoren dan elk van de afzonderlijke TLRs samen zouden kunnen bereiken 
(hoofdstuk 3). Dit noemt men een synergistisch effect. Het vrijkomen van ongewenste endo-
gene liganden als gevolg van weefselschade en celstress zou ook kunnen leiden tot een sy-
nergistische productie van ontstekingsmediatoren en hierdoor is het niet onwaarschijnlijk dat 
de tolerantie wordt doorbroken en een auto-immuun aandoening, zoals RA, kan ontstaan. 
Naast de directe activatie van TLRs door lichaamsvreemde en lichaamseigen liganden in de 
synoviale gewrichten, spelen ook verscheidene ontstekingsmediatoren, zoals cytokines, een 
rol bij TLR-gemedieerde ontstekingsreacties. Zo kunnen de cytokines IL-12 en IL-18, die beide 
voorkomen in het synoviaal weefsel van RA patiënten, leiden tot een sterk verhoogde expres-
sie van TLR2 en TLR4, wat wordt aangestuurd door het cytokine IFNγ (hoofdstuk 2). Voor 
TLR3 en TLR7 is het aangetoond dat IFNα voor een sterke verhoogde expressie kan zorgen, 
wat leidt tot een sterk verhoogde productie van ontstekingsmediatoren na stimulatie van deze 
TLRs (hoofdstuk 6).
In hoofdstuk 3 is aangetoond dat dendritische cellen van RA patiënten aanmerkelijk hogere 
spiegels van de cytokines TNFα, IL-6 en IL-10 produceren na stimulatie van TLR2 of TLR4, 
terwijl stimulatie van TLR3 of TLR7 niet resulteert in een verhoogde cytokineproductie. Mo-
gelijk is ‘allograft inflammatory factor 1’ (AIF-1) betrokken bij deze verhoogde immuunreactie 
bij RA patiënten, omdat deze factor verhoogd is in RA patiënten en correleert met de TLR4-
gemedieerde cytokineproductie (hoofdstuk 5). Tenslotte, wordt in hoofdstuk 7 beschreven dat 
een defect in het TLR4 gen bij RA patiënten leidt tot sterk verminderde cytokineproductie 
na stimulatie met zowel exogene als endogene liganden, terwijl de expressie van TLR4 niet 
verandert. 
Samengevat, dit proefschrift beschrijft een aanzienlijke hoeveelheid data die een rol voor 
TLRs in het ontstaan en de chroniciteit van RA aantonen. Gebaseerd op deze feiten lijken 
TLRs een veelbelovend target voor het ontwikkelen van therapieën voor de behandeling van 
RA patiënten in de toekomst. 
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Dankwoord
Dit is het dan! Mijn proefschrift is af! En aangezien je zo’n proefschrift natuurlijk niet alleen 
schrijft, wil ik in dit laatste deel van mijn proefschrift van de gelegenheid gebruik maken om 
iedereen te bedanken die de afgelopen jaren een bijdrage heeft geleverd aan het tot stand 
komen van dit boekje. 
Allereerst gaat mijn dank uit naar Tim, mijn copromotor. Tim, graag wil ik je bedanken voor 
alle wetenschappelijke ideeën en bijbehorende discussies die verwerkt zijn in dit proefschrift. 
Ik vond het erg fijn dat je me de afgelopen jaren de vrijheid hebt gegeven mijn eigen weg te 
zoeken in het onderzoek; dat zal niet makkelijk geweest zijn voor zo’n enthousiaste en gedre-
ven onderzoeker als jij! Bedankt dat je altijd tijd voor me wilde maken, waar ter wereld je ook 
was. 
Vervolgens wil ik mijn beide promotoren, Wim en Piet, bedanken voor de mogelijkheid mee te 
werken aan deze bijzondere onderzoekslijn, een samenwerking tussen lab en kliniek. Bedankt 
voor jullie vertrouwen in deze nieuwe onderzoekslijn en in mij als jonge onderzoeker.  
En dan natuurlijk Leo. Zeker in de eerste jaren van mijn promotieonderzoek was je mijn vraag-
baak op het lab, ik mocht altijd bij je binnenlopen. Met veel plezier denk ik terug aan onze 
discussies over proefdieren, ik zal nu eenmaal nooit een ‘muizendokter’ worden. Bedankt ook 
voor de gezelligheid tijdens de congressen die we samen bezocht hebben in de afgelopen 
jaren.
Het onderzoek, beschreven in dit proefschrift, had nooit uitgevoerd kunnen worden zonder 
mijn fantastische collega’s binnen onze ‘klinische groep’. Twan, mijn maatje, samen met 
Audrey heb je me wegwijs gemaakt op het lab, waardoor ik me snel thuis voelde in ons (kleine) 
groepje. Bedankt voor de gezelligheid, je kritische instelling, je geduld en begrip in de vier jaar 
die we hebben samengewerkt. Ondanks dat je niet in TLRs gelooft (dat zeg je tenminste), ge-
loof je wel in mij en dat is toch het belangrijkste. Ik wens je alle succes met de laatste loodjes 
van je promotieonderzoek en je opleiding tot reumatoloog, ik weet zeker dat het je allemaal 
gaat lukken!
Mark, drie jaar geleden ben jij ons ‘klinische groepje’ komen versterken. Bedankt dat je altijd 
bereid was mee te denken over mijn onderzoek en eerlijk je mening te geven. Onze manier van 
werken is, op z’n zachtst gezegd, nogal verschillend. Toch ben ik van mening dat we samen 
een goede combinatie waren, welke heeft geleid tot leuk en interessant onderzoek. En Calin, 
wat leuk dat je voor het laatste jaar van je promotieonderzoek bij ons op het lab bent komen 
werken. Ik wil je bedanken voor al je belangstelling! En natuurlijk niet te vergeten Richard, wat 
een verademing dat we vorig jaar eindelijk een analist in onze groep mochten verwelkomen. 
Je hebt je in korte tijd onmisbaar weten te maken. Bedankt voor je analytische ondersteuning, 
met name in de chaotische periodes van de anti-TNF studie, en natuurlijk voor alle gezellig-
heid. 
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Verder zou ik graag de werkgroepleiders, Fons en de beide Peters, en de post-docs, 
Arjen, Nozomi, Henk en Isabel, willen bedanken voor de prettige samenwerking en de 
nuttige discussies op z’n tijd. Marije, ik vergeet steeds dat je inmiddels ook bij de post-
docs hoort. Je was mijn steun en toeverlaat tijdens de voorbereidingen voor mijn promo-
tie en het lay-outen van mijn proefschrift. Bedankt voor al je geduld.
Ook wil ik de (oud)analisten van de afdeling, Miranda, Onno, Elly, Fieke, Cora, Monique, 
Astrid en natuurlijk onze secretaresse Marianne bedanken voor de prettige samenwer-
king. Annet, wat hebben we toch een gezellige tijd gehad toen we samen U-tje 4 deelden. 
Birgitte, bedankt voor alle ondersteuning bij m’n immuno’s en Liduine bedankt dat je, in 
drukke periodes, altijd bereid was me wat RNA-werk uit handen te nemen.
En dan nog een woordje voor de AIO’s die mij voorgegaan zijn en die mij de komende 
jaren nog zullen volgen, Alwin, Alfons, Ruben, Karin, Laure, Jeroen, Sharon, Genoveva, 
Lilianne, Wouter, Bas en Renoud. Bedankt voor jullie interesse, de nuttige wetenschap-
pelijke discussies en natuurlijk de gezelligheid op het lab en op de retraites en con-
gressen. Succes met alles! Lieve Shahla, sinds 2004 werkten we samen aan het TLR 
onderzoek. Je enthousiasme en gedrevenheid zijn bewonderingswaardig. De korte tijd 
dat we samen U-tje 5 deelden hebben we geregeld over ons onderzoek, maar ook over 
niet-wetenschappelijke zaken gesproken. Je was altijd bereid om te luisteren en mee 
te denken. Je eigen promotie zal nu ook niet lang meer op zich laten wachten. Succes 
meid! Je komt er wel! Esmeralda, jou wil ik ook nog even in het bijzonder bedanken voor 
alle steun tijdens de laatste maanden voor mijn promotie; het heeft zo z’n voordelen om 
in hetzelfde schuitje te zitten. Op het moment dat dit boekje gedrukt is, zal je bijna je 
eigen verdediging mogen houden. Succes ermee! Ik weet zeker dat je het fantastisch 
zult doen!
Verder wil ik alle andere collega’s en stagiaires bedanken met wie ik de afgelopen jaren 
even heb mogen samenwerken; in het bijzonder Audrey, Alinda en Fatima voor jullie 
bijdrage aan het TLR onderzoek. Erik en Marieke, jullie wil ik graag bedanken voor jullie 
inzet met betrekking tot het TLR4 polymorfisme onderzoek. Wat fijn dat ik altijd met mijn 
‘genetica’ vragen bij jullie terecht kon.
Voordat ik van de gelegenheid gebruik wil maken om mijn familie en vrienden te bedan-
ken wil ik heel veel dank uitspreken voor de gezonde vrijwilligers en de RA patiënten die 
de afgelopen jaren belangeloos hebben meegewerkt aan mijn onderzoek. Zonder jullie 
bereidwilligheid om bloed te geven zou er van dit onderzoek niets terecht zijn gekomen.
Een bijzonder dankjewel voor mijn familie, schoonfamilie en vrienden. Voor jullie is het 
vaak moeilijk geweest te begrijpen wat ik de afgelopen jaren nou precies gedaan heb. 
Ik hoop dat dit boekje jullie een klein beetje duidelijkheid geeft. In elk geval wil ik jullie 
bedanken voor de belangstelling en het vertrouwen. Maar natuurlijk ook de onmisbare 
afleiding en ontspanning.
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Lieve Ellen, het heeft veel voor mij betekend dat je altijd zo trots was op je ‘grote’ zus. Het 
afgelopen jaar is voor ons allebei erg druk en spannend geweest. Gelukkig konden we 
altijd ons verhaal aan elkaar kwijt en hielpen we elkaar te relativeren en te motiveren. Je 
bent een fantastische zus en ik ben blij dat je mijn paranimf wilt zijn!
Lieve papa en mama, zonder jullie was dit boekje er niet geweest. Bedankt voor jullie 
vertrouwen in mij en de keuzes die ik maakte. Jullie hebben me altijd de kans gegeven om 
te doen wat ik graag wil, en me gestimuleerd en gemotiveerd om alles waar ik aan begon 
tot een goed einde te brengen. Ik kan altijd op jullie rekenen!
En het laatste woord blijft voor Marco. Ik weet dat je het niet nodig vindt dat ik je op deze 
manier bedank. Je vindt het allemaal zo vanzelfsprekend wat je voor me doet. Daarom zal 
ik het kort houden: You’re simply the best!!  
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zaam binnen het clinical trial team van Numico Research B.V.
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Figure 1. Immunohistochemical detection of Toll-like 
receptor 2 (TLR2) and TLR4 in synovial biopsy tissues 
from patients with rheumatoid arthritis (RA), osteoar-
thritis (OA), and healthy individuals. As a control, staining 
was performed with nonrelevant isotype control antibody 
(A and B). Expression of TLR2 (C and D) and TLR4 (E 
and F) was examined in RA synovial tissue, as compared 
with TLR2 and TLR4 expression in synovial tissue from 
patients with OA (G and H) and healthy individuals (I and 
J). Hematoxylin counterstained; original magnification 
400×.
Chapter 2, Figure 1. Chapter 3, Figure 1.
Figure 1. Immunohistochemical detection of TLR3 (left 
panel) and TLR7 (right panel) in synovial biopsy samples 
from RA patients and healthy controls. Top panel shows 
staining with an isotype control antibody. C, E. TLR3 
expression in synovial tissue from healthy individuals 
and RA patients respectively. D, F. TLR7 expression in 
synovial tissue from healthy individuals and RA patients 
respectively.All tissues were counterstained with hema-
toxylin (original magnification × 400).
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Chapter 4, Figure 7.
Figure 7. Immunohistochemical detection of HSPB8 in synovial tissue from RA patients. A. Staining of the synovial 
lining with an isotype control Ab (magnification x200). B. Staining of the synovial lining with a specific Ab against HSPB8 
(magnification x200). C. Staining of synovial vascular endothelial cells with an isotype control Ab (magnification x400). D. 
Staining of synovial vascular endothelial cells with a specific Ab against HSPB8 (magnification x400). All synovial tissue 
sections were counterstained with hematoxylin.
A
C
B
D
154
155
COLOUR FIGURES (PART 2)
CHAPTER 5 - CHAPTER 8
156
                              
    
Chapter 5, Figure 1.
Figure 1. Hierarchical cluster analysis. RNA were isolated from DCs derived from three RA patients (RA) and two he-
althy donors (HE). The individual samples were coded by donor origin and the number. The gene expression profiling 
was performed as described in Materials and Methods. Hierarchical cluster analysis was performed on genes (vertical 
dendrogram) and samples (horizontal dendrogram) according to the algorithm described in Materials and Method. The 
magnified view in the box shows sample information in color blocks (1st row :individual sample color code, 2nd row: blue 
for HE, green for RA. The colors represent relative expression level. Red: up regulation, Blue: down regulation, White: 
avarage. 
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Chapter 6, Figure 1.
Figure 1. Staining of synovial tissue with an isotpe control antibody (A) or with a specific antibody against IFNa. Synovial 
tissue sections were counterstained with hematoxylin, magnification 200x.
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Abbreviations used in this thesis
APC  Antigen Presenting Cell(s)
cDNA  complementary DNA
DC(s)  Dendritic Cell(s)
FACS  Fluorescence Activated Cell Sorter
FcγR  Fcγ Receptor
FCS  Fetal Calf Serum
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase
GM-CSF  Granulocyte / Macrophage Colony Stimulating Factor
HE  Heamatoxylin / Eosin
IFNα  Interferon α
IFNβ  Interferon β
IFNγ  Interferon γ
Ig  Immunoglobulin(s)
IL-1β  Interleukin-1β
IL-10  Interleukin-10
IL-12  Interleukin-12
IL-18  Interleukin-18
IL-4  Interleukin-4
IL-6  Interleukin-6
LPS  Lipopolysaccharide
(m)Ab  (monoclonal) Antibody
MFI  Mean Fluorescence Intensity
MHC  Major Histocompatibility Comples
MMP  Matrix Methalloproteinase
mRNA  messenger RNA
MyD88  Myeloid Differentiation Factor 88
NFκB  Nuclear Factor-kB
PAMP  Pathogen-Associated Molecular Pattern
PBMC  Peripheral Blood Mononuclear Cell(s)
PBS  Phosphate Buffered Saline
PMN  Polymorphonuclear Neutrophil(s)
PRR  Pathogen Recognition Receptor
RA  Rheumatoid Arthritis
(RT-)PCR (Reverse Transcriptase) Polymerase Chain Reaction
Th1  T helper-1
Th2  T helper-2
TLR(s)  Toll-Like Receptor(s)
TNFα  Tumour Necrosis Factor a
WT  Wild-type
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